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ABSTRACT 
One of the most versatile and safe material used in medicine is polymer-based 
nanomaterials. This dissertation describes the use of several formulations of polymeric 
nanomaterials for in vitro and in vivo optical imaging applications. In the first phase of this work, 
the particles assembled from diblock copolymers of poly(D,L-lactic-co-glycolic acid) and 
polyethylene glycol were used as a carrier for diagnostic agents. In chapter 2, the polymeric 
nanoparticles  with a large Stokes shift of >100 nm were employed for in vivo imaging. The large 
Stokes shift was achieved through fluorescence resonance energy transfer (FRET) by 
encapsulating the donor (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine) and acceptor 
(1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine) fluorophores inside a single 
nanoparticle. These nanoparticles were then systematically explored to optimize the fluorophore 
loading and the maximum energy transfer efficiency. The animal studies further demonstrated 
that these nanoparticles could have far-reaching applications for in vivo imaging. In chapter 3, 
we further extended the study by doping the combinations of four different fluorophores, DiO, 
Dil, DiD, and DiR to synthesize particles that exhibited distinct emission signatures ranging from 
the visible to near-infrared wavelength region. This work presents first instance of nanoparticles 
encapsulated with four different energy transfer fluorophores inside a single particle. The 
optimized multicolor nanoparticles could simultaneously emit fluorescence at three different 
wavelengths (at 570, 669, and 779 nm) upon a single excitation (at 485 nm). Furthermore, 
particles with single, double, and triple emissions could be synthesized by changing the 
combination and doping ratio of the fluorophores. We further demonstrated that this technology 
could be applied to multicolor and multiplex imaging.  
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 Various physiological mechanisms are responsible for nanomaterial interaction and 
clearance from the blood circulation. The objective of chapter 4 was to investigate the 
biocompatibility, pharmacokinetics, and biodistribution of peptide-based nanofiber (NFP). In 
vitro studies suggested that NFP is non-toxic, hemocompatible and only showed a minimum 
uptake by the isolated macrophages. Upon systemic injection into mice, NFP could be delivered 
to the tumor in a short period of time and also eliminated rapidly by renal clearance. Overall, our 
results suggested that NFP is a biocompatible, safe, and effective carrier for tumoral delivery.  
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CHAPTER 1. INTRODUCTION 
1.1. Optical imaging 
Optical imaging has emerged as a powerful tool capable of non-invasively detecting and 
visualizing biological processes at the molecular level [1]. In general, the method utilizes the 
light of UV-visible and near-infrared (NIR) wavelengths to characterize the optical properties of 
tissues [2]. The interaction of photons with tissue mainly results in the following phenomenon 
such as the absorption of light [3], the scattering of light [4], or the generation of fluorescence 
emission [5]. These optical properties have been exploited individually for the structural and 
functional characterization of biological tissue for the last five decades [6]. In comparison to 
other imaging modalities, optical imaging offer several advantages such as 1) avoiding the use of 
ionizing radiations, 2) use of simple optical instrumentation and thus cost effective, 3) high 
sensitivity, 4) minimal cell damage, 5) the ease of handling and use, 6) simultaneous 
identification of multiple biological events [7], and 7) real time monitoring [8]. Furthermore, it 
can be easily used in complementation with the other imaging modalities such as positron 
emission tomography (PET) [9], single-photon emission computed tomography (SPECT) [10], 
and magnetic resonance imaging (MRI) [11, 12]. However, the major limitation of the optical 
imaging is the penetration depth of light inside the living tissue [13, 14]. Because of the 
involvement of numbers of absorption and scattering events, the penetration depth inside the 
tissue is highly dependent on the wavelength of light. The photons of the UV-visible wavelength 
region (200-650 nm) are strongly absorbed by tissue chromophores, resulting in small 
penetration depth of few micrometer to millimeters inside the tissue. This allows only superficial 
assessment of the spectral properties of the tissues. On the other hand, the light of NIR 
wavelength region (650-900 nm) penetrates deeply inside the tissue because of the reduced tissue 
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absorption, scattering, and autofluorescence (Figure 1) [15]. Therefore, NIR imaging is mostly 
suitable for in vivo imaging applications especially in deep-tissue level. 
 
Figure 1. The absorption coefficient of the biological tissue at different wavelengths. The optical 
properties of different endogenous and exogenous fluorophores. The figure is adapted from 
reference [13].  
1.1.1. Endogenous contrast agents 
The light absorption by tissue generally originates from a variety of biological molecules 
such as hemoglobin, water, melanin, porphyrin, amino acids (tryptophan and tyrosine), proteins 
(collagen and elastin), and coenzymes (reduced nicotinamide adenine dinucleotide) [16]. Most of 
endogenous molecules also exhibit a characteristic fluorescence emission which is called tissue 
autofluorescence. These endogenous fluorophores have been used for the assessment of the 
metabolic status of biological tissues [16]. In some instances, the changes in the intrinsic 
fluorescence due to specific morphologic and biochemical alternations can be used as a 
biomarker for the disease detection. For example, the changes in levels of collagen and 
nicotinamide adenine dinucleotide phosphate (NAD(P)H) were used for the detection of 
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epithelial precancerous tissues (dysplastic) in cervix and esophagus [17]. Similarly, the cases of 
advanced ulcerated squamous cell carcinoma were identified by protoporphyrin, a red 
fluorescent product formed in the tumor tissue [18, 19]. Although there are a number of 
successful reports on the use of endogenous fluorophores as a contrast agent (Table 1), their 
application is mainly limited by their low brightness (determined by the extinction coefficient 
and quantum yield), high absorption and scattering of the illuminated light by the tissue, and 
only subtle differences in the spectral properties between the normal and diseased tissue. This 
lead to the discovery and use of the exogenous contrast agents. 
Table 1. Endogenous tissue fluorophores used in medical diagnosis.  
Fluorophore λmax 
(nm) 
Disease Diagnosed Reference 
NAD(P)H and Collagen 340, 380 Dysplasia in cervix and esophagus [17] 
Collagen and Elastin 350, 476 Atherosclerotic plaques  [20] 
Collagen 380 Mammary tumor [21] 
Collagen  380 Obesity [22] 
Collagen  390 Malignant tissue [23] 
NADH and Porphyrin 397, 610 Dysplasia in Barrett’s esophagus [24] 
Lipofuscin granules  450 Aging [25, 26] 
Collagen, Elastin, and NADH  460 Neoplastic gynecological tissues [27] 
Flavins 500 Malignant tissue [28] 
Protoporphyrin and Porphyrin 610 Advanced ulcerated  
squamous cell carcinoma 
[18, 19] 
 
1.1.2. Exogenous contrast agents 
1.1.2.1. Non-specific contrast agents  
To address the limitations of the endogenous molecules, numerous types of exogenous 
optical contrast agents have been developed in the past few years [29]. The exogenous contrast 
agents principally provide the opportunity of generation of disease specific signal within tissue, 
thus enabling the display of the physiological and molecular conditions. These agents either 
4 
 
introduce a distinct absorption or fluorescence emission in the tissue and in some cases also help 
to visualize the changes in the optical properties of the native tissue. The examples of the most 
commonly used fluorophores are fluorescein [30, 31], indocyanine green [32, 33], cresyl violet 
[34], isosulfan blue [35], methylene blue [36, 37], and porphyrins [38] (Table 2). These 
fluorophores possess very unique absorption and emission properties and can be efficiently 
delivered via topical as well as intravenous route because of their extremely low molecular 
weight (<1 KDa). However, they are non-specific in nature and therefore have tendency to 
localize in intracellular and extracellular space based on their size and charge distribution.  
Table 2. Exogenous contrast agents and their current medical applications. 
  
Fluorophore Application Reference 
Indocyanine green  Neurosurgery 
Coronary bypass angiography 
Vascular surgery  
Sentinel lymph node mapping 
Lymphography 
Liver surgery and laparoscopy 
Laparoscopic cholecystectomy 
Reconstructive microsurgery 
Muscle perfusion 
Rheumatoid arthritis 
[39, 40] 
[41, 42] 
[43] 
[44, 45] 
[46] 
[47, 48] 
[49] 
[50] 
[51] 
[52] 
Methylene blue Identification of ureter  
Extra hepatic bile ducts identification 
Coronary angiography  
Detection of neuroendocrine tumors 
[53] 
[54] 
[55] 
[56] 
Fluorescein Retinal angiography [57] 
Indocyanine green (ICG) is the first fluorophore that is approved by the food and drug 
administration (FDA) for the human use. ICG is a carbocyanine fluorophore with a characteristic 
absorption and emission in NIR wavelength region. It is used in ophthalmic angiography [58, 
59], hepatic function test [60, 61], and cardiac physiology test [62]. For the ophthalmic 
angiography, fluorescein with absorption and emission in visible region is a more popular 
choice, as it is visible without any electronic camera [57]. Recently, ICG was used for a first-in-
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human clinical trial for image guided intraoperative sentinel lymph node mapping in breast 
cancer patients [63]. The large therapeutic index (LD50 of 50-80 mg/kg for animal models) of 
ICG further potentiate its application in the medical diagnosis (Table 2) [64]. Methylene blue is 
another NIR fluorophore used clinically for the imaging of the ureters [53] and bile ducts [54]. 
Other medical applications of non-specific exogenous contrast agents are illustrated in Table 2.  
1.1.3. Limitation of non-specific contrast agents 
There are some major drawbacks associated with non-specific contrast agents. First is 
their lack of tissue specificity, which results in high background signal and thus poor signal-to-
noise ratio (SNR). Secondly, most of the fluorophores have the tendency to undergo aggregation 
upon storage [65] and binding to serum proteins in the blood stream [66] owing to their 
hydrophobic nature. Lastly, exogenous fluorophores are known to undergo photobleaching [67] 
as well as thermal degradations [68].   
1.1.4. Targeted contrast agents 
One way to improve the specificity of any contrast agent is by use of targeted ligands. 
Among all, monoclonal antibodies are the most widely used targeting ligand for achieving the 
molecular specificity [69]. The fluorophores can be simply attached to antibodies via covalent or 
non-covalent conjugation. Because of the high selectivity and affinity of targeting ligands 
towards the specific receptors, optical mapping can be done with only low doses (nanomolar) of 
the imaging agent. This specificity results in high signal-to-noise in target organ. The first report 
of antibody conjugated fluorophores was demonstrated for the detection of human squamous cell 
carcinoma in nude mice in 1994 [70] and since then numerous targeted imaging probes have 
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been developed [29]. However, monoclonal antibodies as a targeting molecule can be 
detrimental especially from imaging stand point of view because of their long plasma half-life 
(t1/2) and immunogenicity [71]. Furthermore, a large hydrodynamic size of the antibody may also 
prevent the intratumoral uptake and homogeneous distribution in the tumor. Alternatively, small 
targeting ligands such as affibodies (small antibody fragments) [72], peptides [73], and aptamers 
[74] have been used to overcome these shortcomings. Even though the ligand assists in achieving 
the molecular specificity, the fluorophores are still susceptible to photodegradation owing to 
their contact with the surrounding environment [75]. Additionally, the maximum number of 
fluorophores that can be loaded on a single targeting ligand can be limited (1-5 fluorophores per 
ligand). This is mainly because high loading can have unfavorable effects on the avidity and the 
biological activity of the ligand [76]. Also increases in the number of fluorophores per ligand 
may significantly decreases the total fluorescence emission intensity (brightness) due to the self-
quenching [77].  
1.2. Nanoparticles as an imaging probe 
An alternate way to overcome the limitations of the exogenous fluorophores is by doping 
them into/onto the nanoparticles. According to the U.S. National Nanotechnology Initiative 
(www.nano.gov), nanomaterials is any material with at least one dimension in the range of 
approximately 1 to 100 nm. Materials within this nanometer sized range can exhibit unique 
physicochemical and biological properties that are significantly different from the properties of 
bulk materials. Importantly, these unique physicochemical properties such as size, shape, surface 
charge, surface functionality, and composition of nanomaterials play a major role in their 
interactions with the biological system (nano-bio interface) [78-80]. Depending on the nature of 
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nano-bio interfaces, the biodistribution, biocompatibility, and toxicity of nanomaterials can be 
largely affected [81]. One example is the effect of size on the in vivo tissue distribution of 
nanoparticles inside the body [82]. When injected intravenously, the ultra-small nanoparticles (3-
5 nm) are predominantly eliminated by the kidney while the larger nanoparticles (>10-20 nm) 
can be largely retained by the cells of mononuclear phagocytic system (MPS) present in the liver 
and spleen [83-85]. Depending on the particle size, nanoparticles may undergo the selective 
vascular escape from the blood stream via fenestration (small opening) of endothelial barriers. 
For instance, in certain disease conditions such as cancer [86], atherosclerosis [87, 88], and 
rheumatoid arthritis [89], the anatomical and pathophysiological changes results in the formation 
of discontinuous fenestration of 200-800 nm. This unique tumor vascular phenomenon that 
allows the selective passage of the nanoparticles is called the enhanced permeability and 
retention (EPR) effect [90]. These disease specific pathological changes have been extensively 
studied for nanomaterial mediated delivery of therapeutic and diagnostic molecules [91].  
Fluorophore-doped nanoparticles are a new generation of nanomaterial based fluorescent 
probes that were developed recently for in vitro and in vivo applications [92, 93]. Compared to 
other nanoparticle based contrast agents, these particles can be generated simply by doping 
organic/inorganic fluorophores into/onto optical inert matrix. The photophysical behavior of 
fluorophores is highly dependent on their local distribution inside the particles [94, 95]. Because 
of the entrapment of hundreds to thousands of fluorophores inside a single particle, high brighter 
optical signal is generated as compared to a single fluorophore. Moreover, by controlling the 
loading density (number of fluorophores per particle), the brightness (product of quantum yield 
and extinction coefficient) can be enhanced to make ultrasensitive nanoparticles for imaging [96, 
97]. The encapsulation of fluorophores into nanoparticles also enhances the photo- and thermo-
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stability as well as reduces their interactions with the outside environment thorough matrix 
shielding protection [98].  
Among all, silica nanoparticles are the most commonly used platform because of their 
straightforward synthesis and availability of rich surface chemistry [99, 100]. Most importantly, 
silica is a chemically inert and optical transparent material which makes it as an excellent matrix 
for encapsulation of the fluorophores. Silica nanoparticles are generally synthesized by 
hydrolysis followed by condensation polymerization reaction with tetra orthosilicate (TEOS) 
catalyzed in presence of liquid ammonia in following two ways [101]. The first method is called 
sol-gel method or Stober synthesis in which ammonia induces hydrolysis of TEOS in presence of 
water and ethanol. The second method is microemulsification, in which the polymerization 
reaction takes place in hydrophilic core of reverse micelles (W/O emulsion). Size of 
nanoparticles can be controlled by monitoring the reaction parameters such as ammonia 
concentration or water to surfactant ratio. The fluorophores can be incorporated into silica 
nanoparticles via ionic interaction [102], entrapment [103, 104], or covalent conjugation [105, 
106]. For example, positively charged Tris(bipyridine)ruthenium(II) dichloride (RuBPY) 
molecules were successfully entrapped inside negatively charged silica particles by electrostatic 
attraction during the microemulsification method [107]. These particles were subsequently used 
for studying the in vivo biodistribution and urinary excretion by  optical imaging. In another 
study, dual-fluorophores doped silica nanoparticles were reported as a theranostic platform, in 
which an optical contrast agent i.e. IR-780 was covalently conjugated within the silica 
framework and a photo-thermal agent i.e. Si-Naphthalocyanine was physically encapsulated 
inside the cylindrical pores [108]. Likewise, numerous types of organic/inorganic fluorophores 
have been successfully doped into the silica nanoparticles (Table 3). Fluorescent silica 
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nanoparticles modified with targeting ligands have been applied in many areas of bioanalysis. 
For instance, RuBPY-doped Si-NPs modified with mouse anti-human CD 10 antibody were used 
for the identification of human leukemia cells [109]. Similarly, fluorescence anisotropy based 
immunoagglutination assay for the recognition and detection of alpha fetoprotein (AFP), a 
biomarker of hepatocellular carcinoma and germ cell tumors [110], has been developed by 
conjugating anti-AFP antibody to methylene blue doped Si-NPs [111]. Additionally, Si-NPs 
have been also adapted for cellular imaging, multiplexing analysis, DNA hybridization, and 
nucleic acid analysis [99, 100]. Although different types of targets such as proteins, cells, and 
bacteria have been successfully identified by silica nanoparticles at in vitro and ex vivo levels, 
their use for in vivo imaging can be limited by their low aqueous solubility and that they can 
possibly trigger local inflammation by formation of reactive oxygen species and free radicals 
[112, 113].  
Polymer based nanoparticles is another type of optically inert material that is relatively 
non-toxic and biodegradable [114, 115]. In general, the fluorophores diffuse into the polymeric 
matrix and get physically entrapped inside the core through hydrophobic interactions. Beside this 
approach, fluorophores can be doped inside nanoparticles by ionic interactions [116] and 
covalent bonding [117]. Depending on the polymer of interest, the nanoparticles can be 
synthesized by following three methods: 1) emulsion polymerization, 2) nanoprecipitation, and 
3) emulsification. The most commonly used polymer matrices are polystyrene [118], 
poly(methyl methacrylate) (PMMA) [95], and poly(D,L-lactic-co-glycolic acid) (PLGA) [119]. 
These polymeric matrices are extremely hydrophobic in nature and therefore the resulting 
nanoparticles tend to aggregate through non-covalent interactions. The particles can be stabilized 
by using water soluble stabilizer such as polyethylene glycol (PEG), polyvinyl alcohol (PVA), 
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and polyamines [120, 121]. The stabilizer may be added at the time of synthesis or during a 
coating step after the particle formation.  
Fluorophore-doped polymeric nanoparticles serve as excellent optical probe for various 
biological applications (Table 3). For example, fluorescein doped PMMA nanoparticles were 
used as a fluorescent nanosensor in a fluoroimmunoassay for the detection of human chorionic 
gonadotropin (HCG) [122]. In another study, a NIR optical imaging probe based on core cross-
linked polymeric micelle (CCPM) was developed by using Cy7 fluorophores and amine-
terminated amphiphilic block co-polymer [123]. Approximately 21 molecules of Cy7 
fluorophores were successfully entrapped in a single particle. After intravenous injection, optical 
imaging showed a gradual increase in tumor uptake (up to 120 h) suggesting potential of CCPMs 
for detection of solid tumors. Similarly, in vitro and in vivo NIR imaging of breast cancer cells 
was also demonstrated using folic acid conjugated PLGA-lipid hybrid nanoparticles doped with 
indocyanine green [119]. Despite of the successful imaging applications and excellent safety 
profile, polymeric nanoparticles are prone to leakage in blood circulation [98]. Various 
approaches such as covalent conjugation of fluorophores to nanoparticles matrix [117], 
transforming the solubility and size of the fluorophores, creating the electrostatic attraction 
between the matrix and fluorophores [116] have been attempted to overcome these 
shortcomings. These methods are helpful to certain extent but also possess some inherent 
limitations.  
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Table 3. Fluorophore-doped nanoparticles. 
Nanomaterial Fluorophore Mode of doping Reference 
Silica 
Nanoparticles 
 
 
 
 
 
 
 
FITC 
TRITC 
TMR 
Rhodamine 6G  
RITC 
Rhodamine B 
Dansyl chloride  
Methylene blue 
RuBPY 
NIR-1 and NIR-2 
Indocyanine green 
DY776 
Cy5 
Ru(Phen)3Cl2 
Covalent 
Covalent 
Electrostatic 
Entrapment 
Covalent 
Covalent 
Covalent 
Entrapment 
Entrapment 
Covalent 
Electrostatic 
Covalent 
Covalent 
Entrapment 
[124-126] 
[127] 
[128] 
[129] 
[130] 
[106] 
[94] 
[131] 
[96, 107] 
[97] 
[132] 
[133] 
[134] 
[135] 
Iron oxide 
NPs 
Cy5.5 
FITC and Cy5.5  
Covalent 
Covalent 
[136] 
[137] 
Polymeric 
NPs 
Sulforhodamine and fluorescein  
Alexa 488 
Indocyanine green 
Indocyanine green 
Cy7 
RuBPY 
Sulforhodamine 
RuBPY, Fluorescein, Rhodamine 
6G, Rhodamine B 
BODIPY  
Indocyanine green 
RITC and NBD 
Fluorescein  
Cy5 
Cross-linking 
Cross-linking 
Cross-linking 
Entrapment 
Entrapment 
Entrapment & 
Electrostatic 
Entrapment 
Entrapment & 
Electrostatic 
Entrapment 
Entrapment 
Entrapment 
Covalent 
[138] 
[139] 
[98] 
[140] 
[123] 
[95] 
[141] 
[116] 
 
[118] 
[119] 
[142] 
[122] 
[117] 
Hyaluronic 
acid NPs  
Indocyanine green Covalent [143] 
CPNPs  Cy3 
Indocyanine green 
Entrapment 
Entrapment 
[144, 145] 
[146, 147] 
Lipid NPs  Porphyrin 
Indocyanine green 
DiD and DiR 
Entrapment 
Entrapment 
Entrapment 
[148] 
[149] 
[150] 
Abbreviations: Fluorescein isothiocyanate (FITC), tetramethylrhodamine isothiocyanate 
(TRITC), tetramethylrhodamine (TMR), rhodamine B isothiocyanate (RITC), cyanine (Cy), 
Tris(bipyridine)ruthenium(II) dichloride (RuBPY), Tris(1,10-phenanthroline)ruthenium(II) 
chloride hydrate (Ru(Phen)3Cl2), boron-dipyrromethene (BODIPY), 4-chloro-7-nitrobenzo-2-
oxa-1,3-diazol (NBD), 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine (DiD), 1,1'-
dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine (DiR), silica nanoparticles (Si-NPs), 
calcium phosphate nanoparticles (CPNPs) 
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Recently, calcium phosphate nanoparticles (CPNPs) were identified as a novel carrier for 
drug delivery and bioimaging [146, 151, 152]. Because of their ubiquitous presence in the form 
of amorphous calcium phosphate and crystalline hydroxyapatite inside the body, CPNPs are 
relatively non-toxic, biodegradable, and elicit low immune response [153]. The first work of 
CPNPs as carrier for contrast agent was recently reported in which the NIR fluorophore i.e 
indocyanine green was encapsulated into nanoparticles by double reverse microemulsion 
approach [146]. Unlike the other nanoparticles, monomeric state of fluorophores was retained 
after encapsulation inside CP matrix. When injected in animals, preliminary results verified the 
capacity of CPNPs for deep tissue imaging applications. The same nanoparticles were further 
targeted by using anti-CD71 antibody and gastrin peptide for imaging of breast and pancreatic 
cancer, respectively [147]. Apart from these, various other nanomaterials have been used as 
carriers for contrast agents. All the other examples of fluorophore-doped nanomaterials are 
summarized in Table 3.  
1.2.1. Poly(D,L-lactic-co-glycolic acid) based nanoparticles as an optical inert matrix 
Poly(D,L-lactic-co-glycolic acid) (PLGA) is an aliphatic copolymer consisting of 
repeating units of lactic and glycolic acid attached by ester linkages (Figure 2A). These 
copolymers are generally synthesized by ring-opening copolymerization of cyclic lactides and 
glycolides in presence of an appropriate catalyst such as tin(II) 2-ethylhexanoate [154], tin(II) 
alkoxides [155], or aluminum isopropoxide [156]. The copolymer can also be synthesized by 
direct polycondensation of lactic and glycolic acid [157]. However, this method is only suitable 
for synthesis of low molecular weight copolymers because of the inherent limitation such as the 
hydrolysis of growing polymer chain in presence of liberated water from the reaction mixture. In 
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general, during polymerization the monomer units are linked together by ester linkage to yield a 
linear, aliphatic polyester product (Figure 2A). The physical and rheological properties of the 
resulting copolymer largely depend on the ratio of lactic acid/glycolic acid and the 
stereochemistry (D- and/or L-lactic acid) of monomers. Polyglycolic acid (PGA) is a highly 
crystalline material with a melting temperature of 225-230°C. On the other hand, polylactic acid 
(PLA) is a semi-amorphous material with a melting temperature of 173-178°C. Unlike glycolide, 
lactic acid exists in two distinct optically active forms i.e. D-lactide and L-lactide due to the 
presence of a chiral center. By precisely controlling the ratio of lactide to glycolide, the 
physiochemical properties of PLGA copolymer can be fine-tuned to virtually mold into any 
shape and size that has the capacity to encapsulate molecules of any size. The examples of the 
PLGA derived materials include nanofibers, nano-and microparticles, implants, sutures and 
many more [158].  
 
Figure 2. Schematic representation of synthesis and hydrolysis of PLGA copolymers. (A) 
Synthesis of PLGA copolymer by ring-opening copolymerization in presence of stannous 
octoate. (B) Hydrolysis of PLGA copolymer. 
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One important characteristic of PLGA copolymers is their biodegradation and 
biocompatibility. Under physiological conditions, the copolymers can undergo hydrolysis (in 
presence of water) owing to the presence of intrinsically sensitive ester linkages. The hydrolysis 
results in non-toxic components (lactic and glycolic acid) (Figure 2B), which can be easily 
eliminated from the body in the form of water and carbon dioxide via the Krebs cycle. The rate 
of degradation may vary from copolymer to copolymer depending on the monomer composition. 
For example, PLGA copolymers containing high lactide content degrade more slowly as 
compared to the one with high glycolide. This is mainly because the presence of a methyl side 
group in lactic acid imparts a more hydrophobic character and therefore reduces the absorption 
of water and subsequent degradation. In addition, the hydrolytic degradation behavior of 
copolymers also depends on their chemical composition, mechanism of hydrolysis (noncatalytic, 
autocatalytic, enzymatic), additive (such as surfactants), morphology, dimensions, porosity, glass 
transition temperature, and molecular weight distribution. This composition dependent 
degradation of PLGA copolymers have been explored in field of drug delivery.  
PLGA nanoparticles have gained much interest because of their ability to carry a wide 
variety of molecules ranging from small molecules to macromolecules (Table 4) [158, 159]. 
However, PLGA derived particles are extremely hydrophobic and when injected intravenously 
undergo rapid clearance from the circulation with accumulation in major excretory organs such 
as liver and spleen. To overcome these limitations and also to incorporate more flexibility, 
various types of block copolymers of PLGA and polyethylene glycol (PEG) such as PLGA-PEG, 
PLGA-PEG-PLGA, and PEG-PLGA-PEG have been developed [160-162]. The physiochemical 
properties of these block copolymers vastly differ from each other and thus result in different 
kinds of nanostructures. For instance, PLGA-PEG diblock copolymers undergo self-assembly in 
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aqueous environment to form a core-shell type of structures consisting of hydrophobic PLGA 
core surrounded by a layer of hydrophilic PEG. The PEG coating is known to minimize the 
aggregation upon storage as well as to help to improve the circulation time in vivo [163]. 
Additionally, the sheath of hydrophilic PEG also exposes multiple terminal functional groups at 
the surface for bioconjugation of the targeting ligand [164].  
Table 4. Examples of PLGA nanoparticles used as a nanocarrier. 
 Therapeutic/imaging agent Disease 
treated/diagnosed 
Targeting 
ligand 
Reference 
T
h
er
a
p
eu
ti
c 
Cisplatin  
Doxorubicin 
Docetaxel 
Lonidamine 
α-tocopheryl succinate 
Curcumin 
2,4-dinitrophenol 
Docetaxel and cisplatin  
Camptothecin 
Doxorubicin and 
combretastatin-A4 
(-) Epigallocatechin 3-gallate 
Loperamide and Rhodamine-
123 
Prostate cancer 
Breast cancer 
Prostate cancer 
Cancer 
Cancer 
Alzheimer's disease 
Obesity 
Prostate cancer 
Colorectal cancer 
Melanoma and lung 
cancer 
 
Prostate cancer 
 
BBB, Analgesia 
Aptamer 
N/A 
Aptamer 
Peptide 
Peptide  
Peptide  
Peptide 
Aptamer 
Antibody 
N/A 
 
Small 
molecule 
Peptide 
[160, 161] 
[165] 
[166] 
[167] 
[167] 
[167] 
[167] 
[168] 
[169] 
[170] 
 
[171] 
 
[172] 
D
ia
g
n
o
st
ic
 Indocyanine green 
Indocyanine green 
Alexa 488 
AuNC and QD-620 
N/A 
Breast cancer 
Inflammation  
Macrophage labeling 
N/A 
Folic acid 
Peptide 
N/A 
[98] 
[119] 
[173] 
[174] 
T
h
er
a
n
o
st
ic
s MNP and Doxorubicin  
MNP and Doxorubicin  
 
 
Lung cancer 
Breast cancer 
N/A 
Herceptin  
[175] 
[176] 
Abbreviations: Brain blood barrier (BBB), gold nanocrystal (AuNC), quantum dot (QD), 
magnetic Fe3O4 nanoparticles (MNP).  
A wide variety of therapeutic and/or diagnostic agents can be loaded into polymeric 
nanoparticles by following approaches: 1) covalent conjugation with the polymer backbone, 2) 
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direct adsorption on the particle surface, and 3) entrapment inside the core of the particle during 
self-assembly. These agents can be used alone or in combination with each other. The choice of 
technique mainly depends on the physiochemical properties of the molecules of interest, type of 
copolymers, and desired characteristics of synthesized particles. 
Unlike diblock copolymer, triblock copolymers such as PLGA-PEG-PLGA or PEG-
PLGA-PEG are water soluble at lower temperature (<20°C) and undergo phase transformation to 
form a semi-solid hydrogel at body temperature (37°C) [162, 177]. This is mainly due to the 
involvement of strong hydrophobic interactions and hydrogen bonding between the copolymers. 
At lower temperature, the hydrogen bonding between the water and the PEG molecules 
dominate, thus resulting in the dissolution of polymer in water. As the temperature increases, the 
hydrophobic interactions between the PLGA segments of copolymer become dominant and the 
hydrogen bonding gets weaker leading to phase transformation from solution to gel. These 
temperature sensitive polymers can be used for various biomedical applications including drug 
delivery and tissue engineering.  
1.2.1.1. Fabrication of polymeric nanoparticles 
 A number of top-down approaches are available for the preparation of polymeric 
nanoparticles [178]. Most of these methods involves the self-assembly of block polymers having 
two distinct polymeric chains with different solubility. The most common method for the 
synthesis of nanoparticles is single-emulsification/solvent evaporation technique (O/W) [179]. In 
this method, PLGA and the drug of interest are dissolved in water immiscible organic solvent 
and then emulsified in a large volume of water in the presence of emulsifier such as polyvinyl 
alcohol (PVA). The organic phase is then extracted or evaporated under low pressure to yield 
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solid nanoparticles. The size of particles can be controlled by adjusting the process parameters 
such as oil to water phase ratio, concentration of emulsifier, rate of stirring, and sonication time. 
This method is mainly used for the encapsulation of hydrophobic molecules. A modified method 
called double or multiple emulsification method (O/W/O) has also been developed for 
encapsulation of hydrophilic molecules. However, despite of widespread use of the 
emulsification methods, there are some limitations associated with these methods. The first 
drawback is the instability of encapsulated molecules especially proteins and peptides due to the 
high shear speed or sonication to create a stable emulsion. Secondly, the emulsifiers such as 
PVA are known to show concentration dependent toxicity including lysis of red blood cells. 
Lastly, the complete removal of organic solvent is difficult and thus also results in added 
toxicity.  
 Alternatively, nanoparticles can be synthesized by nanoprecipitation or solvent 
displacement method [164]. In this method, the drug of interest and copolymer are first dissolved 
in water-miscible organic solvents such as DMF, acetone, or acetonitrile and then this organic 
phase is added to the aqueous phase. The surfactant may be added to the aqueous phase. Due to 
the solubility differences of PLGA (lipophilic) and PEG (hydrophilic) in aqueous and organic 
phases, a phase separated structure is formed. PLGA is soluble in organic solvent but not in 
aqueous phase. On the other hand, being hydrophilic, PEG is soluble in water but not in organic 
solvent. During the self-assembly, PLGA aggregate in aqueous environment to form the core and 
PEG migrates from the inner core to surface toward the core-water interface. Upon solvent 
evaporation, the core solidifies to form tiny particles. In addition to the conventional methods, 
new approaches have been used for the synthesis of polymeric nanoparticles. These include 
eletro-spraying, premix membrane emulsification, aerosol flow reactor method, and supercritical 
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technology [91]. Recently, a more advanced technique that uses a microfabricated device with 
build-in microscale fluidic channels has been also reported for the fabrication of polymeric 
nanoparticles [180]. There reported devices have shown a dramatic improvement in controlling 
the physiochemical properties (such as size, surface composition, drug loading) of the 
nanoparticles over the bulk synthesis methods. As a result, these microfluidics systems have the 
capacity to synthesize the nanoparticles in a well-controlled, reproducible and high throughput 
manner [181].  
1.2.2. Limitations of single fluorophore-doped nanoparticles 
Also, a variety of nanoparticles encapsulated with near-infrared fluorophores have been 
developed for in vivo optical imaging (Table 3). Unfortunately, the encapsulated fluorophores 
have the disadvantage that their Stokes shift (the difference between the absorption and emission 
λmax) is smaller than 25 nm and therefore they exhibit a high background fluorescence while 
imaging. Additionally, fluorophores with a small Stokes shift also prone to self-quenching 
tendency and thus lead to high level of scattered light measurement error. All of these can result 
in dramatic decrease in signal-to-noise and thus insufficient resolution at the target sites.  
1.3. Strategies to improve the signal-to-noise ratio (SNR) 
 One approach to improve the resolution at the target site is by improving the Stokes shift 
of encapsulated fluorophores. Foster resonance energy transfer (FRET) is a simple way to elicit a 
large Stokes shift by using a combination of two different fluorophore molecules. A typical 
FRET-based contrast agent consists of a donor fluorophore which upon excitation non-radiantly 
transfers its energy to another nearby molecule (an acceptor) via long dipole-dipole interactions.  
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Figure 3. Design of FRET-based contrast agent for in vivo imaging applications. (A) Protease 
activatable polymeric nanoparticles with in-build quenching by using combination of Cy5.5 
fluorophore and black hole quencher. The figure is adapted from reference [182]. (B) A FRET 
mediated large Stokes shifting near-infrared fluorescent silica nanoparticles incorporating a 
FRET pair (RuBpy and Methylene blue) for in vivo imaging The figure is adapted from the 
reference [183].  
Depending on the type of the acceptor molecules, the transfer of energy results in either 
quenching of fluorescence (optically silent) (Figure 3A) or emission of fluorescence at longer 
wavelength region (large Stokes shift) (Figure 3B). As the transfer of energy is not mediated by 
actual emission of photons, the phenomenon is termed resonance energy transfer. When both 
donor and acceptor molecules are fluorescent, the term fluorescence resonance energy transfer is 
commonly used in scientific literature. The rate of energy transfer mainly depends upon 1) the 
percentage overlap between the donor emission and the acceptor absorption spectrum, 2) the 
quantum yield of the donor, 3) the distance between the donor and acceptor molecule, and 4) the 
relative orientation of transition dipoles.    
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1.3.1. Basic principles of FRET 
The concept and theoretical basis of resonance energy transfer was first developed by a 
German scientist, Theodor Foster. According to the Foster theory, energy transfer will takes 
place when an excited fluorophores with an oscillating dipole comes in proximity of another 
molecule with similar resonance frequency (Figure 4). In contrast to the radiative mechanisms, 
both structural and positional information regarding the specific donor-acceptor pair can be 
obtained using the resonance energy transfer.  
 
Figure 4. Jablonski diagram of Foster resonance energy transfer. The figure is adopted from the 
reference [184]. 
According to the Foster theory, the FRET efficiency (EFRET) is proportional to the inverse 
sixth power of the distance between the donor and the acceptor (r).  
       
 
   ( 
 
  
)
  
 
 …………………………………………………………..……………….. (1) 
 Where, Ro is the Foster distance where the FRET efficiency is 50% for a given FRET 
pair.  
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Where, k
2
 (kappa squared) is the orientation factor between the dipoles of two 
fluorophores. QD is the quantum yield of the donor, εA is the extinction coefficient of the acceptor 
in Mol
-1
cm
-1
, and J(λ) is the spectral overlap integral between the normalized emission spectrum 
of the donor (FD (λ)) and absorption spectrum of the acceptor (EA (λ)).  
 ( )   ∫  ( )      ( )    
    ………………………………………………………….. (3)  
1.3.2. Applications of FRET  
Because of the distance dependent energy transfer, FRET has become an important tool 
for investigating a variety of biological phenomena that produce changes in molecular proximity. 
For example, a sensor can be genetically encoded with two fluorescent protein variants for 
monitoring intracellular Ca
+
 activity [185, 186] and apoptosis [187, 188]. Organic donor and 
acceptor molecules can also be cooperated as a FRET pair for sensing disease-associated 
analytes such as glucose [189], zinc [190], lysozymes [191], and cholera toxin [192]. Recently, 
FRET biosensors have been explored for cancer detection and evaluation of drug efficacy [193].  
Beside these applications, FRET has been used to overcome the undesirable photophysical 
properties such as small Stokes shifts (typically less than 25 nm) of exogenous fluorophores.  
1.3.3. Activatable imaging probes 
 One of the approaches to improve the detection sensitivity in vivo is by using the 
activatable imaging probes. These imaging probes are optically silent in native state, however 
become fluorescent when activated by different stimulus such as enzymes [169], temperature 
[194], sugar [195], and lysosomal degradation [196]. Among all, the enzyme activatable probes 
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are the most common, because of the significant differences in the expression level of proteolytic 
enzymes in normal and pathological conditions such as cancer, atherosclerosis, inflammation, 
vascular diseases, and Alzheimer’s disease as well as in infectious diseases such as AIDS, Ebola, 
and malaria [197]. In general, the enzyme activatable probes consist of a donor fluorophore, an 
acceptor (quencher), and an enzyme specific cleavable peptide sequence. The donor and acceptor 
are linked in such a way that their close proximity (2-10 nm) results in energy transfer. To 
achieve significant changes in fluorescence signal, an efficient quencher molecule is utilized as 
an efficient quencher to the donor fluorescence. This approach offers the advantage of high 
quenching, but at the same time requires much complicated synthetic procedures. The simplest 
design of these probes connects a donor fluorophore and a quencher by using protease cleavable 
spacer. For example, a dark quenched fluorogenic probe was synthesized by conjugating Cy5.5 
molecule and a black hole quencher (BHQ-3) at the terminal ends of a short peptide sequence 
(GPLGMRGLGK) [198]. Due to the close proximity of Cy5.5 and BHQ-3, the probe was optical 
silent in its native state. However, upon cleavage of the enzyme cleavable substrate in the core 
peptide by MMP-13, the probe became highly fluorescent owing to the release of the BHQ-3. 
This fluorogenic probe was used for the detection of MMP-13 under in vitro condition as well as 
in osteoarthritis induced rat model. In another study, polymeric nanoparticle based activable 
near-infrared nanosenor consisting of Cy5.5 and BHQ-3 have been developed for determination 
of protease activity in vivo [182]. 
1.3.4. Fluorescent probe based on FRET mediated large Stoke shift  
Another approach to improve the resolution at the target site is by reducing the fraction of 
excitation light and scattered light in the emission window. This can be easily achieved by 
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synthesizing a fluorescent probe with a large Stokes shift. Inorganic fluorescent nanocrystals 
such as quantum dots (QDs) are the fluorescent probes with extremely large Stokes shift of more 
than 200 nm [199]. They are known to be more sensitive (brighter) and less susceptible to photo-
degradation than organic fluorophores. However, their unsure long-term toxicities hinder their 
future application in the clinical settings [200]. Therefore, various alternative strategies have 
been developed to synthesize organic fluorophores with large Stokes shift. FRET is the most 
commonly used strategy to impart a large Stokes shift between the excitation and emission 
maxima. Two different designs mainly prevail in this category. The first design consists in 
energy transfer cassettes in which the donor and the acceptor molecules are covalently linked 
together. Another approach consist in doping two or more fluorophores inside the nanoparticle to 
favor the energy transfer.  
1.3.4.1. Energy transfer cassettes  
Energy transfer cassettes mainly consist of a FRET donor and an acceptor molecules 
covalently linked together using an appropriate spacer molecule [201]. The mode of energy 
transfer is highly dependent on the type of the linker molecule. The fluorophores are linked 
together by a non-conjugated spacer (Figure 5A) and the energy transfer mainly occurs through 
space via non-radiative decay pathway (like the traditional FRET). These energy transfer 
cassettes result in a pseudo-Stokes shift which is larger than the respective Stokes shifts of either 
donor or acceptor fluorophores alone. However, they are still limited by the requirement that 
emission spectrum of the donor must overlap the absorption spectrum of the acceptor. 
Alternatively, the fluorophores can be connected together by electronically conjugated linkers 
(Figure 5B), where the energy transfer primarily takes place through the bond and to some 
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extent through space also. This mode of energy transfer is called a through bond energy transfer 
(TBET). Unlike through space energy transfer, TBET is not constrained by the requirement of 
the spectral overlap between the fluorophores and therefore does not necessarily involve loss of 
sensitivity at high resolutions. Regardless of the mode involved in energy transfer, the main 
advantage of these cassettes is their stability against photodestruction. This is mainly because the 
energy transfer rates are much faster than intersystem crossing and thus reduce photo-bleaching 
by avoiding the population of highly reactive triplet state of the fluorophore.  
 
Figure 5. Energy transfer mechanisms in bichromophoric cassettes.    
Despite of their distinct advantages over a single fluorophore, widespread applications of 
the energy transfer cassettes are mainly restricted because of their limited aqueous solubility. The 
compatibility of cassettes with aqueous media can be improved by introduction of a water 
soluble moiety. However, this approach is very challenging as very small amount of fluorescent 
impurities in the purification step may impair the imaging experiment data. Furthermore, the 
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presence of water solubilizing groups may also result in a decrease in the fluorescence intensity 
by assisting the non-radiative decay process facilitated by solvation sphere rearrangement in 
excited state. All these limitations can be mitigated by encapsulating the energy transfer cassettes 
inside the water soluble nanomaterials. For example, the energy transfer cassettes based on a 
BODIPY as a donor molecule and a cyanine as an acceptor molecule were successfully 
encapsulated in calcium phosphate/silicate nanoparticles (22 nm) using double reverse 
microemulsion method [202]. These particles were water-dispersible and further used for 
labeling of different organelles inside the cells [202, 203].   
1.3.4.2. Multiple fluorophores-doped nanoparticles  
 An alternative approach to achieve a large Stokes shift is by encapsulating two or more 
fluorophores inside a single micro/nano-particle [204, 205]. This is designed to maximize the 
energy transfer among the fluorophores such that maximum emission arises from the 
fluorophores with lowest excited state energy level in the sphere. Unlike the bichromophoric 
cassettes in which the fluorophores are conjugated using covalent bond, these nanoparticles are 
designed using a simple approach by creating high local concentration of the fluorophores to 
facilitate the energy transfer. This approach is relatively easy and straight forward as no covalent 
conjugation among the fluorophores is required. In general, the fluorophores are non-covalently 
entrapped inside the protective matrix. In some cases, covalent conjugation of the fluorophores 
to protective matrix can be used as an alternative method [205]. The advantage of the covalent 
approach is that it allows precise control of fluorophore loading and also that the fluorophores 
are less prone to leakage from the matrix. The energy transfer in multiple-fluorophores doped 
nanoparticles is mainly facilitated by entrapment of hundreds to thousands of fluorophore 
26 
 
molecules in a small space. As the energy transfer largely depends on the distance between the 
two fluorophores, the total concentration inside the particles is the key factor. However, when 
two identical fluorescent molecules comes in close proximity, their fluorescence emission is 
quenched by intermolecular interactions. Therefore a balance between the level of energy 
transfer and fluorescence quenching should be optimized based on the intended application of 
particles. Similarly to single fluorophore-doped nanoparticles, a wide range of organic and 
inorganic energy transfer fluorophores can be entrapped inside the inert matrix.  
Silica nanoparticles are the most extensively studied in this category. An approach has 
been developed for simultaneous encapsulation of two inorganic fluorophores,  Tris(2,2‘-
bipyridyl)osmium(II)bis(hexafluorophosphate) (OsBpy) and Tris(2,2‘-
bipyridyl)dichlororuthenium(II)hexahydrate (RuBpy) [204]. These fluorophores act as a FRET 
pair because of their broad overlapping excitation spectrum and the distinct emission maxima. 
By controlling the ratio and concentration of these two fluorophores, the efficiency of energy 
transfer can be fine-tuned. Subsequently, these two fluorophores-doped nanoparticles can be 
used for parallel and high-throughput screening of biomolecules. In another study, two 
hydrophilic fluorophores, RuBpy and methylene blue (MB), were encapsulated as the model 
donor-acceptor pair in the silica nanoparticles [183]. It was observed that the resulting near-
infrared fluorescent silica nanoparticles possessed strong fluorescence with a large Stokes shift 
of >200 nm and thus, it can effectively helped to increase the discrimination of fluorescence 
signal in the region of interest (ROI) over the background signals. Apart from these studies, 
based on the theoretical modeling, it has been proposed that using silica nanoparticles codoped 
with Cy3 and Cy5 molecules at a controllable ratio, one can achieve a high resolution in far-field 
fluorescence imaging [206].  
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 Polystyrene microspheres is another type of inert matrix that has been employed for the 
encapsulation of fluorophores. The well-known example of multiple fluorophores-doped 
polystyrene nanoparticles is TransFluoSpheres
® 
(http://www.invitrogen.com).  TransFluoSpheres 
are commercially available fluorescent particles which incorporate a series of two or more 
proprietary fluorophores that are carefully chosen to allow excited-state energy transfer between 
the fluorophores, thus producing particles with extremely large Stokes shift. The proprietary 
fluorophores were optimally loaded to ensure that the excitation energy is efficiently transferred 
from fluorophore to fluorophore so that essentially only the longest wavelength fluorophore 
exhibit the maximum fluorescence. These fluorescent tiny particles have been successfully used 
in a wide variety of experimental and diagnostic applications such as detecting cell-surface 
antigens [207], tracing neurons [208], and studying phagocytosis [209]. Recently, polystyrene 
microspheres with a large Stokes shift of 180 nm have also been reported [210]. These particles 
were synthesized by using two julolidine fluorophores through solvent evaporation technology. 
Because of deep embedment of the fluorophore molecules, the particles showed better stability 
than traditional surface labelled microsphere.  
As the fluorescent nanoparticles are discriminated on the basis of colors, they are 
extremely useful in diagnostic field especially for parallel and high-throughput screening in the 
multiplex format [211, 212]. Large number of nanoparticles can be generated based on the 
different amounts of one or more fluorophores emitting in multiple different wavelengths. 
However, the number of colors generated by combination of single or two fluorophores can be 
limited, which restricts their use in multicolor and multiplexed imaging applications [204]. To 
generate versatile colors, a new strategy that encapsulate 3 or more energy transfer fluorophores 
simultaneously inside a single nanoparticle has been developed. By varying the combinations of 
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encapsulated fluorophores, the FRET mediated emission signature can be tuned in such a way 
that the particles exhibit different colors after excitation at a single wavelength. Therefore, a 
large number of encoded nanoparticles can be generated from a combination of limited number 
of individual fluorophores. The first example of this kind of particles is silica nanoparticles in 
which three different organic fluorophores i.e. fluorescein, Rhodamine 6G (R6G) and 6-
carboxyl-X-Rhodamine (ROX) were incorporated [205]. These fluorophores were carefully 
selected based on their overlapping emission and excitation spectra in order to allow efficient 
energy transfer. By doping different combination of three fluorophores, barcoded particles with a 
single wavelength excitation were produced for multiplexed and multicolor imaging. These 
nanoparticles were subsequently used for simultaneous monitoring and identification of multiple 
bacteria or cancer cells [213, 214]. Polymeric nanospheres encapsulating with phosphorescent 
ruthenium metal-ligand complex and cyanine derivatives were applied to time-resolved 
multiplexed bioassays [215]. Apart from multiplexed applications, FRET based nanoparticles 
can also be employed to monitor the integrity of nanoparticles, as the energy transfer is highly 
dependent on the distance between the donor and acceptor molecules (1−10 nm). For example, 
polymeric micelles encapsulating a FRET pair (DiO and Dil) showed a significant change in 
FRET efficiency upon the release of fluorophore molecules, which could be useful for 
monitoring the stability of polymeric micelles in both in vitro and in vivo systems.       
1.4. Thesis objective 
Polymer-based nanomaterials are one of the few materials injected into the body that are 
easily degraded by body’s natural metabolic pathways. They can be synthesized by using 
polymers or peptides that allow them to mold to various materials, which can act as delivery 
cargo for therapeutic agents. Furthermore, their unique structure also makes them ideal carriers 
29 
 
for diagnostic molecules. There exists other materials that may have ideal characteristics of 
delivery cargo, but polymer-based nanomaterials have the most desirable combination of safety, 
biocompatibility, stability, and theranostic platform for variety of applications.     
This dissertation seeks to develop and investigate novel polymeric nanomaterials for 
several applications that range from in vitro multiplex imaging to in vivo optical imaging. A 
systematic approach is reported for the development of fluorophore-doped nanoparticles.  
The specific goals of this Ph.D thesis are as follows:  
 Chapter 1: Design and evaluation of FRET-based polymeric nanoparticles for in vivo 
NIR and FRET imaging.  
 Chapter 2: Design and evaluation of multiple fluorophores doped nanoparticles for 
multicolor and multiplexed imaging.  
 Chapter 3: Evaluation of peptide-based nanofiber as a carrier for tumoral delivery 
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CHAPTER 2. DEVELOPMENT OF BIOCOMPATIBLE POLYMERIC 
NANOPARTICLE FOR IN VIVO NIR AND FRET IMAGING
*
 
* Published in Bioconjugate Chem., 2012, 23 (5), pp 981–992, DOI: 10.1021/bc200637h) 
(Copyright © 2012 American Chemical Society) 
 
2.1. Abstract 
The majority of near-infrared (NIR) fluorophores are organic molecules that show 
significant overlapping between the excitation and emission spectra and therefore exhibit high 
fluorescence backgrounds during in vivo imaging. Recently, cyanine dyes with a large Stokes 
shift have shown great promises for NIR imaging but often undergo rapid photo-degradation and 
non-specific protein adsorption. Alternatively, fluorescence resonance energy transfer (FRET) is 
a promising technique to generate a larger gap between the excitation and emission maxima and 
thus can reduce the background signal. Here, we report the rational design of FRET-based 
polymeric nanoparticles for NIR imaging. The particles were assembled from diblock 
copolymers of poly(D,L-lactic-co-glycolic acid) and maleimide-activated polyethylene glycol, 
which were also encapsulated with both the donor (1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine) and acceptor (1,1'-dioctadecyl-3,3,3',3'-
tetramethylindotricarbocyanine) fluorophores. Because of their extreme hydrophobicity, 
thousands of fluorophores could be encapsulated inside a single particle without causing leakage. 
FRET resulted in a large Stokes shift (>100 nm) of the emission maxima and the transfer 
efficiency could be fine-tuned by further adjusting the doping ratio of the donor and acceptor 
fluorophores. The optimized formulation was less than 100 nm in size, brighter than quantum 
dots, stable in human serum, and demonstrated the similar biodistribution to most nanomaterials. 
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Additional animal phantom studies demonstrated that the developed FRET imaging platform 
could have far-reaching applications in optical imaging. 
2.2. Background 
Optical imaging has become an emerging diagnostic tool that provides several 
advantages, including higher sensitivity, lower cost, and avoidance of using ionizing radiation, 
over other imaging modalities [8]. Optical contrast agents are often required to enhance detection 
sensitivity in vivo. To improve tissue penetration, most contrast agents are incorporated with 
fluorescence reporters that excite and emit photons at the NIR region (650-900 nm) [216]. The 
majority of these reporters are organic molecules that exhibit high background fluorescence 
while imaging, because of the small Stokes shift (difference between the excitation and emission 
maxima of the fluorophore). Alternatively, heptamethine cyanine fluorophores with a larger 
Stokes shift (>100 nm) can be synthesized [217, 218]. These fluorophores are water soluble and 
could be easily coupled with a variety of the biological entities including biomolecules such as 
antibodies, and peptides. However, due to their rapid photo-degradation, nonspecific protein 
adsorption, and biological or chemical degradation, they are not suitable for long term imaging 
[15, 219]. Inorganic fluorescent nanocrystals such as quantum dots (QDs) can be used as an 
alternative [199]. They are known to be more sensitive (brighter) and less susceptible to photo-
degradation than organic fluorophores but the unsure long-term toxicities hinder their future 
application in the clinical settings [200].  
One of the approaches to improve the stability of fluorophores is through doping them 
into/onto nanoparticles [220, 221]. Fluorophores molecules can be incorporated into the 
nanoparticles via ionic interaction, entrapment or covalent conjugation [93]. Unlike organic 
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fluorophores, nanoparticles-based contrast agents are less prone to the rapid photobleaching and 
thus allowing long-term and sensitive tracking of the signal. Furthermore, nanoparticles possess 
unique physiochemical properties that can be exploited in specific disease conditions. For 
example, in cancer, these contrast agents may accumulate at the tumor site via EPR phenomenon 
and thus helps in the early detection. Another advantage of nanoparticles is that more than one 
type of fluorophores can be easily incorporated inside single nanoparticle to favor the FRET 
[205], a process that transfers radiationless energy from an excited state donor fluorophore to a 
ground state acceptor molecule via dipole-dipole interaction [222-224]. Since the energy transfer 
highly depends on the distance between the donor and acceptor molecules (1-10 nm), FRET can 
be also employed to monitor the integrity of nanoparticles. For example, polymeric micelles that 
were encapsulated with FRET pair (DiO and Dil) showed a significant change in FRET 
efficiency upon the release of fluorophore molecule and thus could be useful for monitoring the 
stability of polymeric micelles in both in vitro and in vivo systems [225-227]. However, the 
employed FRET pairs did not absorb and/or emit photons at the NIR region and therefore 
potentially limited their use for in vivo applications [198]. Until now, no one has explored the 
utility of FRET in the development of a NIR contrast agent for in vivo imaging.  
In the present study, we report the development of biocompatible polymeric nanoparticles 
for in vivo NIR and FRET imaging. These particles are composed of diblock copolymers of 
poly(D,L-lactic-co-glycolic acid) (PLGA) and maleimide-activated polyethylene glycol (PLGA-
PEG3500-maleimide) [228], and were encapsulated with two lipophilic NIR fluorophores, DiD 
and DiR, as the donor and acceptor, respectively (Figure 6) [150]. One of the advantages of 
FRET over single fluorophores as the optical reporters is that it has a relatively larger gap 
between the excitation and emission and thus can significantly reduce the background while 
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imaging [217]. It is important to note that the observed FRET transfer was efficient, even if there 
was a smaller overlap between the emission spectra of the donor (DiD) and the excitation spectra 
of the acceptor (DiR) (Table 5) as compared to previously reported Di-series analogues (DiO 
and Dil) [226, 227]. Energy transfer from DiD to DiR resulted in a decrease of the emission 
maxima at 668 nm and was accompanied with an increase of the emission maxima at 795 nm. 
We further demonstrated that these nanoparticles have tremendous potential for in vivo imaging.  
2.3. Experimental procedures 
2.3.1. Chemicals and materials 
All solvents were purchased from Fischer Scientific (Pittsburgh, PA). Poly(D,L-lactic-co-
glycolic acid) (PLGA-COOH, monomer ratio 50:50, 17 kDa) was received as gift samples from 
PURAC Biomaterials (Netherland). Maleimide-activated PEG (Mal-PEG3500-NH2, 3.5 kDa) was 
purchased from JenKem Technology USA, Inc. (Allen, TX). 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD) and 1,1'-dioctadecyl-
3,3,3',3'-tetramethylindotricarbocyanine iodide (DiR), and Qdot® 800 ITK™ carboxyl quantum 
dots (QDs-800) were obtained from Life Technologies Corporation (Grand Island, NY). Cy5 and 
Cy7 monofunctional hydroxysuccinimide ester were purchased from GE Healthcare Biosciences 
(Piscataway, NJ). Trilite™ fluorescent nanocrystal 665 nm (QDs-665) was purchased from 
Cytodiagnostics, Inc. (Burlington, Ontario). Uranyl acetate and copper grids were obtained from 
Electron Microscopy Sciences (Hatfield, PA). 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and N-hydroxysuccinimide (NHS) were purchased from Advanced ChemTech 
(Louisville, KY) and Alfa Aesar (Ward Hill, MA), respectively. Bovine serum albumin (BSA), 
N,N-diisopropylethylamine (DIEA),  20% (w/v) Intralipid emulsion, and agar powder were 
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obtained from Sigma-Aldrich (St. Louis, MO). Whole blood was purchased from Biochemed 
Services (Winchester, VA). Ellman’s reagent was purchased from Enzo Biochem, Inc. (New 
York, NY). CellTiter 96
®
 AQueous One Solution Cell Proliferation Assay (MTS) was provided 
by Promega Corporation (Madison, WI).  
2.3.2. Synthesis of polymeric constructs (PLGA-PEG3500-maleimide) 
 The copolymer was synthesized by standard carbodiimide chemistry, as previously 
described [164]. PLGA-COOH (1 g, 0.06 mmoL) dissolved in anhydrous dichloromethane 
(DCM, 10 mL) was activated by adding excess NHS (0.035 g, 0.30 mmoL) and EDC (0.056 g, 
0.30 mmoL). After 4 h, the activated PLGA-NHS ester was precipitated in ice cold diethyl ether 
(25 mL), washed with a mixture of ice cold methanol and diethyl ether (30:70, 3 × 5 mL) to 
remove the unreacted NHS, and dried under the vacuum. The collected precipitate (0.8 g, 0.047 
mmoL) was then dissolved in chloroform (8 mL). Mal-PEG-NH2 (0.217 g, 0.062 mmoL) was 
then added to the solution mixture, in the presence of DIEA (0.028 g, 0.22 mmoL). The solution 
mixture was stirred in the dark for 12 h at room temperature. The copolymer was then 
precipitated in ice cold diethyl ether (25 mL) and washed with ice cold methanol (3 × 5 mL) to 
remove the unreacted PEG. The final product, PLGA-PEG3500-maleimide, was dried under the 
vacuum to remove the residual solvents and further characterized by 
1
H-NMR spectroscopy. 
1
H-
NMR (400 Hz, CDCl3): δ 6.70 (2H, -CH=, s), δ 5.22 (1H, –C(O)CH(CH3)O–, m), δ 4.83 (2H, –
C(O)CH2O–, m), δ 3.64 (4H, –OCH2CH2–, s), δ 1.58 (3H, –C(O)CH(CH3)O–, dd). 
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2.3.3. Nanoparticle assembly  
All the nanoparticles were fabricated by the nanoprecipitation method as previously 
described in chapter 1.2.1.1 [229, 230]. The single fluorophore-doped nanoparticles were 
synthesized by mixing PLGA-PEG3500-maleimide (2 mg) with different amounts of DiD or DiR 
fluorophores (0.05 to 3% w/w) in DMF (0.2 mL). The solution mixtures were then added 
dropwise to deionized water (2 mL). The resulting particles were allowed to stir for 2 h at room 
temperature. Nanoparticles were then purified by ultracentrifugation (3000 × g, 15 min) using 
SPIN-X UF concentrators with 10 kDa MWCO (Corning Incorporated, Lowell, MA) and washed 
with deionized water (2 × 5 mL) to remove the free fluorophores. The purified nanoparticles 
were re-suspended in deionized water (0.2 mL) and stored at 4°C. Using the same protocol, 
FRET nanoparticles (FRET-NPs) were synthesized by adding a mixture of DiD and DiR 
fluorophores (1:1 ratio) to the copolymer. 
2.3.4. Physical characterization of the particles 
Particle size and zeta potential were measured by dynamic light scattering (Zetasizer, 
Malvern Instruments, Worcestershire, U.K.). The equipment was first calibrated according to the 
manufacturer’s instruction, using the certified zeta potential transfer standard (DTS1050). For 
the size measurement, the samples (0.2 mg/mL) were loaded in a disposable polystyrene cuvette. 
All measurements were recorded with the same particle concentration in deionized water at 
25°C. The solvent parameters such as refractive index and viscosity were set at 1.33 and 0.8872 
cP, respectively. The intensity-weighted mean values were recorded as the average of three 
independent measurements. The zeta potentials of the particles (0.2 mg/mL) were measured in a 
disposable capillary cell (Malvern Instruments, Worcestershire, U.K).  
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The surface morphology and the size of the particles were confirmed by high resolution 
transmission electron microscope (JEM-2100, Jeol Ltd., Peabody, MA). Samples were 
negatively stained with uranyl acetate [231]. Briefly, nanoparticles (2 mg/mL) in deionized water 
(10 μL) were adsorbed on to 200 mesh formvar/carbon coated grids for 5 min and the excess 
samples were blotted off by a filter paper. The grids were stained with 3% (w/v) uranyl acetate in 
deionized water (10 μL) for 5 min and then blotted off. Finally, the grids were air-dried and 
images were acquired using computer controlled camera.  
2.3.5. Determination of particle numbers 
The number of nanoparticles (n) in the stock solution was estimated as previously 
described from the following equation [232]: 
   
  
       
 ……………………………….………………………………….……………… (4) 
Where c is the polymer concentration, d is the particle hydrodynamic diameter obtained 
by dynamic light scattering, and ρp is the density of PLGA nanoparticle core (estimated to be 
1.27 g cm
-3
 at 20°C).  
2.3.6. Determination of fluorophore contents in the particles 
The fluorophore loading (% w/w) of the particles was determined by UV absorbance. The 
numbers of particles in the stock solutions were first determined by using the equation (1). The 
solution mixtures (~3 × 10
13
 particles/mL) were then freeze-dried, weighed (~ 0.5 mg), and re-
dissolved in DMSO (1 mL) to extract the encapsulated fluorophores.  The resulting mixtures 
were centrifuged (10,000 × g, 5 min) to remove any visible aggregate. The amount of 
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fluorophores in the solution mixtures were further quantified by absorbance according to our 
predetermined extinction coefficient values in DMSO (εDiD at 655 nm = 173,000 M
-1
 cm
-1
 and εDiR at 
760 nm = 207,000 M
-1
 cm
-1
).  
The percentage of fluorophore loading was calculated from the following equation [233]: 
                      
                                      
                            
       ................................. (5) 
The loading efficiency was calculated from the following equation [233]:   
                     
                                      
                                                        
       …........... (6) 
The number of fluorophores per particle was calculated from the following equation: 
                                
                                      
                                                   
 ……..….... (7) 
To accurately determine the amount of the individual fluorophore in FRET-NPs, the 
absorbance at the λmax1 and λmax2 were first corrected from the degree of spectral overlap of the 
DiD and DiR fluorophores [234]. 
2.3.7. Measurement of absorbance and fluorescence  
All measurements were recorded in deionized water at room temperature, using a sub-
microcuvette for absorbance or fluorescence (Starna Cells, Inc., Atascadero, CA). For the ease of 
comparison, all samples were diluted to the same particle number (1 × 10
12
 particles/mL) in 
deionized water (100 µL). Absorption spectra were collected from a spectrophotometer 
(Spectramax, Molecular Devices, LLC, Sunnyvale, CA). Fluorescence spectra were measured on 
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a spectrofluorometer (Cary Eclipse, Agilent Technologies, Inc., Santa Clara, CA). The DiD-
doped nanoparticles and FRET-NPs were excited at 650 nm and the DiR-doped nanoparticles 
were excited at 755 nm. Fluorescence emissions were recorded between 660 to 850 nm with a 
scanning interval of 0.2 nm. The excitation and emission slit widths were set at 2.5 and 5 nm, 
respectively.  
2.3.8. Measurement of extinction coefficient (ε) and quantum yield (Φ)  
The number of particles in stock solutions and the number of fluorophores in each 
particle were first determined from equations (4) and (7), respectively. The extinction coefficient 
of the particles (ε) was determined from the Lambert-Beer’s law [235]. Note: The extinction 
coefficient based on the amount of fluorophore (εf) was calculated by dividing the ε value with 
the total number of fluorophores in the respective particles. 
The relative quantum yield was determined in deionized water by the previously 
described comparative method [97, 236], using Cy5 and Cy7 as the reference standards for DiD- 
and DiR-doped nanoparticles, respectively [150]. Each particle sample was prepared in a series 
of four dilutions (0.1-0.5 µM of the fluorophore). The DiD- and DiR-doped nanoparticles were 
excited at 640 and 740 nm, respectively. The entire ﬂuorescence spectra (from 660 to 850 nm) 
were then recorded and integrated using the Prism software (GraphPad Software, Inc., La Jolla, 
CA). The relative quantum yield was then calculated from the following equation as previously 
described [237]:   
      (
 
  
) (
  
  
 )………………………………….………………....…..…...……………… (8) 
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Where, Φ and ΦR are the quantum yields of the sample and its corresponding reference, 
respectively; M and MR are the slopes calculated from a plot of the absorbance at excitation 
wavelength versus the integrated ﬂuorescence spectra, and n is the refractive index of the 
solvent, i.e. deionized water.  
2.3.9. Calculation of net FRET (nFRET), FRET ratio (RFRET), and FRET efficiency 
(EFRET) of FRET-NPs  
 FRET signals were converted to the net FRET value (nFRET) as previously described 
[238, 239]. Briefly, the fractional cross-talks of the DiD and DiR fluorophores in the FRET 
setting were first determined from the following equations: 
  
              (      )
             (      )
………………………………..……………………………………….. (9) 
  
              (      )
              (      )
……………………………...…...………………………....………… (10) 
Where, a = 0.04, was determined by dividing the fluorescence intensity of DiD-doped 
nanoparticles (excited at 650 nm) at the acceptor emission λmax (775 nm) with the intensity at the 
donor emission λmax (668 nm) and b = 0.03, was determined by dividing the fluorescence 
intensity of DiR-doped nanoparticles at the acceptor emission λmax (775 nm) when excited at 650 
nm with the intensity when excited at 755 nm.  
The net FRET (nFRET) was then calculated from the following equation [238]: 
                           ...…………………..………………..………..……... (11) 
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Where IFRET, IDiD, and IDiR are the fluorescence intensities of FRET-NPs at the FRET, 
DiD, and DiR settings.  The FRET ratio (RFRET) was calculated by dividing the nFRET values by 
IDiD [240].    
FRET efficiencies (EFRET) were determined according to the donor-based and acceptor-
based methods as previously described [241, 242]. Briefly, the respective steady-state 
fluorescence emission spectra (excited at 650 nm) were recorded: (1) the emission of FRET-NPs 
(FFRET; recorded at 660-850 nm), (2) emission of DiD-doped nanoparticles consisting of the 
same total fluorophore contents as the FRET-NPs (FDiD; recorded at 660-850 nm) and (3) the 
acceptor emission of DiR-doped nanoparticles consisting of the same total fluorophore contents 
as the FRET-NPs (FDiR; recorded at 660-850 nm). The emission spectra were further integrated 
using Prism software. The donor-based FRET efficiency (ED) was calculated from the following 
equation [241, 242]: 
      
∫        (  ) 
    
   
∫     
   
     (  )
 …………………...………………….……………..……….……. (12) 
The acceptor-based FRET efficiency (EA) was calculated from the following equation 
[241, 242]: 
    
             
             
(
∫        (  )  ∫       (  ) 
    
   
    
   
∫       (  ) 
    
   
  )......................................................... (13) 
Where, εDiD at 650 nm and εDiR at 650 nm are the extinction coefficients of DiD- and DiR-doped 
nanoparticles at 650 nm, respectively.  
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2.3.10. Comparison of the brightness of the particles  
The brightness of single-fluorophore doped nanoparticles was determined using a 
reflectance imaging system (In-vivo system FX, Carestream Health, Inc., Rochester, NY) as 
described previously [243]. The imaging system was equipped with a halogen lamp (150 W) as 
an excitation light source. Band pass filters (Carestream Health, Inc., Rochester, NY) were 
employed to adjust the corresponding excitation wavelengths for DiD (615/645 nm) and DiR 
(700/740 nm) fluorophores. Briefly, the particles (1 × 10
12
 particles/mL) suspended in deionized 
water (100 µL) were added to the wells of a clear-bottom 96-well black plate (Corning 
Incorporated, Lowell, MA). The plates were then exposed to the excitation light source. The 
emitted light were collected using the corresponding band pass filters (Carestream Health, Inc., 
Rochester, NY) for DiD (680/720 nm) and DiR (770/810 nm). All images were acquired with a 
single exposure time of 5 min and were further analyzed using Kodak molecular imaging 
software (Carestream Health, Inc., Rochester, NY). The region of interest (ROI) of individual 
wells was selected for the determination of the relative fluorescence intensities.  
The brightness of the particles was also compared with the commercially available 
quantum dots (QDs-650 and QDs-800) using a spectrofluorometer (Cary Eclipse, Agilent 
Technologies, Inc., Santa Clara, CA). The samples were first diluted to the same number of 
particles (1-5 × 10
12
 particles/mL) in deionized water (100 µL). For the ease of comparison, QDs 
were prepared in a series of four different particle concentrations (1-5 × 10
12-14
 particles/mL) in 
deionized water (100 µL). The QDs were excited at 465 nm and fluorescence emissions were 
recorded (from 600 to 850 nm). 
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2.3.11. Quenching of maleimide groups of FRET-NPs  
The surface maleimide groups of FRET-NPs were neutralized by cysteine. Briefly, 
FRET-NPs (1 mg, 47 nmoL) and cysteine (0.1 mg, 820 nmoL) were dissolved in 1 mL of 
phosphate buffer (pH 8, 100 mM). After 2 h, the resultant FRET-NPs were purified by 
ultracentrifugation (15 min, 3000 × g) using SPIN-X UF concentrators with 10 kDa MWCO. 
The successful quenching of the maleimide groups was confirmed by the determination of 
unreacted cysteine using the Ellman’s reagent as previously described [244]. 
2.3.12. Synthesis of IgG-conjugated FRET-NPs (IgG-FRET-NPs)   
Free sulfhydryl groups were first introduced to IgGs amino acid sequence by reacting the 
primary amino groups of human IgG antibody (100 µg) with a 50 molar excess of 2-
iminothiolane (16.5 µL, 4mM) in PBS (200 µL, 10 mM, pH 8.0) for 2 h. The reaction mixture 
was then washed and purified by ultracentrifugation (15 min, 3000 × g) using SPIN-X UF 
concentrators with 10 kDa MWCO (Coaster, Corning, NY). The resulting thiolated IgG (50 µg) 
was then reacted with the FRET-NPs (500 µg) in PBS (0.2 mL, 10 mM, pH 7.4) for 4 h and 
further purified by size-exclusion chromatography (Sephacryl-300 HR, GE Healthcare, 
Piscataway, NJ). The successful conjugation of the IgG antibody was confirmed by UV-visible 
spectroscopy by recording the absorption at λmax=280 nm.  
2.3.13. MTS assay 
MTS assays were performed as previously described [245]. Both mouse leukemic 
monocyte macrophage (RAW 264.7) and human embryonic kidney (HEK-293) cell lines were 
obtained from American Type Culture Collection (Manassas, VA) and maintained in Dulbecco's 
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Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 
penicillin (50,000 units/L), and streptomycin (50 mg/L) at 37°C. The cells (5000/well) in 
complete DMEM medium (100 µL) were seeded in a clear bottom 96-well plate (Corning 
Incorporated, Lowell, MA). After 12 h, fresh complete DMEM medium (150 µL) mixed with 
FRET-NPs (0.4-2 mg/mL) in sterile PBS (50 µL) were added to the cells and incubated at 37°C. 
Cells incubated with PBS served as a negative control. After 24 h of incubation, fresh complete 
DMEM medium (100 µL) containing MTS reagent (20 µL) was added to each well and the cell 
viability was determined by measuring the absorbance (A) at 490 nm at 1 h. The percentage cell 
viability relative to the negative control was determined by using the following equation:  
(Asample)/(Acontrol) × 100% …………………………………………………………...…………(14) 
2.3.14. Hemolysis assay 
The hemocompatibility of the particles was tested on erythrocytes as previously 
described [246]. The erythrocytes were isolated from the blood by centrifugation (800 × g, 15 
min) and further washed with PBS. The stock of erythrocytes dispersion (3.5 × 10
8 
cell/mL) in 
PBS (100 µL) was mixed with FRET-NPs (0.2-2 mg/mL) in PBS (100 µL) and then incubated at 
37°C. 10% (v/v) Triton X-100 and PBS were used as the positive and negative controls, 
respectively. After 3 h, the intact erythrocytes were separated by centrifugation (800 × g, 15 min) 
and the absorbance of the supernatant (100 µL) was measured at 540 nm to detect the presence 
of the released hemoglobin. All absorption values were corrected for the intrinsic absorbance of 
the particles. The percentage of hemolysis was calculated using the following equation:  
(Asample-Anegative)/ (Apositive-Anegative) × 100……………………...…….………..……………….(15) 
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2.3.15. In vitro stability studies 
To determine the long term colloidal stability, FRET-NPs (1 mg/mL) were first 
suspended in deionized water (1 mL) and then kept at room temperature. The particle size and 
the zeta potential were measured by dynamic light scattering (DLS) for 7 days. The physical 
stability of particles was tested in different biological media as previously described [247]. 
Briefly, FRET-NPs (2 mg/mL) suspended in deionized water (500 µL) were added to different 
media (500 µL), including PBS alone, 9.0% (w/v) of BSA in PBS, and 20% (v/v) of FBS in 
minimum essential medium (MEM). Deionized water was used as a negative control. The 
solution mixtures were incubated at 37°C. At different time points, an aliquot of nanoparticles 
solutions (100 µL) was collected to measure their sizes. Similarly, the changes in the optical 
properties of the particles (0.1 mg/mL) with time was determined [226]. After each time point, 
an aliquot of nanoparticles in the media (100 µL) was collected and the fluorescence intensities 
were recorded between 660 to 850 nm after excitation at 650 nm. The FRET ratio (RFRET) was 
calculated by dividing the nFRET values by IDiD. All the FRET ratio values were normalized 
according to the corresponding samples at t=0 h (RFRET =1).  
2.3.16. Biodistribution studies 
Four to five week old female, Severe Combined Immunodeficiency (SCID) hairless 
outbred (SHO-Prkdc
scid
Hr
hr
)
 
mice (approximately 20 g in weight) were purchased from Charles 
River Laboratories (Wilmington, MA). The animals were maintained in a pathogen-free and 
temperature-controlled environment and were provided with sterilized food and water. All the 
animal experiments were performed according to the guidelines of the Institutional Animal Care 
and Use Committees (IACUC) at North Dakota State University. For the biodistribution study, 
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mice were injected with the same number of FRET-NPs (5 × 10
12
/mL) in PBS (100 µL) via tail-
vein. After 24 h, the mice were euthanized by intraperitoneal injection of pentobarbital (100 
mg/kg) and different organs including livers, hearts, bladders, kidneys, spleens, brains, lungs, 
stomachs, pancreas, and intestines were excised, washed, and imaged using a reflectance 
imaging system by employing the FRET channel (excited at 615/645 nm and recorded at 
770/810 nm). All images were collected with a single exposure time of 5 min and were further 
processed using Kodak molecular imaging software. Following imaging, each organ was 
weighed (50 mg), homogenized with DMSO (200 µL), and centrifuged (5000 × g, 5 min). The 
fluorescence intensity of the supernatant (100 µL) was recorded on a spectrofluorometer and the 
amount of FRET-NPs was quantitatively determined according to the standard curve. The 
standard curve was generated by mixing known amounts of FRET-NPs in deionized water with 
the corresponding isolated organ (50 mg) from an uninjected mouse and extracted as described 
above. All the data was normalized in unit of percentage of injected dose per gram of the tissue 
(% ID/g). 
2.3.17. Phantom studies 
For the phantom study, the mice were first euthanized by intraperitoneal injection of 
pentobarbital (100 mg/kg). A glass capillary tube (1.1 × 90 mm) filled with FRET-NPs or DiR-
doped nanoparticles (5 × 10
12
 particles/mL) in deionized water (10 µL) was then carefully 
inserted into the thoracic region via the mouth of the animal. The images were then acquired at 
the respective channels: DiD (excited at 615/645 nm and recorded at 680/720 nm), DiR (excited 
at 700/740 nm and recorded at 770/810 nm), and FRET (excited at 615/645 nm and recorded at 
770/810 nm). Water soluble QDs-800 (2.5 × 10
13
 particles/mL) in deionized water (10 µL) was 
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used as a positive control and the images were acquired with excitation at 445/485 nm and 
recorded at 770/810 nm. All images were recorded with a single exposure time of 5 min and 
were further processed using Kodak molecular imaging software. 
2.3.18. Imaging data processing and analysis 
 All the raw images were processed using PixFRET ImageJ plug-in freeware as previously 
described [248].  Briefly, the fractional cross-talk values of DiD (a = 0.09) and DiR (b = 0.26) 
fluorophores were first determined from equation (9) and (10), using the phantom containing 
only the DiD- and DiR-doped nanoparticles (2.10% w/w), respectively. The FRET image of the 
FRET-NPs phantom was then corrected for the fractional cross-talk values as well as the 
background fluorescence to obtain the nFRET image. For data analysis, the signal-to-phantom 
background ratio was determined by dividing the signal intensity of the sample with the phantom 
background at the ROIs. The phantom images of DiR-doped nanoparticles and QDs-800 were 
corrected for the background fluorescence. A constant Gaussian blur (2.0) and a threshold (1.0) 
values were applied to all the images.  
2.4. Results and discussion 
2.4.1. Synthesis of the polymeric constructs (PLGA-PEG3500-maleimide) 
The nanoparticles were composed of PLGA-PEG3500-maleimide copolymers (Figure 
6A), which were synthesized by reacting an equivalent amount of maleimide-activated 
polyethylene glycol (Mal-PEG3500-NH2) with poly(D,L-lactic-co-glycolic acid) carboxylic acid 
(PLGA-COOH) in DCM [164]. The resulting copolymer was recovered by precipitation in 
diethyl ether and further washed with methanol to remove the unreacted Mal-PEG3500-NH2. The 
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final product, PLGA-PEG3500-maleimide, was confirmed by 
1
H-NMR (Figure 7). When 
compared to the 
1
H-NMR spectrum of PLGA-COOH (Figure 8), an additional peak (-
OCH2CH2-, s) appeared at 3.64 ppm indicating that the reaction was successful [164]. A small 
peak observed at 6.70 ppm (-CH=, s) also confirmed the preservation of the maleimide groups 
[249]. The coupling efficiency of the reaction was calculated based on the relative integration of 
the peaks at 3.64 and 5.22 ppm for PEG and PLGA, respectively and was estimated to be 
approximately 50%.  
 
Figure 6. The design of FRET-NPs. (A) Nanoparticles was synthesized by nanoprecipitation 
method [164, 229]. DiD fluorophore, with excitation λmax at 644 nm and emission λmax at 665 
nm in methanol, and DiR fluorophore with excitation λmax at 750 nm and emission λmax at 780 
nm, in methanol were encapsulated inside the FRET-NPs. (B) The chemical structures of DiD 
and DiR fluorophores. (C) The close proximity between the entrapped DiD and DiR 
fluorophores favored the phenomenon of fluorescence resonance energy transfer (FRET).  
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2.4.2. Particle assembly 
All particles were assembled from the PLGA-PEG3500-maleimide copolymers by 
previously described nanoprecipitation method (Figure 6) [230]. This method is simple and does 
not require the use of surfactant or toxic solvent [250]. Nanoparticles of various sizes (65 nm to 
300 nm) can be synthesized simply by changing the solvent parameters [251] and polymer 
concentrations [164]. To synthesize nanoparticles of less than 100 nm in size, a mixture of 
copolymer constructs and fluorophores in DMF was added dropwise to deionized water. This 
procedure has been employed previously to encapsulate a large amount of hydrophobic drug 
molecules (~18% w/w) in the nanoparticles [161]. 
 
Figure 7. 
1
H-NMR spectra of PLGA-PEG-maleimide (5 mg/ml) in CDCl3.  
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Figure 8. 
1
H-NMR spectra of PLGA (5 mg/mL) in CDCl3.  
2.4.3. Physical characterization of the single-fluorophore doped nanoparticles 
DiD and DiR are carbocyanine derivatives and are conjugated with lipophilic alkyl tails 
(C18) at the imine nitrogens. The fluorophores were originally developed as organelle sensors for 
cell membrane, mitochondria, and endoplasmic reticulum [252, 253]. To investigate whether 
particles composed of PLGA-PEG3500-maleimide copolymers could be used as a fluorophore 
carrier, a series of particles encapsulated with various amounts of DiD or DiR fluorophores (0.0-
2.10% w/w) were prepared.  
Table 5. The optical properties of FRET pairs. 
FRET Pair Overlap (%)* Wavelength (nm) 
DiO and Dil 61 521 
DiD and DiR 36 700 
* The percentage overlap was determined using Invitrogen fluorescence spectra viewer. 
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Figure 9. The transmission electron microscope (TEM) images of (A) blank nanoparticles, (B) 
DiD-doped nanoparticles (0.72% w/w), and (C) DiR-doped nanoparticles (0.74% w/w). The 
particles were negatively stained with uranyl acetate (3% w/v) (Scale bar = 50 nm). 
Table 6. The physical properties of single fluorophore-doped nanoparticles. 
NPs Fluorophore Content Loading 
Efficiency 
(%) 
Particle 
Size 
(nm) 
Zeta 
Potential 
(mV) 
Polydispersity Number of 
Fluorophores/ 
Particle 
Used 
(% 
w/w) 
Loading 
(% w/w) 
0 0.00 ± 0.00 00 ± 0 57 ± 2 -17.0 ± 2.0 0.17 ± 0.02 0 
D
iD
-d
o
p
ed
 
N
a
n
o
p
a
rt
ic
le
s 
0.05 0.04 ± 0.01 88 ± 9 58 ± 2 -17.5 ± 0.5 0.15 ± 0.05 33 
0.10 0.08 ± 0.01 87 ± 11 61 ± 2 -17.7 ± 1.5 0.13 ± 0.04 70 
0.25 0.20 ± 0.04 83 ± 13 60 ± 1 -17.7 ± 1.5 0.16 ± 0.05 161 
0.50 0.38 ± 0.05 75 ± 10 66 ± 3 -15.4 ± 0.8 0.16 ± 0.04 419 
1 0.72 ± 0.09 72 ± 10 68 ± 5 -17.0 ± 0.7 0.14 ± 0.03 756 
2 1.46 ± 0.09 73 ± 5 71 ± 4 -16.8 ± 0.2 0.11 ± 0.03 2048 
3 2.10 ± 0.17 70 ± 6 84 ± 8 -17.3 ± 0.5 0.17 ± 0.03 4908 
D
iR
-d
o
p
ed
 
N
a
n
o
p
a
rt
ic
le
s 
0.05 0.04 ± 0.01 90 ± 7 56 ± 3 -15.2 ± 0.7 0.16 ± 0.03 31 
0.10 0.08 ± 0.02 88 ± 9 58 ± 4 -16.5 ± 0.8 0.15 ± 0.02 68 
0.25 0.20 ± 0.03 80 ± 10 64 ± 2 -16.3 ± 0.9 0.17 ± 0.04 205 
0.50 0.38 ± 0.08 76 ± 14 60 ± 3 -18.2 ± 0.3 0.15 ± 0.01 323 
1 0.74 ± 0.04 75 ± 4 61 ± 4 -17.1 ± 1.8 0.11 ± 0.02 666 
2 1.50 ± 0.18 76 ± 9 72 ± 4 -15.6 ± 2.3 0.12 ± 0.02 2295 
3 2.10 ± 0.14 69 ± 5 85 ± 5 -16.0 ± 1.0 0.15 ± 0.03 5104 
 The DiD and DiR fluorophores were chosen because of their extreme hydrophobicity, 
therefore hundreds to thousands of the fluorophores could be easily encapsulated inside a single 
particle. Here, all the single fluorophore-doped particles synthesized were less than 100 nm, as 
the sizes were confirmed by DLS (Table 6) and TEM analysis (Figure 9). There was no 
significant difference in their zeta potentials, which suggested that the fluorophores were 
entrapped inside the hydrophobic PLGA matrices (Table 6). However, increasing the 
50 nm40k X50 nm40k X 50 nm40k X
(A) (B) (C)
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fluorophore loadings (from 0.0 to 2.10% w/w) resulted in a gradual increase of the particle size 
(from ~56 to 85 nm). 
 
Figure 10. Optical properties of the single fluorophore-doped nanoparticles. A bar chart shows 
the absorbance and fluorescence emission of (A) DiD- and (B) DiR-doped nanoparticles (0.0-
2.10% w/w). All samples consisted of the same number of particles in deionized water (1 × 10
12
 
particles/mL, 100 µL). Insets: The fluorescence images of the particles in a 96-wells plate were 
acquired by a NIRF reflectance imaging system. A plot of the normalized fluorescence 
intensities of (C) DiD- and (D) DiR-doped nanoparticles versus fluorophore loadings. The 
fluorescence intensities were normalized to same fluorophore content (400 nM). 
2.4.4. Optical properties of the single-fluorophore doped nanoparticles 
Encapsulating a large number of organic fluorophores in a single particle may cause 
significant fluorescence self-quenching, presumably because the fluorophores are constrained in 
a close proximity [254]. To compare the optical properties between the single fluorophore-doped 
nanoparticles, all particles were first diluted to the same particle concentration (1 × 10
12 
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particles/mL) prior to record the absorbance and emission spectra. Our result demonstrated that 
with increasing the fluorophore loading, both the absorbance and fluorescence emission 
increased (Figure 10A and B) and were accompanied with continuous blue-shift and red-shift of 
the absorption and emission λmax, respectively (Table 7), which suggested that the entrapped 
fluorophores were gradually experiencing an increasing hydrophobic environment [146]. 
Particles encapsulated with ~0.70% w/w of fluorophores were among the brightest (Figure 10A 
and B) and were stable from continuous light irradiation (Figure 11). On the other hand, 
significant fluorescence quenching was observed in particles with fluorophore loading ≥ 0.70% 
w/w. 
 
Figure 11. Photostability of single fluorophore-doped nanoparticles. The photostability of DiD- 
(0.72% w/w) and DiR-doped nanoparticles (0.74% w/w) in deionized water were compared with 
their corresponding free fluorophores in DMF. All samples were normalized to the same 
fluorophore contents (1 µM, 10 µL). The samples were loaded into glass capillary tubes (1.1 × 
90 mm) and were continuously exposed to a 150 W halogen lamp in the homogeneous lightening 
ﬁeld for 6 h. The images were then acquired at the respective channels for every 30 min and the 
regions of interest were selected for determination of the relative fluorescence intensities. 
To study the quenching effect, we determined the quantum yield (Φ) of the particles as 
previously described [237]. For particles that consisted of a minimal fluorophore content, i.e. 
0.04% w/w, the Φ values were comparable to the corresponding free DiD and DiR fluorophores 
in methanol (Table 7) [150], as well as other reported carbocyanine derivatives [255]. As 
expected, the Φ values declined with further increase in the fluorophore content. Surprisingly, a 
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plot of the normalized fluorescence intensity (according to the total fluorophore content) versus 
the fluorophore loading revealed that quenching even occurred in particles consisting of low 
fluorophore content (Figure 10C and D). This suggested that there might be a non-uniform 
absorption of the incident light by the encapsulated fluorophores inside the particles, as reflected 
by the linear decrease in the extinction coefficient values with increasing the fluorophore 
contents (Table 7).  
Table 7. The optical properties of single fluorophore-doped nanoparticles.  
NP Fluorophore Content Absorbance 
λmax  
(nm) 
Emission 
λmax  
(nm) 
Extinction Coefficient (ε) Quantum 
Yield 
(Φ) 
Used 
(% w/w) 
Loading 
(% w/w) 
(ε) Per Particle 
x 10
7
 (M
-1
cm
-1
) 
(εf) Per Fluorophore
 
x 10
5
 (M
-1
cm
-1
)* 
D
iD
-d
o
p
ed
 
N
a
n
o
p
a
rt
ic
le
s 
0.05 0.04 ± 0.01 652 665 0.84 2.55 0.34 
0.10 0.08 ± 0.01 652 665 1.51 2.14 0.27 
0.25 0.20 ± 0.04 651 666 2.94 1.82 0.26 
0.50 0.38 ± 0.05 650 667 5.99 1.43 0.21 
1 0.72 ± 0.09 650 668 10.7 1.42 0.10 
2 1.46 ± 0.09 650 668 19.5 0.95 0.05 
3 2.10 ± 0.17 649 668 37.1 0.75 0.02 
D
iR
-d
o
p
ed
 
N
a
n
o
p
a
rt
ic
le
s 
0.05 0.04 ± 0.01 759 769 0.79 2.56 0.46 
0.10 0.08 ± 0.02 758 771 1.54 2.27 0.31 
0.25 0.20 ± 0.03 755 772 3.43 1.68 0.24 
0.50 0.38 ± 0.08 755 774 4.94 1.53 0.16 
1 0.74 ± 0.04 755 773 8.61 1.29 0.08 
2 1.50 ± 0.18 755 775 27.1 1.18 0.04 
3 2.10 ± 0.14 754 781 54.8 1.07 0.02 
*The extinction coefficient per fluorophore was calculated by dividing by εf value with the 
number of fluorophores per particle. 
Next, we compared the brightest of the particles with the water soluble quantum dots 
(QDs-665 and QDs-800). The optimized DiD- and DiR-doped nanoparticles were more than 100 
and 70 times brighter than their corresponding QDs, respectively (Figure 12). 
2.4.5. FRET-based nanoparticles 
FRET is known to be affected by the distance between the donor and acceptor 
fluorophores and the orientation factor of the employed FRET pair [205]. To determine an 
optimum fluorophore loading for the efficient FRET, a series of particles were synthesized by 
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encapsulating an equal mixture of DiD and DiR but different total fluorophore contents (0.20, 
0.38, 0.72, 1.48, and 2.10% w/w) inside our developed polymeric platform. The resulting FRET-
NPs were characterized and found having the similar physical properties as the single-
fluorophore doped nanoparticles (Table 6 and 8). The two absorption maxima, λmax1 and λmax2, 
appeared in the absorption spectra of the FRET-NPs indicated the presence of both DiD and DiR 
fluorophores, respectively (Figure 13A). It was estimated that all the FRET-NPs were composed 
with 1:1 ratio of donor DiD and acceptor DiR (Table 8). 
 
Figure 12. Comparing the fluorescence intensities of the single fluorophore-doped nanoparticles 
with water soluble quantum dots. A bar chart showing the relative fluorescence intensities of (A) 
DiD-doped nanoparticles (0.72% w/w, 1 × 10
12
 particles/mL, 100 µL) and QDs-665 (1 × 10
12-14 
particles/mL, 100 µL) and (B) DiR-doped nanoparticles (0.74% w/w, 1 × 10
12
 particles/mL, 100 
µL) and QDs-800 (1 × 10
12-14 
particles/mL, 100 µL) in deionized water.  
We then compared the optical properties between all the FRET-NPs formulations by 
recording their absorbance and fluorescence spectra in deionized water (Figure 13A and B). As 
expected, the absorbance of particles increased with increase in total fluorophore content. 
Increasing the fluorophore loading from 0.20 to 2.10% w/w resulted in a significant red-shift (24 
nm) of the acceptor emission λmax (Table 9). It was found that 0.38% w/w of FRET-NPs was 
among the brightest (Table 9) and similar results were obtained when the recorded FRET 
intensities were further converted to net FRET (nFRET) in order to remove the cross-talk 
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between the DiD and DiR fluorophores [238]. On the other hand, particles consisting of 2.10% 
w/w fluorophore content were most efficient for FRET (Figure 13B) and the results were also 
confirmed by the calculated donor-based EFRET (ED) and acceptor-based EFRET (EA) values 
(Table 9) [241]. The optimized particles (2.10% w/w) were brighter than QD-800 (Figure 13D), 
but lost some of the brightness (2.5 times dimmer) when compared to the 0.38% w/w, 
presumably because of fluorophore self-quenching.  
 
Figure 13. The optical properties of FRET-NPs. (A) The absorption spectra of FRET-NPs (0.20-
2.10% w/w) in deionized water (1 × 10
12
 particles/mL, 100 µL). (B) The emission spectra of 
FRET-NPs (5 × 10
12
 particles/mL, 100 µL) in deionized water. All emission spectra were 
normalized at 666 nm and the excitation and emission slit widths were set at 2.5 and 5 nm, 
respectively. (C) Emission spectra of FRET-NPs (5 × 10
12
 particles/mL, 100 µL) after dilution in 
DMF (Solid) and deionized water (Dotted). (D) Comparison of the nFRET intensities of FRET-
NPs (0.20-2.10% w/w, 5 × 10
12
 particles/mL, 100 µL) with the fluorescence intensities of 
quantum dots (2.5 × 10
12-14 
particles/mL, 100 µL) in deionized water.  
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Table 8. The physical properties of FRET-NPs. 
To confirm the occurrence of FRET, the particles were further dissolved in DMF and the 
emission spectra were recorded with excitation at 650 nm. As expected, after decomposition, the 
FRET emission disappeared (Figure 13C). FRET-NPs also consisted of multiple thiol-activated 
maleimide groups on the surface. Therapeutic molecules such as antibody could be attached to 
the particles in the future (Figure 14). 
 
Figure 14. Conjugation of human IgG antibody to the FRET-NPs (2.10% w/w). (A) A 
comparison of the absorption spectra of free IgG (0.25 mg/mL), FRET-NPs (1 × 10
12
 
particles/mL), and IgG-conjugated FRET-NPs (1 × 10
12
 particles/mL) in deionized water (100 
µL). (B) A SDS-PAGE demonstrating that IgG was covalently attached to IgG-FRET-NPs. The 
SDS-PAGE gel (15% w/v) was loaded with IgG (2 µg), IgG-FRET-NPs (2 µg), a physical 
mixture of IgG (2 µg) and FRET-NPs (2 µg), and FRET-NPs only (2 µg). After electrophoresis, 
the gel was stained with 2% (v/v) Coomassie Blue for 1 h, de-stained overnight in deionized 
water, and imaged by Fluorchem 5500 imaging system (Alpha Innotech, Sanleandro, 
California). 
FRET-
NPs 
(% w/w) 
DiD/DiR 
Ratio 
Particle 
Size 
(nm) 
Zeta 
Potential 
(mV) 
Polydispersity Total Number of 
Fluorophores/Particle 
0.20 1:1 64 ± 3 -17.3 ± 2.5 0.18 ± 0.02 213 
0.38 1:1 69 ± 4 -17.4 ± 2.0 0.19 ± 0.01 478 
0.72 1:1 72 ± 3 -16.8 ± 1.5 0.16 ± 0.03 1065 
1.48 1:1 84 ± 5 -16.5 ± 3.9 0.17 ± 0.02 3439 
2.10 1:1 93 ± 8 -16.4 ± 0.5 0.16 ± 0.04 6563 
 
 
 
Table 9. The optical properties of FRET-NPs. 
 
FRET-NPs 
(% w/w) 
Absorbance λmax 
(nm) 
Extinction Coefficient (ε) Per 
Particle 
 
x 10
7
 (M
-1
cm
-1
)
 
FRET 
λmax  
(nm) 
FRET 
Intensity 
 
nFRET RFRET EFRET 
λmax1 λmax2 λmax1 λmax2 ED EA 
0.20 651 757 2.55 2.20 771 60 ± 7 34 ± 5 0.14 ± 0.012 0.66 0.47 
0.38 651 756 5.77 4.47 776 89 ± 15 57 ± 11 0.22 ± 0.021 0.67 0.91 
0.72 649 756 9.60 8.09 778 76 ± 23 50 ± 19 0.29 ± 0.089 0.79 1.25 
1.48 649 756 28.7 20.6 790 53 ± 11 40 ± 10 0.70 ± 0.144 0.90 1.70 
2.10 649 756 55.3 38.1 795 24 ± 8 20 ± 8 2.25 ± 0.490 0.97 2.30 
5
7
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2.4.6. The stability of FRET-NPs 
 To examine the long-term stability of FRET-NPs, the particles were monitored by DLS 
for the changes of physical behavior. FRET-NPs were found stable in deionized water, with no 
significant changes in both the size and zeta potential for 7 days (Figure 15A) [256]. In addition, 
there was no observable change in the size of FRET-NPs that were kept in PBS only or 10% 
(v/v) of FBS in MEM media (Figure 15B). However, in the presence of 4.5% (w/v) of BSA in 
PBS, the particles were slightly increased in the size after 24 h. This could be due to the 
adsorption of proteins on the particle surfaces.  
 
Figure 15. Long term stability testing of FRET-NPs. (A) The colloidal stability of FRET-NPs (1 
mg/mL) in deionized water at room temperature. The size (nm) and zeta potential (mV) 
measurements of the particles over a period of 7 days. (B) A bar chart showing the temporal 
changes in the size of FRET-NPs (1 mg/mL) in different biological media at 37°C. (C) A 
comparison of the normalized FRET ratio (Normalized RFRET) of FRET-NPs (0.1 mg/mL) versus 
time in different biological media at 37°C. The RFRET was normalized according to the 
corresponding samples at t=0 h. 
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 Similarly, there was a slight decrease in the normalized RFRET stored in 4.5% (w/v) of 
BSA in PBS or 10% (v/v) of FBS in MEM culture media, which suggested that there might be 
some leakages of the encapsulated fluorophores from the particles with time (Figure 15C).  
2.4.7. Biocompatibility of FRET-NPs   
 Next, we investigated the biocompatibility of the FRET-NPs using MTS assay (Figure 
16A). Mouse leukemic macrophage (RAW 264.7) and human embryonic kidney (HEK-293) 
cells were used as the model of phagocytic and non-phagocytic cell lines. After 24 h of 
incubation with FRET-NPs, no significant difference in the cell viability suggested that they 
were non-toxic. 
 
Figure 16. Biocompatibility and hemocompatibility of FRET-NPs. (A) The relative cell viability 
of RAW 264.7 and HEK-293 cells in the presence of FRET-NPs at 24 h. Cell viability was 
determined by MTS assay. (B) In vitro hemolysis assay. The particles were incubated with the 
RBCs for 3 h at 37°C and amount of the released hemoglobin was determined by absorbance at 
540 nm. The results were expressed as the percentage of hemolysis with respect to the positive 
control (Triton X-100). 
  We also investigated the hemocompatibility of FRET-NPs. According to the standard of 
the American Society for Testing and Materials (ASTM), if the percentage of hemolysis is > 5%, 
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the material is considered causing damage to red blood cells [246]. Here, the hemolysis assay 
was performed using isolated erythrocytes from the blood as previously described [246]. Triton 
X-100 and PBS were used as the positive and negative controls, respectively. The percentage of 
hemolysis increased in a concentration-dependent manner (Figure 16B), with 4.5% of hemolysis 
in the sample containing the highest concentration (1 mg/mL) of FRET-NPs. Our results 
indicated that FRET-NPs did not induce any damage to red blood cells and thus were considered 
to be hemocompatible.   
Table 10. The number of maleimide groups on FRET-NPs before and after reaction with 
cysteine by using the Ellman’s assay.    
Nanoparticles Before the reaction 
(nmoL) 
After the reaction* 
(nmoL) 
FRET-NPs 23.5 2.3 
2.4.8. Biodistribution of FRET-NPs   
 Next, we studied the biodistribution of FRET-NPs. To prevent the possible interaction of 
nanoparticles with the serum proteins, the maleimide groups on the particle surfaces were first 
quenched by reacting with cysteine, prior to injecting the FRET-NPs to the severe combined 
immunodeficiency (SCID) mice (n=3) by tail-vein injections. Ellman’s assay confirmed that 
nearly 85% of initial maleimide groups were quenched (Table 10). Similar to other 
nanoparticles, FRET-NPs showed a typical tissue distribution pattern with a majority of uptake 
in the liver and spleen at 24 h after injection (Figure 17A) [257]. The FRET signal in these 
organs indirectly suggested that FRET-NPs were remaining intact in the body (Figure 17B and 
C). While not a focus of this study, the length and terminal functional groups of PEG chains 
could be varied to bypass the uptake from the reticuloendothelial system in the future [11].  
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Figure 17. Biodistribution of the FRET-NPs in SCID mice. (A) A bar chart showing the organ 
distribution at 24 h after intravenous administration of FRET-NPs (5 × 10
12
/mL) in sterile PBS 
(100 µL) to the SCID mice (n=3, mean ± SEM). The (B) raw and (C) nFRET images of isolated 
organs. The mice were injected with the same number of FRET-NPs (5 × 10
12
/mL) in sterile PBS 
(100 µL) via tail-vein.   
2.4.9. Phantom studies  
Prior to administration of FRET-NPs in a preclinical animal model for imaging, phantom 
studies were performed to evaluate their efficacy as an imaging agent. An animal phantom was 
constructed to simulate the tissue fluorescence while imaging. The phantom was composed with 
a capillary tube was pre-filled with FRET-NPs, DiR-doped nanoparticles, or QDs-800 in 
deionized water, that was inserted into the thoracic region of a SCID mouse via its mouth 
(Figure 18). FRET-NPs consisting of 2.10% w/w fluorophore content were chosen in this study. 
These particles had the highest FRET efficiency (Table 9) and thus were considered more 
applicable for FRET imaging. In the present study, both the raw FRET image of FRET-NPs and 
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NIRF image of DiR-doped nanoparticles showed the similar brightness and signal-to-phantom 
background ratio (1:11) and were also more sensitive than the QDs-800 (Figure 18). Our results 
indicated that FRET-NPs had no advantage over the DiR-doped nanoparticles alone in terms of 
the detection sensitivity and the ability to increase the contrast between the tested sample and the 
animal. However, when the FRET signal was converted into nFRET as previously described 
[238], the processed image of the FRET-NPs showed significant improvement of the signal-to-
phantom background ratio (from 1:11 to 1:39), presumably as a result from removing the 
fractional cross-talk of the fluorophores and reducing the background contributed by the 
phantom (Figure 18). Similar results were also obtained when agarose was used to substitute as 
the phantom (Figure 19). Overall, our results suggested that FRET-NPs can be used for time-
resolved imaging in the future, which will further improve the spatial and temporal resolution, by 
discriminating against light scattering, reflection, auto-fluorescence, and extraneous prompt 
fluorophores [258]. 
 
Figure 18. Phantom studies in SCID mice. The (A) photo, (B) FRET, and (C) nFRET images of 
a mouse inserted with a glass capillary tube (1.1 × 90 mm) that was filled with FRET-NPs in 
deionized water (5 × 10
12
 particles/mL, 10 µL). The fluorescence images of a mouse that was 
inserted with (D) DiR-doped nanoparticles (5 × 10
12
 particles/mL, 10 µL) and (E) QDs-800 (2.5 
× 10
13
 particles/mL, 10 µL). For the data analysis, all the images were corrected for the 
corresponding background fluorescence. The signal-to-phantom background ratio was 
determined by dividing the signal intensity of the samples with the phantom at the region of 
interests (ROIs).  
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Figure 19. Phantom studies using agarose phantom. The (A) photo, (B) FRET, and (C) nFRET 
images of two glass capillary tubes (1.1 × 90 mm) filled with FRET-NPs (5 × 10
12
/mL, 10 µL). 
The tubes were placed on top of a 3% w/v agarose phantom (5 × 3 × 0.15 cm) that was 
constructed as previously described [259]. The fluorescence images of a phantom consisting of 
(D) DiR-doped nanoparticles (5 × 10
12
/mL, 10 µL) and (E) QDs-800 (2.5 × 10
13
/mL, 10 µL). 
2.5. Conclusion 
Numerous types of near-infrared (NIR) fluorescent materials such as organic 
fluorophores [73], rare-earth emitters [260], quantum dots [199], gold nanoparticles [261], long 
circulating polymers with tagged fluorophore [262], and fluorescent proteins [263] have been 
employed for in vivo imaging. However, there is only a limited number of FRET-based contrast 
agents developed for in vivo NIR imaging. In the present study, we investigated polymeric 
nanoparticles that composed of PLGA-PEG3500-maleimide copolymers as a fluorophore carrier 
and DiD and DiR fluorophores as the FRET pair. The particles (FRET-NPs) were synthesized by 
the nanoprecipitation method. The energy transfer was found more efficient in particles that 
consisted of higher fluorophore contents. The optimized FRET-NPs were brighter than the 
quantum dots, stable in biological media, and hemocompatible. Most importantly, the energy 
transfer from DiD (donor) to DiR (acceptor) fluorophore resulted in a large Stokes shift (> 100 
nm) between the excitation and emission maxima. Similar to other nanoparticles, FRET-NPs 
revealed the expected tissue distribution in mice model. For proof-of-principle, an animal 
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phantom was also constructed to demonstrate the potential imaging application of FRET-NPs. 
Our results showed that simply by applying equation (11) during image processing would 
significantly improve the signal-to-phantom background ratio. 
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CHAPTER 3. POLYMERIC NANOPARTICLES WITH SEQUENTIAL 
AND MULTIPLE FRET CASCADE MECHANISMS FOR MULTICOLOR 
AND MULTIPLEXED IMAGING
*
 
*Published in Small, Volume 9, Issue 12, pages 2129–2139, 2013, 
DOI: 10.1002/smll.201202655) (Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, 
Weinheim) 
 
3.1. Abstract  
 
The ability to map multiple biomarkers at the same time has far-reaching biomedical and 
diagnostic applications. Here, we report a series of biocompatible poly(D,L-lactic-co-glycolic 
acid) and polyethylene glycol particles for multicolor and multiplexed imaging. More than 30 
particle formulations that exhibited distinct emission signatures (ranging from the visible to near-
infrared wavelength region) were designed and synthesized. These particles were encapsulated 
with combinations of carbocyanine-based fluorophores, DiO, Dil, DiD, and DiR, and were 
characterized as <100 nm in size and brighter than commercial quantum dots. We identified (1) a 
particle formulation that simultaneously emitted fluorescence at three different wavelengths upon 
a single excitation at 485 nm (via sequential and multiple FRET cascade events) for multicolor 
imaging and (2) three other particles that displayed maximum fluorescence intensity at 570, 672, 
or 777 nm for multiplexed imaging. These particles were individually conjugated with specific 
(Herceptin or IgG2A11 antibody) or non-specific (heptaarginine) ligands for targeting and, thus, 
could be applied to differentiate different cancer cells from a cell mixture according to the 
expressions of cell-surface human epidermal growth factor receptor 2 and the receptor for 
advanced glycation endproducts. Using an animal model subcutaneously implanted with the 
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optimized particles, we further demonstrated that our developed platform could be useful for in 
vivo multiplexed imaging. 
3.2. Background 
A pool of nanoparticles that individually process distinct emission signature (when 
excited at the same wavelength) can be a useful tool for multiplexed bioassay and imaging [264]. 
In the past, many nanoparticle platforms have been tailored for in vitro applications including 
multiplexed bioassay [265], cell labeling [266], detection of cancer cells [214], and monitoring 
of bacteria [213]. Among all of these, quantum dots (QDs) were the most commonly used ones 
because of their broad excitation spectra and size-dependent tunable emission wavelengths [267, 
268]. For example, QDs with distinct luminescence emissions have been used to simultaneously 
visualizing various subcellular structures and multiple molecular markers in a single cancer cell 
[269, 270]. By combining six colored QDs, a library of one million optically encoded polymeric 
microbeads were generated for parallel and high throughput analysis [264]. Apart from these 
applications, QDs have also shown great potential as a multiplexed imaging probe in vivo. In one 
study, five different colored QDs were used for the simultaneous visualization of five distinct 
lymphatic basins in the neck and axillary region in mice [271]. In another study, QDs were 
evaluated for in vivo multiplex imaging of mouse embryonic stem cells [272]. Despite these 
successful attempts, the cumbersome synthetic procedures, sporadic blinking, and the unsure 
long-term toxicity often hinder their in vivo applications [273, 274].  
Nanoparticles assembled from other materials such as silica, polystyrene, and gold have 
also been explored for multiplexed applications [204, 275, 276]. These particles were often 
designed with the encapsulation of more than two different but complementary organic and/or 
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inorganic fluorophores, in order to create a fluorescence resonance energy transfer (FRET) 
cascade upon excitation [204, 205]. With such design, a desired emission signature could be 
fine-tuned by changing the choice, the amount, and the ratio of the fluorescence entities [204, 
205]. For example, silica nanoparticles encapsulated with fluorescein and a variety of rhodamine 
analogues have been used for simultaneous monitoring of multiple bacteria or cancer cells [213, 
214]. Polymeric nanospheres co-encapsulated with phosphorescent ruthenium metal-ligand 
complex and cyanine derivatives were applied to time-resolved multiplexed bioassays [215]. The 
advantage of this approach is that the particles can provide an optimal environment to enhance 
the brightness of the fluorophores [145]. Furthermore, the consequence of FRET cascade could 
further increase the Stokes Shift of the emission maxima and thus significantly minimize the 
crosstalk between the excitation and emission spectra [277].  
We have recently reported fluorophore-doped poly(D,L-lactic-co-glycolic acid) and 
polyethylene glycol (PLGA-PEG) nanoparticles for FRET and NIR imaging [278]. These 
particles were nontoxic, photo-stable, and brighter than QDs. In the present study, we further 
synthesized more than 30 particles with diverse emission patterns, ranging from the visible to 
near-infrared (NIR) wavelength region (500 to 790 nm), for multicolor and multiplexed imaging. 
These particles were encapsulated with a combination of four lipophilic carbocyanine 
fluorophores, including 3,3'-dioctadecyloxacarbocyanine (DiO), 1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine (Dil), 1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine 
(DiD), and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine (DiR). Simply by changing 
the amount as well as the ratio of the doped fluorophores, the optical property of the particles 
could be fine-tuned to display distinct or multiple emission λ maxima (λmax). We further 
selected three of the optimized formulations and utilized them as a multiplexed imaging 
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platform. Each of the particles exhibited a distinct emission maximum at 570, 672, or 777 nm. 
By attaching targeting antibodies (including Herceptin and IgG2A11) to individual particles, we 
demonstrated that the combined multiplexed platform could be applied for imaging the human 
epidermal growth factor receptor 2 (HER2) and receptor for advanced glycation endproducts 
(RAGE) simultaneously in a mixture of breast cancer (SK-BR-3) and melanoma (WM-115-
RAGE) cell lines. Here, multiple transduction domains (RRRRRRRC) were also attached to one 
of the particles for cell labeling. 
3.3. Experimental procedures 
3.3.1. Chemicals and materials 
All solvents were purchased from Fischer Scientific (Pittsburgh, PA). Poly(D,L-lactic-co-
glycolic acid) (PLGA-COOH, monomer ratio 50:50, 17 kDa) was received as a gift sample from 
PURAC Biomaterials (Netherland). Maleimide-activated PEG (Mal-PEG3500-NH2, 3.5 kDa) was 
purchased from JenKem Technology USA, Inc. (Allen, TX). Uranyl acetate and formvar/carbon 
coated grids (200 mesh) were obtained from Electron Microscopy Sciences (Hatfield, PA) and 
SPI Supplies/Structure Probe, Inc. (West Chester, PA), respectively. Trilite™ fluorescent 
nanocrystal 665 nm (QDs-665) was purchased from Cytodiagnostics, Inc. (Burlington, Ontario). 
DiO, Dil, DiD, DiR, Hoechst 33342, and Qdot
®
 800 ITK™ carboxyl quantum dots (QDs-800) 
were obtained from Life Technologies Corporation (Grand Island, NY). N-hydroxysuccinimide 
(NHS) and 9,10-phenanthrenequinone were obtained from Alfa Aesar (Ward Hill, MA). 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide (EDC) and N,N-diisopropylethylamine (DIEA) were 
purchased from Advanced ChemTech (Louisville, KY) and Sigma-Aldrich (St. Louis, MO), 
respectively. Herceptin antibody was purchased from Genentech, Inc. (South San Francisco, 
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CA). The IgG2A11 antibody was a generous gift from Dr. Estelle Leclerc. Heptaarginine peptide 
(RRRRRRRC) was custom synthesized at Tufts Medical School (Boston, MA). 
3.3.2. Synthesis of PLGA-PEG copolymer  
 The PLGA-PEG-Mal copolymer was synthesized by reacting poly(D,L-lactic-co-glycolic 
acid) carboxylic acid (PLGA-COOH) with maleimide-activated poly(ethylene glycol) (Mal-
PEG3500-NH2), employing the standard carbodiimide chemistry, as previously described [164, 
278]. After synthesis, the copolymer was purified and dried under vacuum to remove the residual 
solvents. The resulting PLGA-PEG-Mal was characterized by 
1
H-NMR spectroscopy [278]. 
3.3.3. Synthesis of nanoparticles 
 All the nanoparticles were prepared in an aqueous environment by the nanoprecipitation 
method [164]. Briefly, the PLGA-PEG-Mal copolymer (1 mg) together with different amounts 
and ratios of DiO, Dil, DiD, and DiR fluorophores were dissolved in DMF (100 µL) and then 
added dropwise to deionized water (1 mL). The resulting nanoparticle suspensions were allowed 
to stir for 2 h at room temperature, and the organic solvent was removed by ultracentrifugation 
(3000 × g, 15 min) using SPIN-X UF concentrator with a 10 kDa MWCO (Corning 
Incorporated, Lowell, MA). The samples were purified by washing with deionized water (2 × 1 
mL). The purified nanoparticles were resuspended in deionized water (100 µL) and stored in the 
dark at 4°C.  
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3.3.4. Physical characterization of nanoparticles 
The size (hydrodynamic diameter) and zeta potential of the nanoparticles were measured 
by dynamic light scattering (DLS) using a Zetasizer (Malvern Instruments, Worcestershire, 
U.K.) equipped with a dynamic light scattering detector (5 mW laser, incident beam 633 nm), as 
previously described [278]. The nanoparticles (0.3 mg/mL) were suspended in deionized water 
(1 mL), and the intensity-weighted mean values were recorded as the average of three 
independent measurements.  
3.3.5. Transmission electron microscopy (TEM)  
A drop of particle suspension (0.5 mg/mL) in deionized water was adsorbed on to 200 
mesh formvar/carbon coated grids for 2 min, and the excess sample was blotted by using a filter 
paper. All the samples were then negatively stained with freshly prepared 2% (w/v) uranyl 
acetate in deionized water (10 µL) for 1 min. The grids were washed with deionized water and 
then air-dried. The images were acquired by transmission electron microscope (JEOL 100CX, 
JEOL USA, Inc. Peabody, MA). 
3.3.6. Determination of the particle brightness  
The brightness levels of T3 and M5 were compared with the corresponding commercial 
water-soluble QDs, QDs-665 and QDs-800, respectively, using a spectrofluorometer (Cary 
Eclipse, Agilent Technologies, Inc., Santa Clara, CA). The same numbers of particles (5 × 
10
11/mL) were diluted in deionized water (100 μL). For the ease of comparison, QDs with three 
different particle concentrations (2.5-5 × 10
11-12
/mL) were prepared. The fluorescence spectra of 
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all the particles were recorded upon excitation at 485 nm. IFRET was referred to the fluorescence 
intensity of the acceptor (at λmax) upon excitation of the donor (at λmax).  
The brightness of the particles (5 × 10
11
/mL) was also compared with the QDs using a 
reflectance imaging system (In vivo system FX, Carestream Health, Inc., Rochester, NY), as 
previously described [243, 254]. The particles (5 × 10
11
/mL) suspended in deionized water (100 
μL) were added to the wells of a clear-bottom 96-wells black plate (Corning Incorporated, 
Lowell, MA). The plates were exposed to the excitation light source equipped with an excitation 
band-pass filter for DiO (445-485 nm). The images were acquired using the corresponding 
emission band pass filters for DiD (680-720 nm) and DiR (770-810 nm). All the images were 
acquired with a single exposure time of 5 min and were further analyzed using the Kodak 
molecular imaging software (Carestream Health, Inc., Rochester, NY).  
3.3.7. Synthesis of thiolated antibody 
The free amino groups of the antibody were converted into sulfhydryl groups by using 
Traut’s reagent [278]. Briefly, excess 2-iminothiolane (1 mM, 6.7 µL) was added to the antibody 
(6.7 µM, 100 µL) in PBS buffer (10 mM, pH 8.0) containing ethylenediaminetetraacetic acid (10 
mM). After 2 h, the thiolated antibody was further washed and purified by ultracentrifugation 
(3000 × g, 15 min) using SPIN-X UF concentrator with a 10 kDa MWCO (Corning 
Incorporated, Lowell, MA).  
3.3.8. Conjugation of targeting ligands 
The targeting ligands were conjugated to the nanoparticle surfaces employing the thiol-
maleimide chemistry [279]. The thiolated antibody (50 µg) or RRRRRRRC peptide (50 µg) was 
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added to the maleimide-activated nanoparticles (500 µg) in PBS buffer (200 µL, 10 mM, pH 8.0) 
and allowed to react for 2 h at room temperature. The unreacted maleimide groups of 
nanoparticles were neutralized by the addition of cysteine (50 µg) in the reaction mixtures, and 
further incubated for 30 min at room temperature [278]. The resulting particles were purified by 
size exclusion chromatography (Sephacryl-300 HR, GE Healthcare, Piscataway, NJ), using PBS 
buffer (10 mM, pH 7.4) as an eluent. The successful conjugation of the peptide and antibody was 
confirmed by the absorbance at 205 and 280 nm, respectively, by UV-visible spectroscopy. The 
successful quenching of free maleimide groups was confirmed by the quantification of unreacted 
cysteine using Ellman’s reagent, as previously described [278]. 
3.3.9. Determination of the number of targeting ligands  
The total number of nanoparticles (N) in stock solution was determined by using the 
following equation [278].  
   
  
       
 ………...…………………….……………………..………..….……………… (16) 
Where c is the polymer concentration, d is the hydrodynamic diameter of particles 
determined by dynamic light scattering, and ρp is the density of PLGA nanoparticle core 
(estimated to be 1.27 g cm
-3
 at 20°C).  
The amount of antibodies conjugated to the particles was determined by microBCA assay 
(Thermo Fisher Scientific, Inc., Rockford, IL). Briefly, the antibody-conjugated particles (1 
mg/mL) in PBS buffer (150 µL) were mixed with bicinchoninic acid (BCA) reagent (150 µL) 
and then incubated for 2 h at 37°C. The unmodified nanoparticles were used as a blank. The 
samples were cooled to room temperature in order to measure the absorbance at 562 nm. The 
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corrected absorbance was converted into the actual amount according to a standard curve 
prepared by using known concentrations of albumin standards (1-160 µg/mL). 
The amount of peptides conjugated to the particles was determined by measuring the 
arginine content [280]. Briefly, the peptide-conjugated particles (1 mg/mL) in PBS buffer (50 
μL) were mixed with 9,10-phenanthrenequinone (30 μg/mL) in ethanol (150 μL) and NaOH (2N, 
25 μL) and then incubated for 3 h at 60ºC. An equal volume of HCl (1.2 N, 200 μL) was added 
to the reaction mixture (200 μL), which was then incubated for 1 h at room temperature. The 
fluorescence intensity at 395 nm was recorded upon excitation at 312 nm. The amount of the 
peptide was quantified according to a standard curve generated by using known concentrations 
of free peptide (1-20 µg/mL). 
The number of targeting ligands in the solution was then determined by multiplying the 
amount of the antibody or peptide (nmoL) by Avogadro's number. Finally, the number of 
targeting ligands per nanoparticle (n) was calculating using the following equation: 
  
                                  
 
………….……………………..…….…………..………… (17) 
3.3.10. Estimation of distance between fluorophores  
The average distance between the fluorophores in solution and inside particles was 
estimated by using the following equations, as previously described [281].   
   
    
 
……………………………………………………………...…………………..….... (18) 
  √ 
 
……………………………………………………………………..…………….....… (19) 
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Where VF is volume of a single fluorophore (nm
3
), C is concentration (M), and d is 
average separating distance (nm).  
The volume of a single fluorophore inside nanoparticles was estimated using the 
following equation:  
   
  
  
…………………………………………………………..………………………..…... (20) 
Where VT is the total volume of a single particle (nm
3
) and nF is the estimated total 
number of fluorophores in a single particle, as previously described [278].  
3.3.11. Lifetime measurements 
All the fluorescence lifetime measurements were performed on a fluorescence-lifetime 
instrument obtained from Photon Technology International (PTI). The light emitting diodes 
(LEDs) with the power output at 495 nm was used as a excitation source and emitted light was 
detected at an 90°c angle using a emission monochromator set at 505 nm. A total of 10000 
photon counts were collected. The contribution of the instrument response function (Prompt) was 
corrected from the fluorescence decay curves of nanoparticles. The corrected decay curves were 
fitted in two-exponential model to obtain the individual lifetime (T1 and T2) with their relative 
amplitude (β1 and β2) of the individual samples. The global average lifetime was obtained by the 
following the equation.  
                        ( )   
(    )  (    )
     
………………...………...………..…………(21) 
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3.3.12. Fluorescence microscopy  
The SK-BR-3 cancer cell line was obtained from the American Type Culture Collection 
(ATCC, Manassas, VA). The cells were grown in culture media supplemented with 10% (v/v) 
fetal bovine serum (FBS), penicillin (50,000 units/L), and streptomycin (50 mg/L), as 
recommended by ATCC and maintained in 5% CO2 at 37°C under humidified conditions. The 
WM-115-RAGE cell line was maintained in an Opti-MEM medium supplemented with FBS (4% 
v/v), penicillin (100,000 units/L), streptomycin (100 mg/L), and G418 (0.1% w/v). For 
microscopic study, the cells (3000/well) were seeded on a 4-chambers slide (Thermo Fisher 
Scientific, Inc., Rockford, IL). After 12 h, the same number of particles (9 × 10
11 
/mL) were 
added to the cells in a phenol red free culture medium (400 µL) and allowed to incubate for 15 
min. Hoechst 33342 (2 μg/mL) was added to all the samples for nuclear staining 10 min prior to 
imaging. The cells were washed and then imaged under a fluorescence microscope (Olympus IX-
81, Olympus America, Inc., Melville, NY). A metal cube (Semrock, Inc., Rochester, NY) that 
was assembled with the appropriate excitation and emission band pass filters was employed. To 
acquire FRET images, the excitation band pass filter for DiO (460-500 nm) and one of the 
following emission band pass filters for Dil (525-574 nm), DiD (635-675 nm), and DiR (754-816 
nm) were manually assembled into the cube (Semrock, Inc., Rochester, NY). Images were 
recorded by a CCD camera (Hirakuchi, Hamamatsu, Japan) interfaced with a computer and were 
processed using HCImage software (Hamamatsu Corporation, Bridgewater, NJ).  
3.3.13. MTS assay 
The MTS assay was performed as previously described [245, 282]. The cancer cells 
(5000/well) were seeded in a clear bottom 96-wells plate (Corning Incorporated, Lowell, MA). 
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After 12 h, different amounts (10-500 µg) of the particles suspended in culture medium (100 µL) 
were added to the cell lines at 37°C. Cells incubated with sterile PBS buffer served as a negative 
control. After 24 h of exposure, fresh media containing the MTS reagent (Promega Corporation, 
Madison, WI) were added to each well and further incubated for 1 h  at 37°C. The formation of 
formazan dye was measured by absorbance at 490 nm (AParticle). The results were corrected from 
the intrinsic absorbance of particles at 490 nm (ABackground). The percentage of cell viability was 
determined by using the following equation:  
(AParticle- ABackground)/(APBS) × 100%............................................................................................(22) 
3.3.14. In vivo imaging studies  
All animal experiments were performed according to the guidelines of the Institutional 
Animal Care and Use Committees (IACUC) at NDSU. Four- to five-week old female severe 
combined immunodeficiency (SCID) hairless outbred (SHO-Prkdc
scid
Hr
hr
)
 
mice (20 g) were 
purchased from Charles River Laboratories (Wilmington, MA) and maintained in a pathogen-
free and temperature-controlled environment. For the imaging studies, the mice (n=3) were first 
anesthetized by intraperitoneal injection of ketamine (90 mg/kg) and phenobarbital (5 mg/kg) 
and then injected with the same number of fluorophore-doped nanoparticles (3.5 × 10
11
) or 
quantum dots (3.5 × 10
11-12
) in deionized water (10 µL) via subcutaneous route. Whole-body 
FRET imaging was performed by using a reflectance imaging system (In-vivo system FX, 
Carestream Health, Inc., Rochester, NY) [278]. All the FRET images were acquired using the 
same excitation band-pass filter for DiO (445-485 nm). The emitted light was collected using 
one of the following emission band pass filters for Dil (580-620 nm), DiD (680-720 nm), and 
DiR (770-810 nm). All the images were collected with a single exposure time of 1 min and were 
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processed by using Kodak molecular imaging software (Carestream Health, Inc., Rochester, 
NY). The signal-to-noise ratio (SNR) was calculated by dividing the average signal intensity of 
the particles at the injection site by the background of the mouse at the same region of interest 
(ROI). 
3.4. Results and discussion 
3.4.1. Design and synthesis of the particles 
 All the particles were assembled from PLGA-PEG-Mal diblock copolymers, which were 
synthesized by reacting carboxylic acid-terminated poly(D,L-lactic-co-glycolic acid) (PLGA-
COOH) with maleimide-activated amino polyethylene glycol (Mal-PEG3500-NH2), using the 
carbodiimide chemistry [278]. The reaction was confirmed by 
1
H NMR, as previously described 
[278]. Previous studies have been shown that, in aqueous media, the PLGA segments of the 
copolymers would agglomerate into a hydrophobic core, which might serve as a reservoir for 
carrying different therapeutic and imaging agents such as cisplatin, docetaxol, and indocyanine 
green [280, 283, 284]. Each assembled particle was also surrounded by a sheath of hydrophilic 
PEG and thereby expose multiple terminal maleimides at the surface for bioconjugation of the 
targeting ligand [164]. The PEG coating was able to minimize the aggregation upon storage and 
also helped to improve the circulation time in vivo [163]. By using this approach, we designed a 
series of nanoparticles with tunable emission signatures for multicolor and multiplexed imaging 
(Figure 20A and B). The particles were encapsulated by a combination of four carbocyanine 
fluorophores, with each of them attaching to a lipophilic alkyl tail (C18) at the imine nitrogen. 
Thereby, hundreds to thousands of molecules could be entrapped inside a single particle for 
safeguarding an efficient FRET [227].  
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Figure 20. Design and characterization of nanoparticles. A schematic representation of particles 
designed for (A) multicolor and (B) multiplex imaging. (C) The chemical structures of DiO, Dil, 
DiD, and DiR. (D) A comparison of the normalized absorption and fluorescence emission 
spectra among the fluorophores in methanol. (E) A TEM image of Q7. The samples were 
negatively stained with 2% (w/v) uranyl acetate in deionized water.  
 The differences among the fluorophores are the heterocyclic ring and the length of the 
polymethine bridge (Figure 20C). The heterocyclic structure offered the high extinction 
coefficient to the fluorophore, whereas the polymethine determined the absorption and emission 
λmax [234, 285]. Because of the distinct and overlapping excitation and emission spectra of the 
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fluorophores (Figure 20D), sequential FRET was prompted to occur when they were 
encapsulated inside the particle [227, 278].  
3.4.2. Particles doped with two fluorophores 
The particles were prepared by dissolving the fluorophores along with the PLGA-PEG 
copolymer in anhydrous DMF and then co-precipitated them in deionized water. The surface 
morphology and the size distribution of the resulting particles were confirmed by transmission 
electron microscopy (TEM) (Figure 20E). FRET is proportional to an inverse sixth power of the 
distance between donor and acceptor fluorophores [278, 286]. On the contrary, encapsulating a 
large number of fluorophores inside a polymeric particle could lead to fluorescence self-
quenching [145, 278]. Therefore, we first determined an optimum fluorophore loading that 
favored an efficient FRET compromised with a minimum loss of brightness of the particles. D1-
D7 were prepared by encapsulating the same ratio but different amounts (0.09 to 3.0% w/w) of 
DiO and Dil inside the particles. We observed that the average particle size of the resulting 
particles was 55 ± 9 nm (n=200) under the TEM (Figure 20E). Due to the presence of a 
hydration layer around the particles in aqueous media [287], the particles appeared to be slightly 
larger (75 ± 10 nm) when analyzed by dynamic light scattering (Table 11). Here, all the particles 
possessed the same zeta potential (-18 ± 5 mV), providing evidence that the fluorophores were 
trapped inside the hydrophobic core.  
 
 
 
 
 
 
Table 11. The physical properties of two-fluorophores doped nanoparticles.  
NPs Total Fluorophore 
Loading (% w/w) 
DiO:Dil:DiD:DiR 
Ratio 
Size 
(nm) 
Polydispersity Zeta Potential 
(mV) 
D1 0.09 1:1:0:0 66 ± 1.0 0.109 ± 0.01 -19 ± 1.4 
D2 0.21 1:1:0:0 72 ± 1.0 0.175 ± 0.04 -20 ± 0.5 
D3 0.40 1:1:0:0 75 ± 2.9 0.166 ± 0.03 -18 ± 1.0 
D4 0.80 1:1:0:0 77 ± 1.8 0.140 ± 0.01 -17 ± 0.5 
D5 1.40 1:1:0:0 80 ± 7.7 0.163 ± 0.04 -19 ± 0.6 
D6 2.10 1:1:0:0 88 ± 7.2 0.175 ± 0.02 -17 ± 0.5 
D7 3.00 1:1:0:0 107 ± 2.0 0.174 ± 0.01 -19 ± 0.5 
Table 12. The optical properties of two-fluorophores doped nanoparticles 
NPs Absorbance 
λmax (nm) 
FRET Emission 
λmax (nm) 
IFRET(DiODil) 
(A.U.) 
IFRET(DiODiD) 
(A.U.) 
IFRET(DiODiR) 
(A.U.) 
λmax1 λmax2 λmax3 λmax4 DiODil DiODiD DiODiR  
D1 488 553 N/A N/A 565 N/A N/A 28 ± 2 N/A N/A 
D2 487 553 N/A N/A 566 N/A N/A 75 ± 9 N/A N/A 
D3 486 553 N/A N/A 567 N/A N/A 121 ± 1 N/A N/A 
D4 486 555 N/A N/A 568 N/A N/A 154 ± 9 N/A N/A 
D5 486 555 N/A N/A 569 N/A N/A 185 ± 5 N/A N/A 
D6 485 555 N/A N/A 570 N/A N/A 233 ± 25 N/A N/A 
D7 485 556 N/A N/A 579 N/A N/A 283 ± 14 N/A N/A 
 
 
 
8
0
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To compare the FRET among the particles, we suspended the same number of D1-D7 in 
deionized water and then recorded their absorption and emission spectra. The presence of 
absorption maxima at 485 and 555 nm indicated that the fluorophores were encapsulated inside 
the particles (Figure 21A). When compared to the free DiO and Dil in methanol, there was a 
blue and a red shift of the absorption and emission λmax, respectively (Table 12), mainly 
because the fluorophores were facing a different environment. The two emission max that 
appeared at 505 and 570 nm upon excitation at 485 nm corresponded to the DiO and Dil 
emissions, respectively (Figure 21B). Increasing the encapsulated fluorophore contents led to a 
decrease of the DiO (acceptor) emission, which was accompanied with an increase of the Dil 
(donor) fluorescence (Figure 21B). These observations clearly demonstrated the occurrence of 
FRET from DiO to Dil fluorophores inside the nanoparticles. To confirm the occurrence of 
FRET, we measured the fluorescence lifetimes of DiO fluorophores in presence and absence of 
the acceptor (Dil). For this purpose, the particles with a low total fluorophore loading of 0.4% 
(w/w) was employed, to minimize the effect of self-quenching on the lifetime of fluorophore. 
Upon comparison, a significant reduction was observed in the excited state lifetime of the DiO 
fluorophores in presence of Dil (Figure 21C and D) and thus verified the presence of FRET. 
Assuming that the fluorophores were uniformed dispersed within the hydrophobic core of the 
particles, increasing the fluorophore contents (from 0.09 to 2.10% w/w) would decrease the 
distance between fluorophores (from 37 to 8 nm) and, thus, should favor FRET [288]. Our 
results demonstrated that D7 was among the brightest (Table 12) and significant fluorescence 
self-quenching was observed in the particles with fluorophore loading ≥ 3.0% w/w (Figure 22). 
However, its size was >100 nm (Table 11) and, thus, unlikely to be applicable for in vivo 
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because of the potential uptake by the reticuloendothelial system (RES) [82]. Therefore, D6 was 
considered to have the optimum fluorophore loading (2.10% w/w).  
 
Figure 21. The (A) absorption and (B) fluorescence spectra of two-fluorophores doped 
nanoparticles. The particles were loaded with same ratio (1:1) of the DiO and Dil fluorophores 
with the different total fluorophore loading of 0.21 to 3.00 % (w/v). (C) Fluorescence decay 
curves of the DiO emission at 505 nm in absence and presence of the Dil and DiR fluorophores 
inside the nanoparticles. To minimize the effect of concentration dependent self-quenching on 
lifetime, the particles with lower total fluorophore loading (0.4% w/w) were synthesized instead 
of the optimized fluorophore loading (2.10% w/w). Three different nanoparticle formulations i.e. 
DiO-NPs (1:0:0:0), DiO-Dil-NPs (1:1:0:0), and DiO-DiR-NPs (1:0:0:0.05) were synthesized. (D) 
A bar chart showing a comparison of the global average lifetimes of different nanoparticles. The 
individual lifetime (ns) was obtained by fitting the fluorescence decay vs. time curve of 
nanoparticles in two-exponential model. All the samples consisted of the same number of 
nanoparticles (5 × 10
11/mL) suspended in deionized water (100 μL). 
83 
 
 
Figure 22. The optical properties of two-fluorophores doped nanoparticles. A plot of FRET 
intensity (IFRET) versus fluorophore loadings. The particles were loaded with DiO and Dil 
fluorophores at the same ratio of 1:1. All the samples consisted of the same number of 
nanoparticles (5 × 10
11
/mL) suspended in deionized water (100 μL). 
3.4.3. Particles doped with three fluorophores 
Next, we investigated if FRET cascade occurred in particles encapsulated with multiple 
fluorophores. T1-T5 containing the same total fluorophore content (2.10% w/w) but different 
ratios of DiO, Dil, and DiD were synthesized (Table 13). These particles were characterized as 
above and have similar physical properties as D1-D7 (Table 11). The successful encapsulations 
were confirmed by absorbance (Figure 23A).  
 
 
 
  
 
Table 13. The physical properties of three-fluorophores doped nanoparticles.  
NPs Total Fluorophore 
Loading (% w/w) 
DiO:Dil:DiD:DiR 
Ratio 
Size 
(nm) 
Polydispersity Zeta Potential 
(mV) 
T1 2.10          1:1:0.05:0 88 ± 1.0 0.166 ± 0.03 -19 ± 1.4 
T2 2.10          1:1:0.2:0 88 ± 3.2 0.163 ± 0.03 -19 ± 0.5 
T3 2.10          1:1:0.5:0 86 ± 4.8 0.175 ± 0.04 -18 ± 1.5 
T4 2.10          1:1:0.7:0 90 ± 5.1 0.192 ± 0.02 -17 ± 0.5 
T5 2.10          1:1:1:0 82 ± 5.5 0.173 ± 0.07 -19 ± 0.6 
R1 2.10          0:1:0.05:0 80 ± 1.5 0.170 ± 0.04 -19 ± 1.5 
R2 2.10          1:0:0.05:0 81 ± 3.0 0.190 ± 0.02 -21 ± 0.5 
R3 2.10          0:0:0.05:0 82 ± 4.0 0.170 ± 0.07 -20 ± 0.6 
Table 14. The optical properties of three-fluorophores doped nanoparticles 
NPs Absorbance 
λmax (nm) 
FRET Emission 
λmax (nm) 
IFRET(DiODil) 
(A.U.) 
IFRET(DiODiD) 
(A.U.) 
IFRET(DiODiR) 
(A.U.) 
λmax1 λmax2 λmax3 λmax4 DiODil DiODiD DiODiR  
T1 491 555 654 N/A 571 672 N/A 117 ± 6 329 ± 14 N/A 
T2 491 555 652 N/A 570 672 N/A 76 ± 4 277 ± 23 N/A 
T3 491 555 652 N/A 569 672 N/A 36 ± 1 143 ± 4 N/A 
T4 491 555 652 N/A 568 673 N/A 26 ± 2 112 ± 5 N/A 
T5 490 555 652 N/A 568 673 N/A 15 ± 3 81 ± 5 N/A 
R1 N/A 556 651 N/A 575 667 N/A 37 ± 2 180 ± 15 N/A 
R2 463 N/A 651 N/A N/A 669 N/A N/A 210 ± 20 N/A 
R3 N/A N/A 651 N/A N/A 671 N/A N/A 8 ± 1 N/A 
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Figure 23. The (A) absorption and (B) fluorescence spectra of three-fluorophores doped 
nanoparticles. The particles were loaded with different ratios of DiO:Dil:DiD fluorophores at the 
same total fluorophore loading of 2.10% (w/w). (C) A fluorescence spectra of T3 after excitation 
at 485 and 650 nm. (D)  The fluorescence spectra of control particles (R1-R3) lacking one or 
more intermediate fluorophores of T1.  
 
Because of FRET cascade, upon excitation at 485 nm, all the particles displayed three 
distinct emission peaks at 502, 569, and 672 nm (Figure 23B). When compared to other 
particle platforms with a similar design [204, 205, 289], the emission max of our particles were 
more red-shifted. Among all the particles, T1 was the brightest, despite that it was encapsulated 
with the lowest amount of DiD (Figure 23B and Table 14). In contrast, T5 containing the 
highest DiD content revealed the lowest fluorescence signals. Our results suggested that DiD was 
more prompt to fluorescence quenching than DiO and Dil. Interestingly, T1 showed a complete 
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energy transfer. The particles emitted the same fluorescence upon excitation at 485 and 650 nm 
(Figure 23C). Such phenomenon was attributed to a combination of FRET cascade event and 
direct FRET from DiO to DiD, as shown by the control particles (R2) only encapsulated with 
DiO and DiD also emitted fluorescence at 669 nm, upon excitation at 485 nm (Figure 23D).   
3.4.4. Particles doped with four fluorophores 
To investigate whether we could extend the FRET cascade event to the NIR region, we 
synthesized Q1-Q5. These particles were encapsulated with the same total amount of fluorophore 
but different ratios of DiO, Dil, DiD, and DiR (Figure 24A & Table 15).  
Table 15. The physical properties of four-fluorophores doped nanoparticles. 
NPs Total Fluorophore 
Loading (% w/w) 
DiO:Dil:DiD:DiR 
Ratio 
Size 
(nm) 
Polydispersity Zeta Potential 
(mV) 
Q1 2.10          1:1:1:0.05 88 ± 6.0 0.183 ± 0.02 -19 ± 1.4 
Q2 2.10          1:1:1:0.2 92 ± 1.5 0.193 ± 0.01 -20 ± 0.5 
Q3 2.10          1:1:1:0.5 90 ± 5.0 0.167 ± 0.03 -18 ± 1.0 
Q4 2.10          1:1:1:0.7 89 ± 6.1 0.161 ± 0.03 -17 ± 0.5 
Q5 2.10          1:1:1:1 90 ± 2.0 0.187 ± 0.06 -19 ± 0.6 
Q6 2.10          1:1:0.2:0.05 89 ± 3.2 0.160 ± 0.02 -20 ± 0.6 
Q7 2.10          1:1:0.2:0.2 89 ± 4.0 0.187 ± 0.03 -21 ± 0.2 
Q8 2.10          1:1:0.2:0.5 87 ± 4.5 0.181 ± 0.02 -20 ± 2.0 
Q9 2.10          1:1:0.2:0.7 88 ± 2.9 0.187 ± 0.03 -19 ± 0.5 
Q10 2.10          1:1:0.2:1 82 ± 5.5 0.179 ± 0.03 -18 ± 0.6 
Q11 2.10          1:1:0.2:0.8 81 ± 7.5 0.172 ± 0.07 -21 ± 1.0 
Q12 2.10          1:1:0.14:0.54 84 ± 1.0 0.166 ± 0.04 -20 ± 0.4 
Q13 2.10          1:1:0.1:0.4 86 ± 0.4 0.169 ± 0.02 -18 ± 1.5 
Q14 2.10          1:1:0.067:0.27 81 ± 1.0 0.150 ± 0.07 -20 ± 2.0 
Although all the particles fluoresced at 780 nm, they were all significantly quenched 
(Figure 24B & Table 16), as shown by the fact that the signal intensities were low and 
decreased with increasing DiD and DiR contents (Figure 24C). To overcome this problem, we 
redesigned Q6-Q10 by reducing the ratio of DiD and DiR. The FRET in Q6 and Q7 were 
significantly higher as compared to Q1-Q5 (Figure 26D). However, when both the encapsulated 
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DiD and DiR contents were too low, only a small fraction of the energy was able to transfer from 
the donor to the acceptor fluorophores (Figure 24F). Because DiD and DiR were prompt to 
enact fluorescence quenching, we were unable to fine-tune a particle formulation that would only 
emit DiR fluorescence (Figure 26E and F). Nevertheless, the multiple emission pattern of Q7 
upon a single excitation should be applicable for multicolor imaging [290].  
 
Figure 24. The (A,C,E) absorption and (B,D,F) fluorescence spectra of four-fluorophores doped 
nanoparticles. 
  
 
Table 16. The optical properties of four-fluorophores doped nanoparticles. 
NPs Absorbance 
λmax (nm) 
FRET Emission 
λmax (nm) 
IFRET(DiODil) 
(A.U.) 
IFRET(DiODiD) 
(A.U.) 
IFRET(DiODiR) 
(A.U.) 
λmax1 λmax2 λmax3 λmax4 DiODil DiODiD DiODiR  
Q1 490 554 653 760 570 674 770 22 ± 4 60 ± 5 40 ± 2 
Q2 490 554 652 760 568 673 777 18 ± 1 34 ± 2 40 ± 4 
Q3 490 554 652 758 565 673 780 14 ± 2 13 ± 1 25 ± 1 
Q4 490 554 652 758 564 672 781 14 ± 2 9 ± 3 23 ± 4 
Q5 491 554 652 757 564 672 782 14 ± 3 6 ± 1 13 ± 1 
Q6 492 556 654 757 572 670 773 59 ± 6 142 ± 8 70 ± 6 
Q7 492 556 654 757 570 669 779 56 ± 5 65 ± 6 53 ± 4 
Q8 492 556 654 757 568 666 779 31 ± 3 12 ± 1 23 ± 1 
Q9 492 556 654 757 565 660 779 27 ± 3 6 ± 1 15 ± 3 
Q10 492 556 654 757 562 658 780 28 ± 2 5 ± 1 12 ± 4 
Q11 490 554 655 758 566 665 781 25 ± 4 6 ± 2 18 ± 1 
Q12 491 554 655 758 566 661 782 30 ± 4 9 ± 1 24 ± 2 
Q13 491 554 655 758 566 660 782 38 ± 4 10 ± 1 24 ± 2 
Q14 490 554 655 758 569 660 782 61 ± 6 32 ± 3 39 ± 2 
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To demonstrate the applicability of Q7 for multicolor imaging, we attached multiple 
copies of protein transduction domains (RRRRRRRC) to the particle surfaces. The successful 
conjugation of peptides to the nanoparticles was confirmed by absorbance (λmax=205 nm). Gel 
electrophoresis was also employed to ascertain the covalent conjugation of the peptides (Data not 
shown). The resulting R7-Q7 was characterized for the number of peptides attached to the 
surface by 9,10-phenanthrenequinone reagent [280] and showed increased size and zeta potential 
(Table 17 & 18). Subsequently, the particles were applied to image SK-BR-3 breast cancer cells. 
The images were acquired at three different channels (Dil, DiD, and DiR) upon a single 
excitation and were found completely overlapping with each other (Figure 25).   
Table 17. The optical properties of particles chosen as a multiplexed and a multicolor platform. 
Platform NPs DiO:Dil:DiD:DiR 
Ratio 
Color λmax 
(nm) 
IFRET*
 
(A.U.) 
Stokes Shift** 
(nm) 
Multiplexed D6 1:1:0:0 Red 570 233 ± 25 85 
T3 1:1:0.5:0 Far red 672 143 ± 4 187 
M5 1:0:0:0.05 NIR 777 120 ± 10 292 
Multicolor Q7 1:1:0.2:0.2 Red 
Far red 
NIR 
570 
669 
779 
56 ± 5 
65 ± 6 
53 ± 4 
85 
184 
294 
Abbreviations: Nanoparticles (NPs), near-infrared (NIR), FRET intensity (IFRET), and arbitrary 
unit (A.U.) *IFRET was the fluorescence intensity of the acceptor (at λmax) upon excitation of the 
DiO (at λmax) and **The Stokes shift was calculated according to the distance between the 
absorption and emission λmax.  
Table 18. The physical properties of the particles conjugated with targeting ligands.  
NPs Ligand Size 
(nm) 
Polydispersity Zeta Potential 
(mV) 
No. of 
Ligands/NP 
HER-D6 Herceptin 98 ± 5.5 0.165 ± 0.04 -18 ± 1.0 30 
RAGE-T3 IgG2A11 94 ± 5.0 0.176 ± 0.03 -15 ± 1.5 35 
R7-M5 RRRRRRRC 89 ± 3.0 0.180 ± 0.03 +10 ± 1.5 55 
R7-Q7 RRRRRRRC 88 ± 2.5 0.185 ± 0.04 +11 ± 1.0 60 
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Figure 25. Multicolor imaging. R7-Q7 (9 × 10
11
/mL, 400 µL)
 
was chosen for imaging the SK-
BR-3 cell line. The nuclei were counterstained with Hoechst 33342 (blue). (A) The bright light 
and (B-D) FRET images acquired at the Dil, DiD, and DiR channels. All the images (B-D) were 
merged into (E). (F) A merged image of the cells treated with control Q7 (9 × 10
11
/mL, 400 µL). 
The FRET images were simultaneously acquired with the same excitation at 485 nm (original 
magnification, 20X).  
Table 19.  The optical properties of FRET pairs. 
Donor : Acceptor 
Overlap 
(%)* 
Absorbance λmax of 
Donor (nm)** 
Emission λmax of 
Acceptor (nm)** 
Stokes 
Shift 
(nm) 
DiO : Dil 61 485 564 79 
Dil : DiD 40 550 665 115 
DiD : DiR 36 644 773 129 
DiO : DiR 7 485 773 288 
*The percentage overlap was estimated using Invitrogen fluorescence spectra viewer and **The 
calculation was based on the absorption and emission spectra of free fluorophore in methanol.  
To confirm that the energy was transferred from DiO to DiR in Q7, we interrupted the 
FRET cascade event by dissolving the particles in DMF. After dissolution, the original emission 
peaks disappeared and, in exchange, we observed the recovery of DiO fluorescence (Figure 
26A). We also synthesized M1-M4 to serve as controls by removing the intermediate 
fluorophores (DiD and DiR) of Q7 (Table 20 and 21). Yet M4 emitted fluorescence at 779 nm 
in the absence of Dil and DiD (Figure 26B). This phenomenon was attributed to a direct FRET 
from DiO to DiR, since the particles did not show the same fluorescence upon excitation at 555 
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or 650 nm (Figure 26C) or after dissolved in DMF (Figure 26D). The fluorescence lifetime 
studies further confirmed the occurrence of a direct FRET from DiO to DiR, even at a lower total 
fluorophore loading of 0.4% w/w (Figure 21).  
Table 20. The physical properties of two-fluorophores doped nanoparticles 
NPs Total Fluorophore 
Loading (% w/w) 
DiO:Dil:DiD:DiR 
Ratio 
Size 
(nm) 
Polydispersity Zeta 
Potential 
(mV) 
M1 2.10          0:1:0.2:0.2 83 ± 1.0 0.165 ± 0.04 -20 ± 1.4 
M2 2.10          1:0:0.2:0.2 84 ± 2.9 0.176 ± 0.03 -21 ± 0.5 
M3 2.10          1:1:0:0.2 82 ± 2.9 0.160 ± 0.03 -22 ± 1.0 
M4 2.10          1:0:0:0.2 86 ± 1.5 0.170 ± 0.01 -21 ± 0.5 
M5 2.10          1:0:0:0.05 89 ± 4.0 0.186 ± 0.01 -22 ± 1.5 
M6 2.10          1:0:0:0.1 89 ± 5.5 0.185 ± 0.02 -20 ± 0.3 
M7 2.10          1:0:0:0.5 90 ± 3.1 0.172 ± 0.02 -19 ± 1.7 
M8 2.10          1:0:0:0.7 90 ± 1.0 0.169 ± 0.02 -20 ± 0.2 
Furthermore, the control particles containing DiR alone (DiR-NPs) did not fluoresce 
upon excitation at 485 nm (Figure 26E). In fact, the calculated FRET efficiency (0.55) of M4 
was high, despite the mere 7% overlap of the absorption and emission spectra of DiO and DiR, 
respectively (Table 19). This could be explained by the relatively higher DiO content; a small 
fraction of the DiO (donor) emission was sufficient to excite the majority of DiR (acceptor). To 
confirm this hypothesis, we prepared two particles that, individually, were only encapsulated 
with the same amount of DiO or DiR as M4. As expected, there was a large overlap (>65%) of 
the emission of DiO-containing particles and the absorption of DiR-containing particles (Figure 
26F). However, we did not rule out the possibility that energy could be transferred via the 
migration of electrons along the polymeric constructs of our particles [277]. 
 
 
  
 
Table 21. The optical properties of two-fluorophores doped nanoparticles  
NPs Absorbance 
λmax (nm) 
FRET Emission 
λmax (nm) 
IFRET(DiODil) 
(A.U.) 
IFRET(DiODiD) 
(A.U.) 
IFRET(DiODiR) 
(A.U.) 
λmax1 λmax2 λmax3 λmax4 DiODil DiODiD DiODiR  
M1 N/A 555 651 757 565 666 779 10 ± 1 5 ± 1 10 ± 1 
M2 459 N/A 653 757 N/A 668 779 N/A 8 ± 1 23 ± 2 
M3 492 555 N/A 756 569 N/A 779 68 ± 5 N/A 57 ± 3 
M4 461 N/A N/A 757 N/A N/A 779 N/A N/A 40 ± 2 
M5 492 N/A N/A 756 N/A N/A 777 N/A N/A 120 ± 10 
M6 492 N/A N/A 756 N/A N/A 779 N/A N/A 108 ± 13 
M7 492 N/A N/A 756 N/A N/A 779 N/A N/A 14 ± 2 
M8 493 N/A N/A 757 N/A N/A 779 N/A N/A 11 ± 1 
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Figure 26. The optical properties of fluorophore-doped nanoparticles. (A) Fluorescence spectra 
of Q7 in deionized water and DMF. The number of particles in DMF was 10X lower than in 
water. (B) Fluorescence spectra of M1-M4 in deionized water. (C) Fluorescence spectra of M4 
after excitation at different wavelengths. (D) A comparison of M4 in DMF and deionized water. 
The number of particles dissolved in DMF was 10X lower. (E) the fluorescence spectra of 
particles that encapsulated with DiR alone in deionized water. (F) The emission spectrum (black) 
of particles encapsulated with DiO alone (1.75% w/w) and the absorption spectrum (red) of 
particles encapsulated with DiR alone (0.35% w/w).  
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Figure 27. The (A) absorption and (B) fluorescence spectra of two-fluorophores doped 
nanoparticles. The particles were loaded with different ratios of the DiO and DiR fluorophores at 
same total fluorophore loading of 2.10% (w/w).  
Considering that the distance between the excitation and emission λmax of M4 was more 
than 250 nm, the particles could still become a useful imaging platform. Hence, to improve the 
brightness of M4, we synthesized M5-M8 by lowering the ratio of DiR versus DiO (Figure 27A 
and Table 20). As expected, the amount of DiR was crucial for controlling the brightness of M5-
M8 (Table 21). However, more quenching was found when we attempted to enhance the FRET 
by increasing the encapsulated DiR content. This observation was similar to the four-
fluorophores doped nanoparticles (Figure 24B), where we found that the DiR fluorophores were 
more prone to fluorescence quenching with the increasing concentration. As a result, M5 
consisting of the lowest DiR content displayed the highest FRET at 777 nm, but due to an 
insufficient amount of DiR inside the particles to accept all the energy from the donor (DiO) 
emissions, the particles also exhibited a significant DiO fluorescence at 505 nm (Figure 27B).  
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3.4.5. A multiplexed imaging platform 
Next, we combined a mixture of particles into a multiplexed imaging platform. D6, T3, 
and M5 were selected because each of them displayed a distinct fluorescence emission at 570, 
672, and 777 nm, respectively, upon excitation at 485 nm (Table 17). These particles were 
brighter (>10 times) than water-soluble QDs (Figure 28), and their emission peaks were well 
resolved from one another, with a separation distance of ˃100 nm.  
 
Figure 28. Brightness of nanoparticles. A comparison of the brightness of T3 (emission λmax at 
672 nm) and M5 (emission λmax at 777 nm) with the corresponding water-soluble QDs. Note: 
1X refers to 5 × 10
11 
particles/mL. Inset: The FRET images of the particles in a 96-wells plate.  
To introduce binding specificity to the particles, we also attached multiple antibodies 
against HER2 (Herceptin) and RAGE (IgG2A11) to the surfaces of D6 and T3, respectively 
[279] (Figure 29). Protein transduction domains were conjugated to M5 as the non-specific 
particles for cell labeling [291, 292]. The resulting particles, HER-D6, RAGE-T3, and R7-M5, 
were characterized for the number of antibodies and peptides attaching to the surface by BCA 
protein assay and 9,10-phenanthrenequinone reagent, respectively (Table 18) [280]. There were 
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no significant changes in the morphology and the optical property of the surface-modified 
nanoparticles, as compared to the unmodified ones.  
 
Figure 29. Synthetic scheme for conjugation of nanoparticles to the antibody using Traut’s 
reagent as a linker. The Traut’s reagent was reacted with the amino groups of the antibodies to 
generate free sulfhydryls. The modified antibodies (IgG-SH) could be anchored to the surface of 
maleimide-terminated PLGA-PEG nanoparticles (NPs-Mal) via thioether bonds.  
Next, we employed SK-BR-3 and WM-115-RAGE as the cell models to evaluate the 
specificity of the particles. SK-BR-3 is a breast cancer cell line that naturally overexpresses 
HER2 [293]. WM-115-RAGE is derived from the WM-115 melanoma cell line that was stably 
transfected with the cDNA of full-length RAGE and was a generous gift from Dr. Leclerc [292, 
294]. The two cell lines could be easily distinguished from one another based on their 
 97 
 
morphologies and, thus, were selected for proof-of-principle experiments. Prior to performing 
cellular imaging, all the particles were confirmed to be non-toxic by MTS assay (Figure 30).  
 
Figure 30. Cytotoxicity assay. The particles were incubated in (A) SK-BR-3 and (B) WM-115-
RAGE cell lines for 24 h. The percentage of cell viability was determined by MTS assay.  
We observed that both HER-D6 and RAGE-T3 bound specifically to the SK-BR-3 and 
WM115-RAGE cell lines, respectively (Figure 31A and B). The discrete fluorescence signals 
localized at the cell membranes and appeared within the cytoplasm, indicating that these particles 
were taken up by the cancer cells via receptor-mediated endocytosis [295]. On the other hand, 
the control particles i.e., the unconjugated D6 and T3 did not show any non-specific binding 
(Figure 32). Similar to other polyarginine-conjugated nanoparticles [296], R7-M5 was most 
likely internalized into both SK-BR-3 and WM115-RAGE via the non-endocytic pathways [297] 
and, thus, was found distributed throughout the cytoplasm, with some of the particles 
translocated to the nucleus and perinuclear regions (Figure 31C and D) [298, 299]. A collection 
of multiple particles with diverse emission signatures can be a useful tool for detecting different 
cancer cell targets simultaneously [300-302]. Here, using a combination of HER-D6, RAGE-T3, 
and R7-M5 (1:1:1), we were also able to identify SK-BR-3 and WM-115-RAGE in a mixture of 
cell lines according to the expression of cell-surface receptors (Figure 31E).   
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Figure 31. Multiplexed imaging. All the cells were exposed to the same number of particles (9 × 
10
11
/mL, 400 µL)
 
for 15 min at 37°C. Hoechst 33342 (blue) was employed as the nuclear 
staining. FRET images of (A, C) SK-BR-3 and (B, D) WM-115-RAGE after the exposure of 
HER-D6 (green), RAGE-T3 (magenta), or R7-M5 (red). (E) The multiplexed platform i.e., a 
mixture of the particles could image SK-BR-3 and WM-115-RAGE simultaneously. All the 
FRET images were acquired with the same excitation wavelength at 485 nm and were adjusted 
to the same window settings at the corresponding channels (original magnification, 20X).  
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Figure 32. Control studies on the specificity of ligand-conjugated particles employed for the 
multiplexed imaging platform. All the cells were exposed to the same number of particles (9 × 
10
11
/mL, 400 µL) for 15 min at 37°C. Hoechst 33342 (blue) was employed as the nuclear stain. 
FRET images of (A, C) SK-BR-3 and (B, D) WM-115-RAGE after the exposures of the 
unconjugated D6, T3, and M5. All the FRET images were acquired with the same excitation 
wavelength at 485 nm and were adjusted to the same window settings at the corresponding 
channels as Figure 5 (original magnification, 20X).  
3.4.6. In vivo multiplexed imaging 
Next, we explored the potential of our platform for in vivo multiplex imaging in live 
animal. The imaging capability of RAGE-T3 and R7-M5 were compared with their 
corresponding water-soluble QDs, QDs-665 and QDs-800, respectively. For ease of comparison, 
the same numbers of particles were subcutaneously injected into different regions (near the 
abdomen) of a severe combined immunodeficiency (SCID) mouse to perform a whole-body 
FRET imaging [278]. The fluorescence emissions of RAGE-T3 and R7-M5 were higher than the 
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QDs, since our particles were 10 times brighter (Figure 33A and B). The results were in good 
agreement with our in vitro data (Figure 28). Here, HER-D6, RAGE-T3, and R7-M5 could be 
used together as a multiplexed platform for in vivo imaging (Figure 33C). However, the 
calculated signal-to-noise ratios (SNR) among the particles were significantly different and 
increased with the following order: HER-D6<RAGE-T3<R7-M5 (Figure 33D). This result could 
be explained by a lower autofluorescence generated from the mouse tissue at the NIR region 
[14].  
 
Figure 33. In vivo multiplexed imaging. A comparison of (A) RAGE-T3 and (B) R7-M5 with 
the corresponding QDs-665 and QDs-800, respectively. (C) A merged FRET image and a merge 
FRET and X-ray image of a SCID mouse that was subcutaneously injected with HER-D6 
(green), RAGE-T3 (magenta), and R7-M5 (red) particles (3.5 × 10
11
) in deionized water (10 µL) 
at different regions. Inset: The pseudo-color assigned for each particle. (D) A bar chart was 
plotted to compare the signal-to-noise ratio (SNR) of different nanoparticles and QDs, where 1X 
and 10X are referred to 3.5 × 10
11 
and 3.5 × 10
12 
particles, respectively.  
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3.5. Conclusion 
In the present study, we report a series of FRET-based polymeric nanoparticles for 
multicolor and multiplexed imaging applications [213, 275, 303, 304]. For the first time, four 
complimentary carbocyanine-based fluorophores, DiO, Dil, DiD, and DiR were encapsulated 
inside a single particle to engender a broad range of code ranging from the visible and NIR 
wavelength region. Because of the hydrophobic nature of both fluorophores and the particle core, 
the fluorophore molecules were confined in close proximity to enable sequential resonance 
energy transfer [278]. Thus, by doping the different combinations, numbers, and concentrations 
of the fluorophores, the optical properties of the particles could be fine-tuned for multicolor 
imaging [305] and multiplexing imaging [214, 269]. The particles were nontoxic, 10 times 
brighter than QDs, and exhibited extremely low background signals, as compared to previously 
reported nanoparticles [204, 205]. Here, we identified an optimized particle formulation (Q7) 
that emitted fluorescence at multiple wavelengths upon a single excitation for multicolor 
imaging. We also combined three other particles (D6, T3, and M5) as a multiplexed imaging 
platform. By conjugating specific targeting ligands to the particle surfaces, we demonstrated that 
the developed platform was able to identify the target cancer cells by FRET imaging. Unlike 
other multiplexed systems [204, 205, 270], the emission maxima of particles composed in our 
platform were well resolved (≥100 nm). Therefore, minimal spectral deconvolution was required 
during imaging analysis [270, 306, 307]. Overall, we believe that our particle platform, when 
used in combination with multispectral imaging, could have far-reaching potential for identifying 
multiple cell types or tissue structures in vivo [308].  
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CHAPTER 4. A SHORT CIRCULATING PEPTIDE NANOFIBER AS A 
CARRIER FOR TUMORAL DELIVERY 
* Published in Nanomedicine: Nanotechnology, Biology and Medicine, Volume 9, Issue 4, Pages 
449-457, May 2013, doi:10.1016/j.nano.2012.10.009) (© 2013 Elsevier Inc.) 
 
4.1. Abstract 
The cellular interactions and in vivo distribution of the nanomaterials are known to be 
strongly influenced by their physiochemical properties. Here, we investigated and compared the 
biocompatibility, pharmacokinetics, and biodistribution of previously reported peptide-based 
nanofiber (NFP), with commercially available nanomaterials. The NFP was a 2-dimensional 
(2D) structure with an extremely narrow width (4 nm) and a controllable length (50 to 400 nm). 
NFP was found to be non-toxic, hemocompatible, and with a minimum uptake by macrophages. 
In vivo studies further demonstrated that NFP could be delivered to the tumor site more 
effectively, and within a very shorter period of time, than spherical nanoparticles. Importantly, 
the undelivered NFP was rapidly eliminated by renal clearance and, thus, avoiding its 
accumulation in the spleen or liver. Overall, our data suggested a new paradigm in drug delivery 
via using a short circulating NFP, rather than a long circulating 3D nanoparticle, as a delivery 
cargo.  
4.2. Background 
Many nanomaterials have been proposed as drug carriers [309]. Particularly in cancer, 
because of the leaky vasculature and poor lymphatic drainage, nanomaterials tend to accumulate 
at the tumor site via enhanced permeability and retention (EPR) effect [310]. For this reason, 
drug delivery using nanomaterials can offer an advantage of reducing adverse effects of 
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chemotherapeutic agents. For example, paclitaxel, SN-38, doxorubicin, or cisplatin has been 
encapsulated into polymeric nanomaterials to reduce the administration dosage [160, 311-314]. 
In fact, several nanoparticle formulations such as liposomal doxorubicin (Doxil
®
) and albumin 
particles encapsulated with paclitaxel (Abraxane
®
) have been already approved by the food and 
drug administration (FDA) for the treatment of Kaposi’s sarcoma, ovarian, and breast cancer 
[315, 316].  However, due to the prolonged circulating time in the body, Doxil is known to suffer 
from new side effects, including hand-foot syndrome and mucositis. Furthermore, the 
pharmacokinetic and in vivo distribution of a nanomaterial can be affected by many 
physicochemical properties [82]. 
Smaller nanoparticles (< 3-5 nm) are often eliminated from the body by renal clearance 
and thus have relatively shorter plasma half-lives [84]. On the other hand, larger particles (> 10-
20 nm) are prompt to be captured by the reticuloendothelial system (RES) [85], and therefore, 
are more likely to be taken up by the liver and spleen [317]. Apart from size, the shape and 
charge of a nanomaterial can also play important roles in the pharmacokinetic property and 
biodistribution [318, 319]. For example, after intravenous injection, the uptake of gold nanorods 
by the liver was found to be lower than its spherical counterpart of same size [320]. In another 
study, the negatively charged liposomes were shown to have a significantly shorter plasma half-
life than the neutral ones [319]. Given that no universal rule can be applied to predict the in vivo 
behavior of nanomaterials, the safety of the nanomaterials should be evaluated on a case by case 
basis. Besides, understanding the biocompatibility of a nanomaterial is essential to predict its 
future applications in vivo.  
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Peptide based nanomaterials have gained much interest because of their design flexibility 
and structural diversity that enabled their diverse applications [282, 321, 322]. Self-assembling 
peptides have been employed as a novel platform for the local delivery of hydrophilic peptides, 
proteins, and hydrophobic anticancer agents [323]. For example, EAK16-11 is a class of self-
assembling peptide, which can stabilize hydrophobic molecules such as pyrene and ellipticine 
and serve as an efficient slow delivery carrier for releasing the molecules in a controlled manner 
[324]. Similarly, our laboratory has previously developed a new type of peptide-based nanofiber 
(NFP) for imaging and drug delivery [243, 282]. NFP was composed of multiple peptide 
constructs. Each peptide construct consisted of (a) a self-assembling peptide sequence 
(kldlkldlkldl) that has been used for tissue engineering [325] and (b) a hydrophilic polyethylene 
glycol (PEG) to prevent aggregation and possible uptake by the RES [326]. In an aqueous buffer, 
multiple peptides self-assembled together to form a nanofiber (NFP). Unlike the other 
nanofibers, NFP has a unique dimension (4 nm in width × 50-400 nm in length) and does not 
fuse to form the cylindrical nanotubes [327]. The presence of hydrophilic mPEG chain also 
prevents the formation of hydrogel network by inhibiting the possible interfibril interactions 
[328].  
Despite of wide spread use, there are very limited studies available for exploring the 
biocompatibility and tissue distribution of peptide-based nanomaterials. In the present study, we 
investigated the biocompatibility of previously designed NFP to extend the application to in vivo 
system. We also compared the hemocompatibility and biodistribution of NFP with various 
commercially available nanomaterials that were different in terms of composition, size, charge, 
surface area, and shape (Table 1). In vivo studies demonstrated that the optimized NFP was more 
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effective as a tumoral delivery platform and, thus, has potentials as a delivery platform for cancer 
treatment.  
4.3. Experimental procedures  
4.3.1. Chemicals and materials 
All solvents were purchased from Fischer Scientific (Pittsburg, PA). All amino acids 
were obtained from EMD4Bioscience (Gibbstown, NJ). The poly(D,L-lactic-co-glycolic acid) 
(PLGA-COOH, monomer ratio 50:50, 17 kDa) was received as a generous gift from PURAC 
Biomaterials (Netherland). N-hydroxysuccinimide activated methoxy polyethylene glycol (NHS-
PEG2470-OCH3) was purchased from JenKem Technology USA, Inc. (Allen, TX). N,N-
diisopropylethylamine (DIEA), fluorescein isothiocyanate (FITC), and gelatin veronal buffer 
were obtained from Sigma-Aldrich (St. Louis, MO). Uranyl formate and formvar/carbon coated 
grids (200 mesh) were obtained from Electron Microscopy Sciences (Hatfield, PA) and SPI 
Supplies/Structure Probe, Inc. (West Chester, PA), respectively. Trilite™ (QD-6) was purchased 
from Cytodiagnostics, Inc. (Burlington, Ontario). 1,1’-dioctadecyl-3,3,3',3'-
tetramethylindodicarbocyanine, 4-chlorobenzenesulfonate salt (DiD), and Hoechst 33342 
trihydrochloride trihydrate were purchased from Life Technologies Corporation (Grand Island, 
NY). Fluorophorex
TM 
(PS-50 and PS-100) were obtained from Phosphorex, Inc. (Fall River, 
MA). Multi-walled carbon nanotubes (MWNT-2000) were purchased from US Research 
Nanomaterials, Inc. (Houston, TX). All gold nanoparticles (AU-60 and AU-80) were obtained 
from BioAssay Works (Ijamsville, MD). Cy5.5 monofunctional hydroxysuccinimide ester 
(Cy5.5-NHS) was purchased from GE Healthcare Biosciences (Piscataway, NJ). Whole blood 
was purchased from Biochemed Services (Winchester, VA). Human serum and antibody 
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sensitized sheep erythrocytes were purchased from Complement Technology, Inc. (Tyler, TX). 
Alexa Fluor
®
 488 rat anti-mouse CD31 antibody was purchased from BioLegend, Inc. (San 
Diego, CA). Cyanmethemoglobin reagent and hemoglobin standards were provided by Ricca 
Chemical (Arlington, TX) and Stanbio Laboratory (Boerne, TX), respectively. 
4.3.2. Synthesis of the peptide construct 
The peptide construct, mPEG2470-BK(FITC)SGRSANA-kldlkldlkldl-CONH2, was 
synthesized on an automated solid-phase peptide synthesizer (PS3
TM
, Protein Technologies, Inc., 
Tucson, AZ, USA) by employing the standard Fmoc-protected amino acids on rink-amide resin 
as previously described [243]. After synthesis, the peptide was cleaved from the resin, 
precipitated, and washed in methyl tert-butyl ether. The crude peptide was purified by high-
performance liquid chromatography (Agilent Technologies, Santa Clara, CA, USA) and 
characterized using MALDI-TOF mass spectrometry at Tufts Medical School (Boston, MA).  
4.3.3. Synthesis of NFP-50, NFP-100, and NFP-400  
The NFP was assembled in an aqueous environment as previously described [243]. 
Briefly, the solid peptide (1 mg) dissolved in DMSO (20 µL) was added to 50% (v/v) acetonitrile 
in PBS buffer (400 µL). The solution mixture was then stirred vigorously at room temperature 
overnight inside a fume hood to evaporate the solvent. Stock NFP (75 µM) suspended in PBS 
buffer (200 µL) was conjugated to Cy5.5-NHS (132 µM, 200 µL) according to the 
manufacturer's instruction. The resulting NFP was purified by size exclusion chromatography 
(Sephadex G-100, GE Healthcare Biosciences, Piscataway, NJ) and further homogenized into 
NFP-50, NFP-100, or NFP-400, by passing through a mini-extruder (Avanti Polar Lipids, Inc., 
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Alabaster, AL, USA) using a polycarbonate membranes (GE Healthcare Biosciences, 
Piscataway, NJ, USA) of different pore sizes (50 nm, 100 nm, and 400 nm). The concentrations 
of NFP and Cy5.5 were determined by absorbance based on their molar extinction coefficients in 
95% (v/v) methanol in PBS buffer, where εFITC at 485 nm = 65,000 M
-1
cm
-1
 and εCy5.5 at 675 nm 
= 250,000 M
-1
cm
-1
. It was calculated that the average number of Cy5.5  molecules per two 
peptides was one.  
4.3.4. Synthesis of PLGA-100 
 The PLGA-PEG copolymer was synthesized by carbodiimide chemistry and the 
nanoparticles encapsulated with DID fluorophore (PLGA-100) were fabricated by the 
nanoprecipitation method as previously described [278]. Briefly, a mixture of PLGA-PEG 
copolymer (10 mg) and DiD fluorophore (0.1 mg) dissolved in DMF (1 mL) was added dropwise 
to deionized water (10 mL). The resulting particles were allowed to stir for 2 h at room 
temperature. The particles were then purified by ultrafiltration (3000 × g, 15 min) using SPIN-X 
UF concentrators with a 10 kDa MWCO (Corning Incorporated, Lowell, MA, USA) and washed 
with deionized water (2 × 5 mL). The purified nanoparticles were re-suspended in deionized 
water (2 mL).  
4.3.5. Physical characterization of the nanomaterials 
The size of the nanomaterials was determined by dynamic light scattering (Zetasizer, 
Malvern Instruments Ltd., Worcestershire, UK) at 25°C. The length of non-spherical 
nanomaterials including MWCT and NFP was determined by dynamic light scattering as 
previously described [329]. The intensity-weighted mean values were recorded as the average of 
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three independent measurements with the same particle concentration (0.1 mg/mL) in deionized 
water. The refractive index and viscosity of the solvent i.e. deionized water was set at 1.33 and 
0.8872 cP, respectively. The zeta potentials of the nanomaterials were measured using a 
disposable capillary cell (Malvern Instruments, Worcestershire, UK) with the same particle 
concentration (0.1 mg/mL) in deionized water. 
The size and morphology of NFP was confirmed by transmission electron microscope 
(JEOL 100CX, Jeol Ltd., Peabody, MA, USA) as previously described [328]. The NFP (5 µM) 
in deionized water (10 µL) was adsorbed onto formvar/carbon coated grids for 1 min and the 
excess samples were blotted off by filter paper. The grids were negatively stained with 0.75% 
(w/v) uranyl formate in deionized water (10 µL) for 1 min and then air-dried. The images were 
acquired using a computer controlled station.  
4.3.6. MTS assay 
The MTS assay was performed as previously described [282]. Both the mouse leukemic 
macrophage (RAW 264.7) and the human embryonic kidney (HEK-293) cell lines were obtained 
from American Type Culture Collection (Manassas, VA, USA). The cells were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum 
(FBS), penicillin (50,000 units/L), and streptomycin (50 mg/L) and maintained in 5% CO2 at 
37°C. The cells (5000/well) were seeded in a clear bottom 96-well plate (Corning Incorporated, 
Lowell, MA) for 12 h. The nanomaterials (0.4 and 4 mg/mL) in PBS buffer (50 µL) were mixed 
with complete DMEM medium (150 µL) and incubated with cells at 37°C. Cells incubated with 
PBS buffer served as a negative control. After 24 h of incubation, fresh media containing the 
MTS reagent (Promega Corporation, Madison, WI) was added to each well and cells were 
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further incubated for 1 h at 37°C. The absorbance of the reduced formazan products (A) was 
directly measured at 490 nm using a spectrophotometer (Spectramax, Molecular Devices, Inc., 
Sunnyvale, CA, USA). All the absorbance values were corrected for the blank (media only). The 
interference of the respective nanomaterials at 490 nm was corrected by measuring the 
absorbance of same amount of the nanomaterial in the complete culture media. After all 
corrections, the percentage cell viability was determined by using the following equation:  
(Asample)/(Acontrol) × 100%........................................................................................................... (23) 
4.3.7. Hemolysis assay 
The hemolysis of the nanomaterials was tested according to new American Society for 
Testing and Materials (ASTM) standard E2525-08 as previously described [246]. Briefly, red 
blood cells (RBCs) were isolated from the blood by centrifugation (800 × g, 15 min), then 
washed and re-suspended in PBS buffer (3.5 × 10
8
 cells/mL). The nanomaterials (0.2 and 1 
mg/mL) in PBS buffer (100 µL) were added to the stock of erythrocyte dispersion (100 µL) and 
then incubated for 3 h at 37°C. Triton X-100 in deionized water (10% v/v) and PBS buffer were 
used as the positive and negative controls, respectively. The intact erythrocytes were then 
separated by centrifugation (800 × g, 15 min) and the absorbance (A) of the supernatant (100 µL) 
was measured at 540 nm to detect the released hemoglobin. The total hemoglobin concentration 
in the supernatant was quantified by the cyanmethemoglobin method [246]. The results were 
extrapolated from a standard curve, which was generated from a linear fit of hemoglobin 
standard samples over a range of concentrations (1-80 mg/mL). The results were corrected from 
the background absorbance of the all the corresponding nanomaterials (at 540 nm) and were 
expressed as percentage of hemolysis with respect to the positive control.  
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4.3.8. Leukocyte count 
The nanomaterials (0.2 and 1 mg/mL) in PBS buffer (50 µL) were added to the citrated 
blood (50 µL) and incubated for 30 min at 37°C. PBS buffer was used as the negative control. 
The sample (20 µL) was then mixed in 3% (v/v) glacial acetic acid in deionized water (380 µL) 
and the total number of leukocytes was counted using a hemocytometer.  
4.3.9. Platelet count  
Platelet rich plasma (PRP) was obtained by centrifugation (800 × g, 5 min) of citrated 
blood. The nanomaterials (0.2 and 1 mg/mL) in PBS buffer (50 µL) were mixed to the PRP (50 
µL) and incubated for 30 min at 37°C. PBS buffer was used as the negative control. A sample 
(20 µL) was diluted with 1% (w/v) ammonium oxalate in deionized water (380 µL) and the total 
number of platelets was determined by using a hemocytometer. 
4.3.10. Whole blood clotting time (WBCT) 
Fresh blood (50 µL) was mixed with an equal volume of either PBS buffer as a negative 
control or the nanomaterials (0.2 and 1 mg/mL) in PBS buffer (50 µL) and then incubated at 
37°C. After 15 min of incubation, aqueous calcium chloride (CaCl2) solution (50 mM, 25 µL) 
was added to the blood mixture (100 µL). The WBCT was determined as the time required for 
clot formation after the addition of CaCl2.  
4.3.11. Complement consumption assay 
The complement consumption of the nanomaterials was determined as previously 
described [330]. Briefly, human serum (10 µL) was incubated with the nanomaterials (0.4 and 2 
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mg/mL) in gelatin veronal buffer (30 µL) for 1 h at 37°C. Zymosan (10 mg/mL) and PBS buffer 
were used as the positive and negative controls, respectively. The samples (40 µL) were further 
diluted with gelatin veronal buffer (960 µL) and incubated with an equal volume of antibody 
sensitized sheep erythrocytes (5 × 10
8
 cells/mL) for 1 h at 37°C. Finally, the unlysed 
erythrocytes were separated by centrifugation (800 × g, 15 min) and the absorbance of 
supernatants (100 µL) was measured at 415 nm for the released hemoglobin. The intrinsic 
absorbance of the nanomaterials at 415 nm was corrected by measuring absorbance of equivalent 
of nanomaterial in gelatin veronal buffer. The percentage of complement consumption was 
determined using the equation:  
(C-Ct)/C × 100% ………………………………………………………………………………(24) 
where C is the total complement consumption of the negative control and Ct is the 
complement consumption of the test nanomaterial. The term (C-Ct) represents consumption of 
complement by the test nanomaterials. 
4.3.12. In vitro uptake by macrophages 
The rat peritoneal macrophages were freshly harvested from male Sprague Dawley rats 
(Charles River Laboratories International, Inc., Wilmington, MA, USA). Briefly, rats (100-125 
g) were first euthanized by cervical dislocation and the skins were peeled off to expose the 
peritoneum. Ice cold DMEM (20 mL) was then injected into the peritoneal cavities and the 
macrophages were isolated by aspirating the medium. The isolated macrophages were then 
washed with ice-cold sterile PBS buffer (2 × 5 mL) and then re-suspended in a complete DMEM 
medium (1 mL) for immediate use. The nanomaterials (0.2 and 1 mg/mL) in PBS buffer (100 
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µL) were added to the macrophages (1 × 10
6
/mL, 100 µL) and incubated for 3 h at 37°C. The 
cells were then centrifuged and washed with ice cold PBS buffer (2 × 1 mL). The intracellular 
contents of the cells were extracted using 10% (v/v) Triton X-100 in acetonitrile (200 µL). The 
amount of nanomaterials was determined by a fluorometer (Cary Eclipse, Agilent Technologies, 
Santa Clara, CA) according to the standard curve. The lysate obtained from PBS-treated cells 
were used to correct the baseline fluorescence. To generate the standard curve, same number of 
macrophages (1 × 10
6
/mL, 100 µL) were mixed with different amounts of the test materials in 
PBS buffer (100 µL) and cellular contents were extracted as described before in this section. The 
uptake of gold nanoparticles was determined indirectly by analyzing the particles in the 
supernatant as previously described [331]. 
4.3.13. Pharmacokinetic studies  
Three to four week old female, severe combined immunodeficiency (SCID) hairless 
outbred (SHO-Prkdc
scid
Hr
hr
)
 
mice (approx. weight 20 g) were purchased from Charles River 
Laboratories (Wilmington, MA, USA). All animal experiments were performed according to the 
guidelines of the Institutional Animal Care and Use Committees (IACUC) at NDSU. The 
animals were randomly divided into six groups. Each group of animals (n=3) was administered 
with one type of nanomaterial (80 µg) in sterile PBS buffer (200 µL) via tail-vein injection. At 
different time points, the blood (40 µL) was collected through the submandibular vein. The 
plasma (20 µL) was separated from whole blood by centrifugation (5000 × g, 15 min) and further 
diluted with PBS buffer (80 µL). The fluorescence intensity of the diluted plasma was measured 
by a fluorometer. The amount of nanomaterials was quantified according to a standard curve, 
which was generated by adding different amounts of the test materials to the plasma of an 
 113 
 
untreated mouse. The pharmacokinetic parameters were determined by fitting the percentage of 
injected dose per milliliter of blood (% ID/mL) versus time (h) curve into a two-compartmental 
pharmacokinetic model using PK Solver Microsoft Excel plug-in freeware as previously 
described [332]. 
4.3.14. In vivo imaging studies  
For the in vivo study, human glioblastoma U87 cells (1 × 10
6
) suspended in complete 
DMEM medium (50 µL) were injected into the chest region of SCID mice. Tumor growths were 
measured bi-directionally using a digital caliper and the tumor volumes were determined using 
the following equation:  
0.52 × L × W
2 ………………………………………………………………………………….(25) 
 Where L is the length and W
2
 is the square width. When tumors reached approximately 
15 mm
3
, the animals were randomized into three different groups (n=3) and were treated with the 
same mass concentration (80 µg) of NFP-100, PLGA-100, or PS-100 in sterile PBS buffer (200 
µL) via tail vein injections. In vivo imaging was performed in real-time by optical imaging using 
a reflectance imaging system (In-vivo system FX, Carestream Health, Inc., Rochester, NY, 
USA). The whole body fluorescence images were acquired using the Cy5.5 channel (excited at 
615/645 nm and recorded at 680/720 nm) at different time points (0, 1, 4, 12, and 24 h). The 
images were further processed and merged with respective X-ray images using Kodak molecular 
imaging software.  
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4.3.15. Biodistribution study 
For biodistribution study, mice (n=3) were euthanized after imaging. The organs were 
isolated, washed, and snap frozen in liquid nitrogen. The organs were defrosted, weighed (30 
mg), and extracted using 1% (w/v) sodium dodecyl sulfate lysis buffer in 150 µL of Tris buffer 
(20 mM, pH 7.6). To ensure a complete cell lysis, samples were heated to 80°C for 10 min. The 
fluorescence intensity of tissue extracts (100 µL) was measured by a fluorometer and the amount 
of nanomaterials was quantified according to the standard curve. The results were corrected for 
the baseline fluorescence of the corresponding tissue extracts of an untreated mouse. The 
biodistribution of the nanomaterials in various organs was then calculated and normalized in unit 
of percentage of injected dose per gram of tissue (% ID/g).   
4.3.16. Immunohistochemistry 
For immunohistochemistry, the frozen tumors were sliced into thin sections (8 µm) using 
a cryostat (Tissue-Tek, Sakura Finetek USA, Inc., Torrance, CA, USA). The sections were 
washed with PBS buffer and then immunostained with Alexa Fluor
®
 488-conjugated rat anti-
mouse CD31 antibody (10 µg/mL) in PBS buffer (500 µL) for blood vessel (CD31). The sections 
were washed with PBS buffer and nuclear staining was performed by incubating with Hoechst 
33342 (1 µg/mL) in PBS buffer (500 µL) for 10 min at room temperature. The slides were 
observed under an epifluorescence microscope (IX-81, Olympus America, Inc., Melville, NY, 
USA). The corresponding combination of excitation and emission filters were employed for the 
visualization of Hoechst (330-385/420 nm), Alexa Fluor
®
 488 (430-480/500 nm), and Cy5.5 
(635-675/716 nm). The images were recorded on a CCD camera (Hirakuchi, Hamamatsu, Japan) 
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interfaced with a computer and further processed using HCImage software (Hirakuchi, 
Hamamatsu, Japan). 
4.3.17. Statistical analysis 
All results were expressed as mean ± standard deviation (SD) of at least triplicate 
samples. The statistical analysis was performed using Student's t-test and analysis of variance 
(ANOVA) using Prism software version 5.01 (GraphPad software, Inc., La Jolla, CA, USA). The 
results were considered statistically significant if the p-values were < 0.01.  
4.4. Results and discussion 
4.4.1. Design, synthesis, and characterization of NFP-50, NFP-100, and NFP-400 
NFP was composed of multiple peptide constructs (mPEG2470-BK(FITC)SGRSANA-
kldlkldlkldl-CONH2, where the lower case and upper case letters represent the D- and L-
configuration, respectively) [243, 328]. The self-assembling segment (kldlkldlkldl) of NFP was 
an ionic-complementary amino acid sequence, which was characterized by the presence of 
alternative hydrophobic (aspartic acid) and hydrophilic (lysine) amino acid residues. In an 
aqueous environment, multiple peptide constructs would self-assemble to form a single layer 
NFP (~4 nm in width) via electrostatic and hydrophobic interactions [326]. On the other hand, 
the functions of hydrophilic mPEG were to prevent the individual nanofibers from aggregation 
[325, 326, 333] and also to improve the blood circulation time in vivo [163]. The surface of NFP 
was covalently conjugated with multiple Cy5.5 fluorophores as the near-infrared (NIR) reporters, 
via the -NH2 groups of the lysine residues (Figure 34). The conjugation was shown to be 
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successful, as confirmed by the absorbance (Figure 35A). It was estimated that approximately 
one molecule of Cy5.5 was attached to two peptide constructs.  
 
Figure 34. The design of NFP. (A) Molecular model of the self-assembling peptide. Color 
scheme: red (C), white (H), blue (O), and green (N). (B) Schematic representation of NFP. The 
basic peptide construct of NFP is composed of the self-assembling peptide (kldlkldlkldl-CONH2) 
conjugated to a hydrophilic polyethylene glycol (2470 Da). In the aqueous environment, multiple 
peptide constructs assembled into a nanofiber. The surface of NFP was also conjugated with 
multiple Cy5.5 fluorophores as the near-infrared (NIR) reporters via the -NH2 groups of the 
lysine residues. (C) The transmission electron microscope (TEM) image of NFP-100.The fibers 
were stained with 0.75% (w/w) uranyl formate.   
To synthesize NFP of different lengths (50, 100, and 400 nm), the nanofibers were 
homogenized using a mini-extruder as previously described [243]. The resulting NFP-50, NFP-
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100, and NFP-400 were characterized for the morphology and size by transmission electron 
microscopy [243, 326, 328]. As expected, all the NFPs were homogenous with no sign of 
aggregation (Figure 34C). The sizes and zeta potentials of all the NFPs were also confirmed by 
dynamic light scattering (Table 21). The NFP could also serve as a nanocarrier, since a 
significant amount (26% w/w) of a model drug, such as doxorubicin, could be physically 
adsorbed on the surface (Figure 35B).  
 
Figure 35. The absorbance spectra of (A) NFP and Cy5.5-conjugated NFP in 95% (v/v) 
methanol and doxorubicin loaded NFP-Cy5.5 in 70% (v/v) methanol.  
Table 21. The physiochemical properties of different nanomaterials. 
 
Abbreviations: Poly(D,L-lactic-co-glycolic acid)-polyethylene glycol (PLGA), transmission 
electron microscopy (TEM), dynamic light scattering (DLS), outside diameter (OD), width (w), 
length (l), diameter (d). * Size determination by TEM was provided by the manufacturer.  
 
Nanomaterials Material of construction Dimension & 
Shape 
Size (nm) Zeta Potential 
(mV) TEM DLS 
NFP-50 
NFP-100 
NFP-400 
Amino acid 2D Fiber 4 (w) × 50 (l) 
4 (w) × 100 (l) 
4 (w) × 400 (l) 
51 ± 4 (l) 
85 ± 5 (l) 
380 ± 10 (l) 
-10 ± 2.0 
-10 ± 2.0 
-10 ± 2.0 
PLGA-100 PLGA  3D Sphere 70 (d) 93 ± 7 (d) -15 ± 3.0 
AU-60 
AU-80 
Gold 3D Sphere 60 (d)* 
80 (d)* 
71 ± 1 (d) 
90 ± 1 (d) 
-34 ± 2.5 
-33 ± 2.5 
PS-50 
PS-100 
Polystyrene 3D Sphere 50 (d)* 
100 (d)* 
65 ± 2 (d) 
110 ± 3 (d) 
-33 ± 2.5 
-54 ± 4.5 
QD-6 Cadmium & Selenium  3D Sphere 6 (d)* 27 ± 2 (d) -14 ± 1.5 
MWCT-2000 Carbon  3D Rod 10 (OD) × 2000 (l)* 2580 ± 150 (l) -38 ± 3.0 
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4.4.2. Cytotoxicity studies 
Depending on the cell type, a nanomaterial may induce cell death through different 
pathways [334, 335]. To investigate the biocompatibility of NFP, we performed MTS assays in 
both mouse leukemic monocyte macrophage (RAW 264.7) and human embryonic kidney (HEK-
293) cell lines. The nanomaterials that showed toxicity exhibited a more profound effect towards 
the phagocytic RAW 264.7 than the non-phagocytic HEK-293 cell lines (Figure 36).  
 
Figure 36. MTS assay. The nanomaterials were incubated with (A) RAW 264.7 and (B) HEK-
293 cells for 24 h. Cell viability was measured by the MTS assay. * Significant as compared to 
PBS control (P < 0.05).   
Both the quantum dots (QD) and multi-walled carbon nanotubes (MWCT) were toxic, 
with less than 60% of the RAW 264.7 cells remaining viable after 24 h of incubation. The results 
were expected, since these nanomaterials are known to induce oxidative stress and to cause 
damage of the cell membranes [336]. Interestingly, the toxicity of the polystyrene nanoparticles 
(PS) increased with their size, presumably because the larger particles were more prompt to be 
taken up by the cells than the smaller ones [336]. On the other hand, both the pegylated poly(D,L-
lactic-co-glycolic acid) nanoparticles (PLGA) and the gold nanoparticles (AU) showed only 
marginal decreases in the cell viability (< 10%). Unlike the carbon nanotubes where the toxicity 
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can be affected by aspect ratio [130], all the NFPs, regardless of the length, were found to be 
nontoxic.  
4.4.3. Hemocompatibility studies 
A nanomaterial that causes damage to red blood cells (RBC) can be life-threatening 
[246]. Here, we performed an in vitro hemolysis assay to investigate whether NFP was 
hemocompatible [246]. Triton X-100 and phosphate buffered saline (PBS) were employed as the 
positive and negative controls, respectively. In all cases, the percentage of hemolysis increased 
with the concentration of nanomaterials (Figure 37A). NFP exhibited the minimum hemolytic 
effect when comparing to other nanomaterials but the degree of hemolysis was inversely 
increased with the length, in the order of NFP-400 (1.0%) < NFP-100 (3.0%) < NFP-50 (3.8%). 
In contrast, AU, PS, and QD caused significant damage to the RBC (> 5%).  MWCT-2000 was 
highly hemolytic (> 50%). This result was in agreement with the previous report that MWCT 
could destabilize the cell membranes and, subsequently, causing the damage to RBCs [337].  
Next, we evaluated the effect of NFP on the leukocyte and platelet numbers, as certain 
nanomaterials can induce leukopenia or thrombus formation, mainly caused by platelet 
aggregation. Our results demonstrated that all the tested nanomaterials, except MWCT, did not 
affect the leukocyte and platelet counts (Figure 37B and C). The decrease in the platelet number 
in the presence of MWCT-2000 (20%) was attributed to the platelet aggregation that induced by 
the activation of glycoprotein integrin receptor [338]. To confirm that NFP would not induce 
blood clotting via the activation of coagulation system, we investigated its effect on blood 
clotting time. Our result showed that NFP did not affect the whole blood clothing time (WBCT) 
(Figure 37D). In contrast, we recorded a significant delay of the WBCT in presence of QD-6, 
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with a 2.4-fold increase when comparing to the PBS control (P < 0.05). This result was 
contradicted to the previous report that quantum dots could promote thrombosis [339]. This 
might be due to fact that the size and zeta potential of the quantum dots used in our studies were 
different as compared to reported studies.                                                                                          
 
Figure 37. Hemocompatibility studies (A) Hemolysis assay. The nanomaterials were incubated 
with RBCs and the release of hemoglobin was quantified by the cyanmethemoglobin method. 
The results were expressed as the percentage of hemolysis with respect to the positive control 
(Triton X-100). A comparison of the effects of different nanomaterials on (B) leukocyte number, 
(C) platelet number, and (D) whole blood clotting time (WBCT). * Significantly higher as 
compared to NFP-50, NFP-100, and NFP-400 (P < 0.05).   
Based on the new “Standard Test Method for Analysis of Hemolytic Properties of 
Nanoparticles” from the American Society for Testing and Materials (ASTM) E 2524-08 [246], 
we concluded that NFP was hemocompatible, since it was non-hemolytic (< 5% hemolysis) and 
show no significant effect on the leukocyte and platelet numbers and the WBCT. 
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4.4.4. Complement consumption assay 
After intravenous injection, a circulating nanomaterial that binds to complement proteins 
may induce hypersensitivity reactions such as complement-mediated anaphylaxis. Here, we 
determined the consumption of complement proteins by NFP using a CH50 assay [330]. 
Zymosan, a well-known complement system activator, was used as a positive control. Among all 
the nanomaterials, NFP showed the minimum complement consumption (< 11%). This was 
attributed to the presence of hydrophilic PEG chains that might prevent the absorption of 
proteins onto the nanofiber surfaces. On the other hand, both the PS and MWCT significantly 
consumed 25-40% of the CH50 units (Figure 38A) [340, 341]. Overall, these results suggested 
that NFP were unlikely to trigger the complement cascade as compared to other nanomaterials. 
 
Figure 38. (A) Complement consumption assay. A bar chart showing the percentage of 
complement consumption by different nanomaterials. (B) In vitro macrophage uptake assay. The 
same number of freshly isolated rat peritoneal macrophages (1 × 10
6
/mL) was incubated with the 
nanomaterials in complete DMEM medium for 3 h at 37°C. The intracellular contents of cells 
were extracted and quantified by a fluorometer. 
#
 Significant as compared to the PBS control (P 
< 0.05). * Significantly higher as compared to NFP-50, NFP-100, and NFP-400 (P < 0.05). ** 
Significantly higher as compared to NFP-50 and NFP-100 (P < 0.05).   
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4.4.5. In vitro uptake by macrophages 
A nanomaterial that is taken up by circulating macrophages normally has a lesser chance 
of reaching the target sites [82]. To predict the uptake of NFP via phagocytosis, we performed an 
in vitro uptake assay using freshly isolated rat peritoneal macrophages (Figure 38B). We 
observed that significant (P < 0.05) amounts of AU and PS were taken up by the macrophages 
(>70%), presumably because these nanoparticles were extremely hydrophobic [342, 343]. 
Among all the nanomaterials, NFPs demonstrated the least uptake by the macrophages (< 30%), 
whereas a significant (P < 0.05) amount of spherical PLGA nanoparticles were taken up by the 
macrophages (67%). The observed differences in phagocytic uptakes could be due to differences 
in the total PEG content. As the NFP contains relatively higher PEG content (50 vs. 13% w/w) 
and thus providing better protection against macrophage uptake when compared with the PLGA 
nanoparticles [344].  In addition, since the NFP is a single layer fiber like structure (Figure 
34B), nearly all the PEG chains could expose toward the nanofiber surface and, thus, creating a 
uniform and dense PEG shield. Whereas, in case of the PLGA nanoparticles, some of the 
hydrophilic PEG chains could be buried inside the core of nanoparticles during nanoprecipitation 
[345]. Given that the shape of the nanomaterial can also play a crucial role in the phagocytosis, a 
relatively lower uptake of NFP suggested that the macrophages required a longer membrane 
wrapping time for NFP than the spherical nanomaterials [320, 346].  
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4.4.6. Pharmacokinetic studies  
It is well known that immune cells in the blood (such as leukocytes, platelets, and 
monocytes) and in tissues (such as macrophages) have a tendency to engulf and eliminate the 
nanomaterials from the systemic circulation. Here, we investigated the pharmacokinetic of NFP. 
The physical pharmacokinetic parameters were obtained by fitting our data into a two-
compartment model (Table 22). All the NFPs, regardless of the length, showed a biphasic 
plasma clearance profile (R
2
 > 0.99) (Figure 39A). The elimination half-life (t1/2β) of NFP-100 
was short (3.9 h) but was longer than both NFP-50 (1.3 h) and NFP-400 (2.6 h), possibly because 
of the shorter NFP-50 was rapidly eliminated by renal clearance and the longer NFP-400 was 
more likely to be removed by circulating macrophages (Figure 39B) and the RES organs.  
 
Figure 39. Pharmacokinetic study. (A) A plot of the pharmacokinetic profile of NFPs. (B) A 
comparison of the pharmacokinetic profile among NFP-100, PLGA-100, PS-100, and QD-6. All 
the nanomaterials (80 µg) in sterile PBS buffer (200 µL) were intravenously administered into 
SCID mice (n=3 for each group of animals). The data were plotted as a percentage of injected 
dose in blood (% ID/mL) versus time. 
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We then compared the pharmacokinetic profile of NFP-100 to other 3D nanoparticles of 
similar size (100 nm). As expected, the pegylated PLGA-100 showed a longer t1/2β (8.7 h) as 
compared to the non-pegylated PS-100 (1.4 h), since coating a hydrophilic PEG on the 
nanoparticle surface might minimize the plasma clearance. As expected, the area under the curve 
(AUC) and mean residence time (MRT) were also significantly higher in the case of PLGA-100 
(Table 22). It is important to note that despite of higher PEG content, NFP-100 showed a 
relatively shorter t1/2β than PLGA-100. This could be attributed to the fact that NFP had a narrow 
width (4 nm) and therefore eliminated rapidly by renal clearance [347].   
Table 22. The pharmacokinetic parameters of the nanomaterials. 
Nanomaterials t1/2 (α) 
(h) 
t1/2 (β) 
(h) 
AUC0-24 h 
(h. μg/mL) 
MRT 
(h) 
CL 
(mL/h) 
Vd 
(mL) 
NFP-50 0.26 1.3 26.2 1.6 2.5 1.7 
NFP-100 0.41 3.9 24.6 3.4 2.5 7.1 
NFP-400 0.32 2.6 24.2 2.6 3.3 5.2 
PLGA-100 0.03 8.7 254 12.5 0.3 2.3 
PS-100 0.15 1.4 0.70 1.5 158.7 95.9 
QD-6 0.21 1.9 6.50 1.9 11.9 13.5 
Abbreviations: Distribution half-life (t1/2α), elimination half-life (t1/2β), area under the curve 
(AUC), mean residence time (MRT), clearance (CL), and volume of distribution (Vd). 
4.4.7. In vivo imaging and biodistribution studies 
It is possible that, after intravenous injection, a nanomaterial can be taken up by a 
circulating macrophage or captured in the liver [82]. Therefore, we investigated the tissue 
distribution of NFP in a human glioblastoma U87-implanted SCID mouse model by fluorescence 
imaging (Figure 40). NFP-100 was chosen as an optimized formulation in this study, since it had 
the lower macrophage uptake (Figure 38B) as well as possessed the longest elimination plasma 
half-life (t1/2β =3.9 h) among all the NFPs and, thus, considered more suitable for in vivo 
applications. We also compared NFP-100 with the spherical nanomaterials i.e. PLGA-100 and 
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PS-100 of similar size (100 nm). For a fair comparison, the same amounts of nanomaterials were 
injected into the animals and the distribution in the major organs including liver, spleen, bladder, 
and tumor were monitored non-invasively by fluorescence imaging.  
 
Figure 40. Biodistribution study. The merged fluorescence and X-ray images of U87-implanted 
SCID mice (n=3 for each group of animals) at different time points after intravenous 
administration of the same amount (80 µg) of (a-d) NFP-100, (e-h) PLGA-100, and (i-l) PS-100 
in sterile PBS buffer (200 µL). 
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Both the PLGA-100 and PS-100 were found predominantly accumulated in the liver 
within 1 h of injection. On the other hand, NFP-100 was efficiently delivered to the tumor site 
(Figure 40), despite the fact that a substantial amount was present in the bladder which suggest 
that NFP-100 was also rapidly eliminating by renal clearance [84]. This strongly suggested that a 
rapid translocation of NFPs from the vascular compartment to the urine compartment through 
glomerular filtration [347]. Interestingly, NFP-100 remained in the tumor at a considerably high 
level with time (Figure 40). Overall, our imaging data confirmed the results from the 
pharmacokinetic study that NFP-100 has a short distribution half-life (< 1 h).  
To further quantify the amount of nanomaterial in each organ, all the animals were then 
euthanized at 24 h after injection. The whole organs were removed, homogenized, and further 
quantified for the amount of nanomaterials in the tissue extracts (Figure 41A and B). As 
expected, > 30% of the injected dose (ID/g of tissue) was found in the livers of the animals 
injected with PLGA-100 and PS-100 (P < 0.05). On the other hand, there was a higher 
percentage of NFP-100 accumulated in the tumors (5%) when compared to PLGA-100 (2.5%) 
and PS-100 (0.4%).  
In order to have a better understanding of the overall distribution, the percentage of 
injected nanomaterials remaining in the animals was calculated. After taking account for the 
tissue mass and blood volume (assuming the weight of the blood was 6% of the total body 
weight), the percentage of NFP-100 remaining (22%) at 24 h after injection was considerably 
lower than both the PLGA-100 (50%) and PS-100 (70%). Our results suggested that NFP-100 
could deliver to the tumor more effectively but at the same time was less likely to accumulate in 
the body when compared to other spherical nanoparticles.  
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Figure 41. Quantitative tissue distribution of nanomaterials. (A) A bar chart shows the 
percentage of injected dose (% ID/g of tissue) in (A) different organs and (B) tumors. The 
nanomaterials were extracted from the organs and quantified by a fluorometer. * Significantly 
higher as compared to NFP-100 (P < 0.05). ** Significantly higher as compared to NFP-100 (P < 
0.01). *** Significantly higher as compared to PLGA-100 and PS-100 (P < 0.05). 
 
Figure 42. Fluorescence microscopy. Fluorescence images showing the excised tumors of U87-
implanted SCID mice at 24 h after injection with (A-C) PBS buffer and (D-F) NFP-100. The 
tumor sections (8 µm) were immunostained with Alexa Fluor
®
 488-conjugated rat anti-mouse 
CD31 antibody (green) and Hoechst 33342 (blue) for visualization of the blood vessel and 
nucleus, respectively. The NFP-100 (red) was found located at the blood vessels and the 
surrounding tumor.  
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Finally, fluorescence microscopy was performed on the excised tumors to confirm the 
presence of NFP-100 in the tumor (Figure 42). The NFP-100 (red fluorescence) appeared to 
localize in the tumor blood vessels (green fluorescence) and extravasated into the surrounding 
tumor tissue. Our results suggested that NFP could penetrate deeply inside the tumor. This 
indicates that NFP could be potentially useful as a vector in poorly permeable tumors, where 
nanoparticles entry is mainly restricted due to their hypovascular and hypopermeable 
characteristics [348]. 
4.5. Conclusion 
Using long circulating nanoparticles may be a promising approach to enhance the 
therapeutic efficacy of chemotherapeutic agents [160, 311-314] but at the same time it may also 
give rise to long-term toxicity because of the extended circulation time. Furthermore, the 
delivery of the particles from the systemic circulation to tumor interstitium can be slow, 
depending on the size of the particles [348]. Here, we reported a NFP that could be delivered to 
the tumor after intravenously injection in a short period of time and also eliminated rapidly by 
renal clearance. Our in vitro studies confirmed that the NFPs were nontoxic and biocompatible. 
Most importantly, the NFPs showed a higher tumor accumulation than some spherical 
nanoparticles with the same size and thus they may offer a safer and more effective drug delivery 
approach [160]. Given the unique pharmacokinetic and biodistribution, we believe that these 
NFPs could be also a useful carrier for contrast agents, since a rapid clearance may offer a lower 
signal-to-background ratio in imaging [349]. In the future, specific ligands such as antibodies, 
proteins, and aptamers could be immobilized on the nanofiber surfaces for targeting delivery. 
Overall, we believe that the developed NFPs form a versatile theranostic platform, which 
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promises a more efficient delivery of the payload to the tumor. This study also may provide 
useful information for the design of nanomaterials in the future. 
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CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS 
The application of nanotechnology for the delivery of diagnostic and therapeutic agents 
has exerted considerable impact on medicine in the past few decades [350]. The unique 
physiochemical properties of nanomaterials open the possibility of interaction with biological 
tissues, spurring the emergence of the field of bionanotechnology and the creation of 
nanoparticle-based therapeutics, in vitro diagnostics, and in vivo contrast agents. Using 
nanotechnology, one can prolong the circulation of hydrophobic small molecules or 
macromolecules in blood plasma, tailor their delivery to specific tissues or intracellular locations, 
and even visualize sites of delivery by combining therapeutic agents with imaging modalities and 
many other applications. Over 20 nanoparticle-based therapeutics are already approved by the 
FDA for clinical use, and numerous others are at various stages of preclinical and clinical 
development. Among all, polymer-based nanomaterials have been studied extensively and 
imparted huge success in clinical use in delivering the different therapeutic agents. However, the 
nanomedicine field still lacks the use of nanomaterials for the diagnostic applications particularly 
for optical imaging. This dissertation employs several polymeric based nanomaterial 
formulations for the delivery of diagnostic agents for medical imaging. All the nanomaterials 
were synthesized in house by using either polymeric construct or peptide/polymer construct. As 
desired, the nanomaterials were then modified with different targeting ligands to achieve the 
specificity.  
In chapter 2, FRET based polymeric nanoparticles were designed and successfully 
employed for in vivo NIR and FRET imaging. The preliminary experiments with a single 
fluorophore-doped nanoparticles were the starting point for determining the optimal conditions 
such as fluorophore loading, particle size, and zeta potential for the encapsulation of the 
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fluorophores. After initial experimentations, two fluorophores-doped nanoparticles were shown 
to demonstrate FRET using DiD as a donor fluorophore and DiR as a acceptor fluorophore. With 
the encapsulation of hundreds to thousands of fluorophore molecules, these nanoparticles 
showed efficient energy transfer which could be further fine-tuned by changing total fluorophore 
loading. When compared with DiR-doped nanoparticles, optimized FRET-NPs (2.10% w/w) 
have shown no advantages in terms of the detection sensitivity and the ability to increase the 
contrast between the tested sample and the animal. Therefore, the raw FRET images were further 
processed by using a mathematical model. The experimental results showed a significant 
improvement of the signal-to-phantom background ratio (from 1:11 to 1:39) post processing. It 
was hypothesized that this marked improvement in signal-to-noise was due to removal of the 
fractional cross-talk of the fluorophores and reduced the background contributed by the phantom. 
This will open up many possibilities for in vivo optical imaging especially for deep tissues, as 
current optical imaging techniques are unable to reach sufficient penetration depth. The next step 
would be to employ these nanoparticles for the detection of human tumor in preclinical mouse 
xenograft model (such as subcutaneous and orthotropic). The delivery of nanoparticles can be 
achieved by both passive and active targeting approaches. For achieving the targeting specificity, 
the surface of nanoparticles may be modified with different targeting ligands such as monoclonal 
antibody, peptide, or aptamers. This should be a relatively simple task as we already 
demonstrated the successful conjugation of IgG antibodies on the particle surfaces. The potential 
drawbacks of the present system may include the following: 1) long term instability under in vivo 
conditions, 2) uptake by circulating macrophages and then clearance by excretory organs such as 
liver and spleen, and 3) in vivo biocompatibility. If required, the composition of nanoparticles 
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such as length of PEG chains, terminal functional groups, and composition of PLGA polymer 
should be optimized to achieve the desired effect.  
In chapter 3, after successfully demonstrating the use of FRET-based nanoparticles for in 
vivo imaging, we further extended the study toward the rational development of multiple 
fluorophores doped nanoparticles for multicolor imaging and multiplexing imaging. In this 
design, we incorporated up to four different fluorophores inside a single nanoparticle to create a 
library of color coded nanoparticles with a single excitation wavelength. It was observed that 
there was involvement of both sequential and multiple FRET cascade inside the nanoparticles. 
We further demonstrated that by using the different combinations, numbers, and concentrations 
of the fluorophores, the optical properties of the particles could be fine-tuned for multicolor 
imaging and multiplexing imaging. We further examined the ability of distinguish different cell 
types by using color coded nanoparticles that contained various types of targeting ligands. To 
allow fair comparison, all the nanoparticles shared a near constant targeting ligand density (~ 30-
40 per particle). With multiple copies of targeting ligands, these nanoparticles can bind to surface 
receptors overexpressed on cancer cells at a much higher affinity than the unmodified 
nanoparticles counterpart. Importantly, in complex mixture of cells, nanoparticles can only bind 
and internalize into target cancer cells in significant amount to allow identification of specific 
cell type using a single excitation wavelength. Preliminary animal studies showed that after 
subcutaneous injection the particles can be easily applied in in vivo multiplexing applications. 
The next step would be to apply these particles for identifying multiple cell types or tissue 
structures in vivo in multiplexing format.   
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A major challenge in multi-color FRET is the involvement of large number of donor to 
acceptor photon pathways present in multicomponent system. As the number of fluorophores 
increases, the number of possible donor to acceptor pathway increases. For examples, in case of 
three-fluorophores doped nanoparticles (T1-T5) in our system, following six different pathways 
might be possible after a single excitation at 485 nm: 1) DiO excitation and emission, 2) Dil 
excitation and emission, 3) DiD excitation and emission, 4) DiO excitation-Dil emission, 5) DiO 
excitation-DiD emission, and 6) Dil excitation-DiD emission. Each of these photon transfer 
pathways represent different routes of energy migration and therefore in-detail mechanistic 
studies will be required to elucidate the contribution of each energy pathway. The future studies 
should include fluorescence lifetime studies, donor and acceptor based FRET efficiency, and 
FRET ratio determination in case of three and four fluorophores doped nanoparticles. 
Another future study should include the possible role of the PLGA-PEG polymeric chains 
in assisting the long-range energy transfer. As our results indicated with the nanoparticles 
entrapped with DiO and DiR fluorophores, there was a long range energy transfer from DiO to 
DiR fluorophores. Since, the overlap between the emission spectra of DiO and absorption spectra 
of DiR was very small (<7%), therefore only small amount of emitted light from DiO 
fluorophores was sufficient to excite the DiR molecules. There was also the possibility of 
electron transfer through polymeric chains. Therefore, the possible role of PLGA-PEG polymeric 
chains in assisting the long-range energy transfer should be evaluated.  
The chapter 4 describe the evaluation of peptide-based nanofiber (NFP) as a cargo for 
tumoral delivery. Here, systematic in vitro studies were carried out to evaluate the 
biocompatibility of NFP. The preliminary in vitro results suggested that the NFP is non-toxic and 
 134 
 
compatible with most of the blood components. Although significant progress has been made 
toward understanding the system, other areas of research should be addressed before successful 
implementation of the developed NFP in the imaging and drug delivery field. The future studies 
should address in-detail in vitro studies for sterility testing (i.e. detection of endotoxin, microbial, 
and mycoplasma contamination), immunological testing (i.e. leukocyte proliferation assay, 
chemotaxis assay, granulocyte macrophage colony-forming unit assay, induction of leukocyte 
procoagulant activity), and toxicity studies (i.e. oxidative stress, cytotoxicity (necrosis and 
apoptosis), and autophagy). In addition, the in vivo compatibility in animals cannot be 
underestimated. Therefore, the acute, sub-acute, and chronic toxicity studies must be carried out 
to investigate the in vivo biocompatibility of NFP in future. These studies should include 
determination of maximum tolerated dose (MTD) in animals, single or repeat-dose toxicity, 
blood sample examinations (serological, hematological, and histopathological), and histological 
examination of mouse tissues after NFP injection.  
The in vivo tissue distribution studies in mouse xenograft model showed that NFP could 
be delivered to the tumor site more effectively within a very shorter period of time and the 
undelivered NFP was rapidly eliminated by renal clearance. This property of NFP could be 
beneficial for drug delivery applications because it may avoid the undesirable uptake inside the 
body, and the dose dependent adverse effect could be circumvented. Therefore, future studies 
should investigate the utility of NFP as a delivery cargo for the therapeutic agent such as 
doxorubicin. Given the unique properties of NFP, we believe that nanofibers could improve the 
efficacy and safety of doxorubicin.  
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The avoidance of the reticuloendothelial system (RES) uptake has long been a key 
consideration in designing nanoparticles to achieve prolonged circulation. Biodistribution studies 
have shown that there was very minimal uptake of NFP by the reticuloendothelial system 
including liver and spleen. It is well known that beside the size, the geometry of nanomaterials 
can dictate the uptake of micro- and nanosized objects by macrophages in vitro. In animal model, 
PEGylated gold nanorods demonstrate more effective evasion of uptake by the liver and spleen 
than PEGylated gold nanoparticles. Therefore, careful elucidation of the effect of particle 
geometry on RES clearance of NFP should be evaluated.  
Lastly, our preliminary studies showed that doxorubicin can be physically adsorbed on 
surface of NFP (Figure 35). The potential limitations associated with this NFP-DOX complex 
could be stability of in blood stream after intravenous injection. Therefore, long term stability 
studies including changes in physical characteristics (such as size, shape, zeta potential), 
interaction with plasma proteins, and stability in whole blood should be carried out. If required, 
the doxorubicin can be immobilized on the NFP surface via covalent bonding. After in vitro 
studies, the results can be extended to examine the pharmacological behavior of NFP-based 
therapeutics in disease animal models (e.g., cancer). 
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